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ABSTRACT 
 
 
 
SEX-BASED DIFFERENCES IN REGULATORY T CELLS 
 
Lum Doreen Nebane-Ambe 
 
November 18, 2005 
 
 
 
Females have a higher incidence of autoimmune diseases than males for reasons  
that are currently unknown.  CD4+CD25+ regulatory T cells play an important role in the 
maintenance of immunological homeostasis and self-tolerance by suppressing 
autoreactive T cells that could potentially cause autoimmune diseases.  
Given that autoimmune diseases are more prevalent in women compared to men, we 
hypothesized that sex steroids could influence the incidence and/or progression of 
autoimmune disease through an effect on CD4+CD25+ regulatory T cell number and/or 
function.  The overall objective of this project was then to determine whether sex steroids 
mediate sex-based differences in  CD4+CD25+ regulatory T cell number, function and 
phenotype, and through this mechanism influence the differential incidence of systemic 
lupus erythematosus in females and males.  To attain our objectives, we 1) assessed the 
influence of androgens (dihydrotestosterone) on CD4+CD25+ regulatory T-cell number, 
phenotype and function;  2) assessed the influence of estrogens (estradiol) on 
CD4+CD25+ regulatory T cell number and function; 3) assessed CD4+CD25+ T cells and 
the effects of androgens in an animal model of systemic lupus erythematosus (SLE). 
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We found that androgens increased the numbers of CD4+CD25+, 
CD4+CD25+CD103+ and CD4+CD25+CTLA4+ cells.  Moreover, male 
CD4+CD25+CD103+ cells expressed more of the regulatory cell-associated transcription 
factor, Foxp3, than females, which also correlated with an enhancement in in vitro 
regulatory function, because male CD4+CD25+ and CD4+CD25+CD103+ cells suppressed 
the proliferation of responder CD4+CD25- cells better than those from females.  
Conversely, estrogens had a very little effect on regulatory T cell numbers, phenotype 
and function.  Our conclusion was that androgens, but not estrogens, can in fact, have an 
influence on the numbers, function and phenotype of CD4+CD25+ regulatory T cells.  In 
radiation bone marrow chimera experiments, we determined that androgens increase 
CD4+CD25+ regulatory cell numbers through an effect on the thymic epithelium, but 
influence the development of CD4+CD25+  regulatory function through a direct effect on 
the bone marrow-derived precursor (not mature) cells.    
In the second part of our project, we assessed CD4+CD25+ T cells and the effects 
of androgens in a murine model of systemic lupus erythematosus (NZB x NZW) in which 
only females get disease, and found that female NZB x NZW mice had significantly 
lower levels of CD4+CD25+ and CD4+CD25+CD103+ T cells compared with male mice.  
Furthermore, androgen deprivation (castration) led to a reduction in the percentages of 
CD4+CD25+CD103+ cells in male mice to levels lower than those found in intact male 
mice, or comparable to levels in intact females.  Moreover, male NZB x NZW mice have 
more potent and greater numbers of CD4+CD25+CD103+ cells.   Androgen deprivation in 
males led to an increase in disease as indicated by the increase in antibodies to dsDNA 
and a coincident reduction in CD4+CD25+ cell numbers.  On the other hand, the 
 vii
administration of androgens to females inhibited disease progression, as reflected in  
significantly lower levels of dsdNA antibodies compared to placebo-treated females, and 
this decrease correlated with enhanced CD4+CD25+ cell number and function.  
 Taken together, these data strongly suggest that androgens could influence the 
incidence and/or severity of disease by affecting the numbers and/or function of 
regulatory T cells.  It also suggests that androgens appear to be associated with an 
increase in the percentage of CD4+CD25+ cells that express the important trafficking 
molecule, CD103, which may facilitate the ability of male CD4+CD25+ regulatory cells to 
reach sites of inflammation.  These androgen-mediated changes appear to correlate with 
prevention of disease, thus androgens may confer, at least in part, resistance to 
autoimmune disease in males through an enhansive effect on CD4+CD25+ cell numbers 
and function.    
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INTRODUCTION 
 
General overview of CD4+CD25+ regulatory T cells. 
In 1969, Nishizuka and Sakakura discovered that neonataly thymectomized mice 
developed autoimmune oophoritis that resulted in infertility (1). However, subsequent 
studies showed that the phenomenon could be prevented by transferring thymocytes or 
splenocytes from mice of any age or splenocytes of adult mice (2).  Sakaguchi and others 
later showed that there was a subpopulation of CD4+ T cells which could prevent the 
induction of autoimmune diseases, that were subsequently designated regulatory T cells 
(3).  They observed that the adoptive transfer of CD4+CD25+-depleted T cells induced 
several organ-specific autoimmune diseases in immunodeficient recipient mice.  On the 
other hand, the adoptive transfer of CD4+CD25+ T cells prevented the development of 
organ-specific autoimmunity in some strains of mice that were thymectomized on day 3 
of life.  The above studies provide powerful evidence that CD4+CD25+ regulatory cells 
are critical for generating and establishing peripheral self-tolerance (4). 
  A growing body of evidence in recent years has shown that CD4+CD25+ 
regulatory cells play an active role in maintaining immunological self tolerance 
(immunological unresponsiveness to self antigens) and the regulation of other immune 
responses to non-self antigens (5-7).  The normal process of T cell maturation in the 
thymus generates a naturally-occurring subset of CD4+CD25+ Treg (nTreg) cells that 
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develop and acquire their suppressive phenotype in the thymus, and subsequently migrate 
to the periphery where they establish and exhibit a stable function that may potentially 
prevent autoimmune diseases (3, 8-11).  Eventually, CD4+CD25+ regulatory T cell 
expansion in the periphery, is promoted by the self-antigens that mediated their selection 
in the thymus (11), which finally generates 5-10% of peripheral CD4+ T cells in normal 
naïve mice (3, 8) and healthy humans (12-14).  Nevertheless, without requiring the 
thymus, normal CD4+CD25- possess an inherent ability to spontaneously convert in the 
periphery into CD4+CD25+ regulatory T cells that are physically and functionally 
indistinguishable from naturally occurring CD4+CD25+ regulatory T cells (15-17).
Naturally occurring regulatory T cells have been shown to inhibit inappropriate 
activation of cell- and antibody-mediated immune responses against self antigen (18) as 
well as innate immune responses (19).  They have also been shown to prevent the 
development of autoimmune disease in animal models and also play an important role in 
transplantation tolerance and the prevention of graft rejection (20).  CD4+CD25+ 
regulatory T cells express CD25, the high-affinity receptor for IL-2 (3, 21) and studies 
have shown that IL-2 is required for the production of CD4+CD25+ nTreg cells during 
thymic development (22).  Others have shown that IL-2 signaling is required for CD4+ 
regulatory T cell function (23).  Although the identification of CD4+CD25+ regulatory T 
cells is associated with expression of CD25, this receptor is also expressed on normal 
activated T cells.  Thus, CD25 is an activation marker for T cells, and activated effector T 
cells also express CD25+, suggesting that not all CD25+ cells are regulatory cells (24).  
CD4+CD25+ T cells can inhibit in vitro T cell proliferation that is induced by anti-CD3 
(25).  CD4+CD25+ T cells are anergic to TCR stimulation in vitro, and do not proliferate 
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or produce IL-2 in response to T cell stimuli such as concanavalin A or anti-CD3.  
However, they require activation via the TCR to exert their regulatory/suppressive 
functions (26-28).  Once activated, CD4+CD25+ regulatory T cells suppress both CD4+ 
and CD8+ T cell responses in an antigen non-specific manner (4).  Although CD4+CD25+ 
Treg cells cannot proliferate in vitro, they are capable of proliferating in vivo in response 
to stimulating antigens (29).  A remarkable feature of these regulatory cells is that they 
are highly sensitive to antigenic stimulation.  They require a much lower concentration of 
antigen for stimulation to exert suppressive activity, compared with the antigen 
concentration required for the activation/proliferation of naïve CD4+CD25- T cells with 
the same antigen specificity (28). 
 
Accessory molecules associated with the regulatory activity of CD4+CD25+ T cells. 
Recent studies indicate that CD25 is not the most specific cell surface marker for 
the CD4+CD25+ naturally-occurring Treg cells because it is also an activation marker for 
other T cells; for example CD4+CD25- T cells can also upregulate expression of CD25 
after TCR activation.  Since CD25 is not a specific marker for naturally produced 
regulatory T cells, other surface markers specific to regulatory cells have been sought.  
Apart from the CD25 receptor, naturally-occurring T regulatory cells also constitutively 
express various cell surface/intracellular molecules associated with activated/memory 
cells, including;  CD45RB, cytotoxic T lymphocyte antigen-4 (CTLA-4), glucocorticoid-
induced tumor necrosis factor receptor-related gene (GITR), CD134 (OX-40), CD38, 
TGF-β, Foxp3, CD103 (αΕβ7 intergrin), and CD62L (3, 30-35).  Most of these markers 
have been shown to segregate with suppressive function (35-39).  GITR, CTLA-4, 
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CD134 (OX-40) and CD103 were reportedly highly expressed on CD4+CD25+ regulatory 
T cells, but not at all or to a lesser extent on naïve CD4+CD25- T cells (35).  Although 
CD4+CD25+ T cells are the only CD4+ T cells to constitutively express CD25 as well as 
CTLA-4 and GITR in the non-activated state (14), no phenotypic surface markers are 
currently available to readily distinguish activated effector cells from naturally-occurring 
CD4+CD25+ Tregs (4).  Nevertheless, the above markers and others to be discussed are 
essential for inducing, propagating or maintaining the regulatory (suppressive) activity of 
CD4+CD25+ regulatory cells.   
CD4+CD25+ regulatory T cells constitutively express CTLA-4, a costimulatory 
molecule that may be needed for their survival and/or suppressive activity when ligated  
(32, 33).  CTLA-4 is a homologue of CD28 and a positive costimulator of CD4+CD25+ 
regulatory T cell activity.  However, CD28 has higher T cell surface expression levels 
than CTLA-4, but lower affinity for ligands B7.1 and B7.2 (40-44).  On the other hand, 
CTLA-4 has high affinity for its ligands B7.1 and B7.2 on APCs and is a negative 
costimulator of T cell activation/function (45, 46).  Treg cells express CTLA-4 which is 
perhaps the most well documented signaling molecule involved in the suppression of an 
immune response.  The proposed mechanisms of suppression mediated by Treg cells, 
which ranges from direct cell-cell contact to the release of regulatory cytokines (47-49), 
includes CTLA-4 as a potent costimulatory molecule involved in Treg-mediated 
suppression of effector T cells.  Cell-to-cell contact demonstrated by ligation of CD80 
and CD86 on effector T cells by CTLA-4 on suppressor cells resulted in the suppression 
of the effector T cells, implying contact between suppressors and effectors is needed for 
in vitro suppression (50, 51).  To emphasize the importance of CTLA-4 in Treg-mediated 
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suppression, other researchers have shown that coating allogeneic cells with anti-CTLA-4 
Ab cells engages CTLA-4 and induces immune tolerance to these cells through selective 
induction of an Ag-specific CD4+CD25+CTLA-4hi regulatory T cell (Treg cell) 
population (52).  When the CTLA-4 on these activated allogeneic cells is engaged in this 
manner, the cells induce immune hyporesponsiveness through up-regulation of the 
regulatory cytokines IL-10, TGF-β1, and IL-4 and suppression of proinflammatory 
cytokines IFN-γ and IL-2.  
Treg cells also differentially express CD45RB, which in mice, is best delineated by high 
and low expression of CD45 exon B-containing isoforms, respectively designated 
CD45RB  and CD45RB  hi lo (53, 54).  Naïve CD4+ T cells from normal mice generally 
express high levels of CD45RB (CD45RBhi) but when they encounter antigen, they 
down-regulate the expression to lower levels of CD45RB (CD45RBlo).  Transfer of 
CD4+CD45RBhi  cells into immunocompromised mice induces colitis which is prevented 
by co-transfer of CD4+CD45RBlo cells, suggesting that this population contains a potent 
subset of regulatory cells which may include the CD4+CD25+ cells (55).
GITR is a member of the TNFR superfamily.  It is another surface marker that is 
not exclusively expressed by CD4+CD25+ regulatory T cells, for it is constitutively 
present on a very small population of CD4+CD25- non-activated T cells (34, 35, 56) and 
is also upregulated by activated T cells (9, 57).    Studies have shown that GITR is a 
costimulatory molecule for mouse T cell subpopulations (58, 59).  Although analysis by 
both microarray and FACS® have shown that non-activated CD4+CD25+ regulatory T 
cells constitutively and abundantly express GITR, up-regulation of GITR also occurs 
following activation of CD25– T cells (34, 35).  The high-level, basal expression of GITR 
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by CD4+CD25+ regulatory T cells suggested an important and regulatory role for GITR 
on this subset, which was further supported by functional studies in which the addition of 
agonistic anti-GITR Abs to cocultures of suppressor and responder T cells led to a 
reversal of suppressive activity by CD4+CD25+ (34, 35).  However, using combinations 
of CD4+CD25+ and CD4+CD25– T cells from wild-type and GITR–/– mice in coculture 
experiments, Stephens et al later found that ligation of GITR on the CD25– responder T 
cells, not the CD25+ suppressor T cells, was required to abrogate suppression (60).  In the 
absence of CD4+CD25+ T cells, GITR–/– T cells mounted proliferative responses similar 
to those of wild-type animals.  They suggested that GITR/GITR-L engagement provides 
an undefined signal that renders effector T cells resistant to the inhibitory effects of 
CD4+CD25+ T cells. 
CD4+CD25+ regulatory T cells also produce high levels of TGF-β in vitro (21, 61, 
62).  Although the function of TGF-β in suppression of T cell proliferation is 
controversial, some in vitro studies have shown that anti-TGF-β abolishes suppression by 
CD4+CD25+ (62).  This concept, however, is controversial since both cell contact and 
cytokine-based mechanisms have been proposed; for instance, roles for soluble 
interleukin-10 and transforming growth factor-beta (TGF-β) have been suggested (44, 
63-67).  However, other in vitro studies show that CD4+CD25+ regulatory T cells require 
cell-to-cell contact-dependent, surface-bound TGF-β, but not a cytokine-dependent 
(soluble factor), to mediate their suppressive activity (27, 62, 68).  Moreover, 
CD4+CD25+ regulatory T cells, but not CD4+CD25- T cells, express cell-surface TGF-β.  
This suggests that cell-mediated immunosuppression may be mediated by cell surface 
presentation of TGF-β to TGF-βR on target cells (62); for instance, the suppression of 
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CD8  T cells that mediate autoimmunity (69) or tumor rejection (51) by CD4 CD25  T 
cells requires an intact TGF-
+ + +
β receptor II on the CD8  T cells.  Studies using a model of 
CD8  T cell-mediated autoimmune diabetes have shown that CD4 CD25  T cells can 
suppress disease caused by wild-type effector T cells but do not inhibit T cells that 
express a dominant negative TGF-
+
+ + +
β receptor (69). 
TGF-β may not only be involved in suppression of CD8+ effector T cells but also may 
contribute to generation and/or proliferation of CD4+CD25+ suppressor cells, as mice 
defective in TGF-β receptor II have reduced numbers of such cells (70). Nevertheless, 
although the involvement of TGF-β in in vitro assays remains controversial, reports have 
shown that TGF-β is required for regulatory cell function in vivo, based on the results that 
anti-TGF-β administration abrogates regulatory cell protection from colitis (33).  
Moreover, TGF-β is also essential in the prevention of autoimmune thyroiditis in rats 
(71).  Others have shown that TGF-β is a cytokine, mediating generalized control of 
autoimmunity (65, 71-75) and oral tolerance (76).  TGF-β treatment of CD4 +CD25- cells 
may also lead to the induction of the transcription factor FoxP3 in naïve cells CD4+CD25- 
(44, 77).  Since FoxP3 is crucial for development of regulatory activity (78), these data 
imply that TGF-β may play an important role in the development and maintenance of 
CD4+CD25+ regulatory T cells in vivo.  Others have demonstrated that the systemic 
expression of TGF-β in overtly diabetic NOD mice blocks islet destruction, facilitates 
regeneration of endogenous cell function, and cures overt diabetes (79).  They 
demonstrated that such a protective effect is related to the local emergence of 
CD4+CD25+ Foxp3+ T cells.  Overall, TGF-β appears to have a variety of functions in the 
immune system that generally favor immunosuppression, although the exact mechanism 
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by which TGF-β mediates immunosuppression remains to be fully elucidated.  TGF-β 
may be involved in CD4+CD25+ regulatory function. 
 
Foxp3, CD103 and CD62L may identify the most potent subpopulation of 
CD4+CD25+ regulatory T cells. 
Foxp3 (forkhead box P3) is a regulatory gene which encodes a forkhead/winged 
helix transcription factor, scurfin and may act as a transcriptional repressor (63).   
Disruption of scurfin (Foxp3), results in the fatal lymphoproliferative disorder that 
characterizes the scurfy mouse.  Foxp3 is exclusively expressed by CD4+CD25+ T cells 
in mice and humans, and correlates with the suppressive activity of these cells.  
CD4+CD25+ T cells account for almost all of the Foxp3 expression within lymphoid cells 
(78, 80-84).  Studies have shown that 3-day-old mice already contain a significant 
compartment of Foxp3-expressing CD4+CD25+ splenocytes (85).  Foxp3 is not only 
specifically and exclusively expressed in regulatory T cells, but is also absolutely 
required for the generation, thymic development and function of the regulatory T cells 
(78, 81, 82).  Foxp3 is expressed by CD4+CD25+ T cells in the thymus and periphery of 
normal mice and humans (63) and is a specific marker for regulatory activity (78).  It is 
currently the most definitive marker of regulatory function (80-82).  Recent studies by 
Fontenot et al have shown that Foxp3 acts as the regulatory T cell lineage specification 
factor and mediator of the genetic mechanism of dominant tolerance (83).  They show 
that the expression of Foxp3 is highly restricted to the subset of αβ of T cells and 
strongly correlates with CD25 expression and suppressor activity.  Mutations in Foxp3 
lead to the depletion of CD4+CD25+ regulatory (81, 82).  Scurfin-deficient (sf) mice lack 
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Treg cells and suffer autoimmunity (82) and conversely, transgenic mice that over-
express Foxp3 have increased numbers of Treg cells and display increased 
immunosuppressive activity when compared to wild-type mice (81, 82).  Normal non-
regulatory CD4+CD25- T cells adopted a functional phenotype similar to CD4+CD25+ 
Treg cells by induced Foxp3-overexpression, and were capable of suppressing pathology 
in a mouse model of colitis (81, 82).   Mice with the X-linked scurfy mutation develop a 
lymphoproliferative disease, whereas the human beings with a similar mutation develop 
IPEX  (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), 
which is characterized by the development of an array of autoimmune diseases similar to 
those found in mice deficient for CD4+CD25+ T cells (80).  The mutation common to 
both of these diseases is in the Foxp3 gene (86).  Collectively, these studies strongly 
suggest that Foxp3 plays a central role in the generation of CD4+CD25+ Treg cells, and 
illustrate the importance of CD4+CD25+ regulatory T cells in the maintenance of 
homeostasis and prevention of autoimmune and inflammatory diseases in mice and 
humans.  In summary, these findings indicate that Foxp3 may be a master gene that 
controls the development and function of CD4+CD25+ regulatory T cells and is currently 
the only known specific marker for CD4+CD25+ regulatory T cells.   
CD103 (αEβ7 intergrin) which recognizes epithelial cadherin (E-cadherin) is a 
critical component for the intraepithelial homing of T cells.  Most CD8+ T cells in or 
adjacent to the intestinal epithelium and 40-50% of the CD4+ T cells in the intestinal 
lamina propria express CD103 which mediates binding to E-cadherin at the basolateral 
side of the epithelium (87-89).  CD103 is also expressed by lymphocytes within the 
bronchial epithelium, by some alveolar wall lymphocytes, and by bronchoalveolar fluid T 
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cells (90, 91).  Therefore, in general, the αEβ7 intergrin is expressed at high levels in T 
cells that seed mucosal tissues (88, 92, 93).  Expression of the αEβ7 intergrin (CD103) 
delineates murine CD4+CD25+ subsets, which differ in their suppressive and functional 
abilities (31).  CD103 identifies the most potent subpopulation of regulatory CD25+ T 
cells (31), and thus can be regarded as a novel marker for subsets of highly potent, 
functionally distinct regulatory T cells specialized for crosstalk with epithelial 
environments (31).  It is expressed by subsets of highly active CD4+CD25+ cells (Ding et 
al, 2003) in naïve mice (31, 35, 56, 94) with CD4+CD25+CD103+ being more potent both 
in vitro and in vivo.  In other studies, CD103+CD25+ cells are more suppressive in vitro 
and are more effective at inhibiting inflammatory disease than CD4+CD25+CD103- cells 
(95).  It is therefore tempting to suggest that CD103+ expressing subsets, by combining 
high suppressive potential with specific migration behavior into inflamed sites, could 
have a strong therapeutic potential in established autoimmune diseases.  To support these 
data, Belkaid et al have shown that the expression of αEβ7 intergrin is necessary for the 
homing of regulatory T cells to sites of Leishmania major infection (96).  The vast 
majority of these regulatory cells during the L. major infection expressed the αE chain 
(CD103) of αEβ7 intergrin and their results also showed that CD103 is induced and 
maintained on regulatory cells following or just prior to their arrival in tissues.    
Many studies have also reported on the expression of CD62L by CD4+CD25+ T 
cells.  The CD62L antigen is a 74 kDa glycoprotein and is a member of the selectin 
family of cell surface molecules, also referred to as L-selectin, LECAM-1, or LAM-1.  
CD62L binds a series of glycoproteins, including CD34, GlyCAM-1 and MAdCAM-1 
that are expressed by high endothelial venules (HEV).  CD62L is important for homing 
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of naive lymphocytes via the high HEV to peripheral lymph nodes and Peyer's patches, as 
well as into chronically inflamed tissues through HEV-like structures (97).  The CD62L 
molecule also contributes to the recruitment of leukocytes from the blood to areas of 
inflammation.  Most hematopoietic cells express CD62L including most peripheral blood 
B cells, T cells, monocytes, granulocytes and some myeloid cells from bone marrow and 
thymocytes.  You et al reported that regulation of autoimmune diabetes was mediated by 
CD4+CD62L+ T cells, which could also be involved in homeostatic mechanisms (98).  
Other studies show that CD4+CD25+ splenocytes that delay the adoptive transfer of 
diabetes express CD62L (99).  CD4+CD25+CD62L+ cells but not CD4+CD25+CD62L- 
cells express high levels of the chemokine receptor, CCR7 and migrate toward secondary 
lymphoid tissue chemokines (SLC), where they could inhibit activation of autoreactive 
effector cells.  Such studies show that CD4+CD25+CD62L+, unlike CD4+CD25+CD62L- 
splenocytes delay diabetes transfer (99).  Other in vivo studies using models of 
autoimmune gastritis and colitis also show that the CD62L+ population is far more potent 
and suppressive than the CD62L- population, and are concomitantly more responsive to 
chemokine-driven migration to secondary lymphoid organs (100).   
 
CD28/B7-1/B7-2/CTLA-4 and regulatory T cells. 
It has been observed that regulatory T cells are readily found both in the thymus 
and the periphery of mice expressing transgenic clonotypic (MHC class II restricted) 
TCR but are lost upon back-crossing onto a RAG-deficient background (8), implying a 
role for TCR specificity as a determining factor in regulatory T cell development.  The 
binding of B7-1 (CD80) and B7-2 (CD86) which are expressed on APC to CD28 on T 
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cells induces a strong co-stimulatory signal which plays a major role in T cell activation.  
In contrast to CD28, CTLA-4 is only expressed on activated, and not resting, T cells and 
binds to B7-1 and B7-2 with high affinity to provide a negative or inhibitory signal.  
Other studies show that B7/CD28 interactions appear to promote the thymic development 
and peripheral homeostasis of regulatory T cells (58).  In such studies, comparing thymic 
CD4+CD25+ T cells in WT and CD28-deficient mice demonstrated that disruption of the 
CD28/B7 pathway resulted in a significant 80% reduction in the levels of CD4+CD25+ in 
the thymus.  Similarly, treatment of mice with a combination of B7 blocking antibodies 
(anti-B7-1 and anti-B7-2 Abs) for 10 days reduced the number of regulatory T cells in the 
thymus by 66% compared with PBS-treated controls. CD4+CD25+ regulatory T cells 
constitutively express CTLA-4 (35, 101), which leads to the suggestion that CD28/B7 
and/or CTLA-4/B7 interactions may be necessary for the development and/or effector 
function of regulatory T cells.  For example it has been suggested that signaling through 
CD28 and/or CTLA-4 via B7.1/B7.2 is required for the development and maintenance of 
CD4+CD25+ regulatory T cells (58, 101, 102).  Both CD28-deficient mice and B7-1/B7-
2-deficient mice lack CD4+CD25+ regulatory T cells, indicating that the development of 
CD4+CD25+ regulatory T cells requires B7/CD28 costimulation (101).  Some studies 
have shown that B7-1 and B7-2 have different effects on regulatory T cell function. B7-1, 
but not B7-2, is required for the regulatory T cells to inhibit resting human T cells (68).  
On the other hand, blockade of B7-2 instead of B7-1 prevented disease progression in 
some murine disease models (103).   In some autoimmune disease models, such as lupus 
and diabetes, B7-2 plays a role as the dominant costimulatory ligand for the activation of 
autoreactive effector T cells (101, 104).  
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Human T cells with regulatory function can be induced in vitro from naïve cord blood or 
peripheral T cells by stimulation with anti-CD3 and anti-CD28 in the presence of TGF-
β (105), while others show that B7 co-stimulation is required for CD4+CD25- cells to 
spontaneously convert into CD4+CD25+ regulatory T cells in vivo (17), because 
CD4+CD25- cells transferred into B7-/- mice failed to convert into CD4+ CD25+ cells 
that exhibit the regulatory phenotype.  In summary, the above data demonstrate that 
CD28/B7 and CTLA-4/B7 signaling pathways may be essential for regulatory cell 
development and/or function. 
Relationship between sex steroids and autoimmune disease. 
Within the past two decades, there has been intensive investigation on why autoimmune 
diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus 
erythematosus are more prevalent in women compared with men, irrespective of the fact 
that women are generally known to have more potent immune responses compared with 
men.  For example, females mount higher antibody responses to many microorganisms 
and elicit more vigorous T cell activation than males.  Furthermore, the proinflammatory 
(IL-1 secretion) and TH1 (IFN-γ) secretion) responses observed in females are also 
greater than those observed in males (106, 107).  The discrepancy between the sexes 
could occur from the influence of sex chromosomes, sex hormones and/or a complex 
influence of neuronal and endocrine pathways (108).  Furthermore, fluctuations of 
multiple sclerosis and systemic lupus erythematosus disease activity during pregnancy 
has suggested that sex hormones could modulate autoimmunity (109-113).  Research has 
shown that the phenomenon observed in female mice is reminiscent of that in female 
human beings and may be mediated by sex hormones (114-119) through mechanism(s) 
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which are currently unknown.  It has long been suspected that naturally fluctuating levels 
of estrogens influence different autoimmune diseases by different mechanisms, resulting 
in women on the average being 2.7 times at greater risk than men to acquire autoimmune 
disease in general.  In recent epidemiological studies carried out by the American 
Autoimmune Related Diseases Association, the autoimmune disease ratios between 
females and males were as reported in Table 1.  This obvious discrepancy of autoimmune 
disease prevalence in females and males also occurs in animal models of autoimmune 
disease (Voskuhl et al, 1996; Jacobswon et al, 1997; Bebo et al, 1996; Roubinian et al, 
1978).  For example, a similar phenomenon has been observed in a model of multiple 
sclerosis, experimental autoimmune encephalomyelitis (EAE) in SJL mice, models of 
SLE in New Zealand Black (NZB) mice and also models of spontaneous diabetes, (non-
obese diabetic NOD mice) (114, 115, 117, 119).   
Although the sex steroid hormones, estrogens, testosterone and progesterone all 
have the same precursor, cholesterol, the differences amongst them arise from the fact 
that a series of enzymes in different organs act accordingly to generate each end-product.  
The intermediate metabolites such as dehydroepiandrostenedione (DHEA) (120) and 
16α-estradiol (121) as well as progesterone, estrogen and testosterone have been 
proposed to interact with the immune system.  Due to their lipophylic nature, steroid 
hormones can diffuse across the cell membrane, and bind to classical steroid hormone 
receptors found primarily, but not exclusively intracellularly, (122, 123).  Some steroid 
receptors can also be found on the cell membrane (124).  When the steroid binds to the 
intracellular steroid receptor, it results in the translocation of the complex to the nucleus.  
The steroid/steroid receptor complex then serves as a transcription factor, regulating 
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genes which have a binding site for the complex in the promoter region (125). The 
reaction of tissue/cells to sex steroids is a result of the binding of these hormones to their 
receptor.  How, when and where each particular steroid product influences the immune 
system is very complex and remains obscure.  Many autoimmune diseases, including 
multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), 
myasthenia gravis (MG), Sjogren’s syndrome and Hashimoto’s thyroiditis, are 
characterized by a distinct female preponderance (112).  Disease onset in females 
typically occurs soon after puberty (126-137).  In males, disease onset, when it occurs, 
usually does so later in life, (age 30-40), coinciding with the age at which serum 
testosterone levels begin to decline in normal healthy men (138).  Additionally, it has 
been reported that 24% of male MS patients tested had significantly lower levels of 
testosterone as compared to age-matched healthy men ((138).  Estrogen is thought to 
contribute to the increased frequency of autoimmune disorders occurring in females by its 
ability to affect immune organs or cells.  Estrogens exert their biological effects through 
estrogen receptors alpha (ERα) and beta (ERβ (139).  The same estrogen binding to the 
alpha or beta receptors can produce opposite effects in the same system (140).  In the 
lymphocyte population, ERs have been found only in suppressor or cytotoxic T cell 
subsets, while helper lymphocytes showed no significant steroid binding, indicating their 
absence in the latter (130, 135).   However, mRNAs for ERs were present in both 
lymphocyte populations.  This could imply that in helper lymphocytes the mRNA is 
probably not translated into the protein receptor itself. 
Studies show that the estrogen receptor alpha (ERα) appears to be required for 
both the development of a full-sized thymus, and in conjunction with a second receptor, 
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possibly estrogen receptor beta (ERβ), the generation of maximum thymic atrophy in 
response to estrogens (127, 128).  The thymus undergoes atrophy and phenotypic 
alterations when exposed to elevated levels of estrogens during puberty (126, 141) and 
also during pregnancy when estrogens and progestins are high.  ERα has also been 
detected in thymic epithelial cells, thymocytes, macrophages, bone marrow non-
hematopoietic cells and B-lymphocyte precursors (129-136).  ERβ on the other hand has 
been found in bone marrow non-hematopoietic cells, thymus and spleen (129-136).  
Conflicting data however exists regarding the effects of estrogens; while some data show 
that estrogens may improve EAE and other autoimmune diseases like adjuvant-induced 
arthritis in mice (142-144), others show that estrogens exacerbate disease in several 
models of SLE (145).  There is apparently some controversy surrounding the role of 
estrogens in EAE, SLE and other autoimmune diseases. 
On the other hand, androgens and/or gene products from sex chromosomes may 
be responsible for the decreased susceptibility to autoimmune diseases observed in males 
(138).  Although androgen receptors have been found in many tissues of the immune 
system, the thymus (thymocytes and thymic epithelium) is the most prominent (146, 
147).  A role for sex hormones in protection against autoimmunity is supported by 
changes in disease symptomatology that correspond to alterations in sex hormone levels 
during pregnancy and exogenous hormone treatment.  Studies show that estrogen-
induced thymic involution occurs much more slowly than androgen-induced thymic 
involution (148). The thymus atrophies in response to androgens (126).  Castration of 
adult male mice results in enlargement (hypertrophy) of the thymus (146, 149, 150) and 
replacement therapy with physiologic doses of androgens reverses this phenomena (151).  
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Androgen-resistant testicular feminization (testicular feminization mouse; Tfm) mice, 
which have defective androgen receptors, also exhibit significant thymus enlargement 
(146), indicating that the androgen receptor (AR) probably mediates these changes.  
Furthermore, such studies indicate that the cellular targets of androgen action in the 
thymus may include the lymphoid cells (thymocytes) which express AR.  Phenotypic 
analyses of lymphocytes in mice whose thymic epithelium lack the AR have shown 
androgens suppress normal responses, suggesting that AR expressed by thymic 
epithelium are also important modulators of thymocyte development, and that thymic 
epithelial expression of AR is required for androgen effects on thymocyte development 
(146).  Research shows that castration and sex hormone treatment modulate the 
incidence/exacerbation of disease in many animal models of autoimmune disease (115, 
117, 152).  The removal of physiologic levels of testosterone from male mice via 
castration increased EAE disease susceptibility (116, 138) and testosterone levels have 
been shown to be decreased in male mice during EAE relapse (138).  However, 
reconstitution of the castrated mice with androgens reverses the phenomenon (116, 117, 
152).  More detailed studies have been performed in recent years to evaluate the potential 
role of androgen in the prevention/cure of autoimmune diseases like SLE, with results 
that generally suggest that androgens are responsible for the protection against 
autoimmune disease.  In some of such studies the role of testosterone in the treatment of 
SLE was emphasized, wherein the administration of various forms of the steroid 
alleviated SLE, or SLE development was seen to occur if levels of testosterone dropped 
(87, 117, 153-155).  In the Lupus prone NZB x NZW mice, more suppressor cells were 
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generated in the presence of testosterone, suggesting their role in protecting susceptible 
mouse strains from the production of autoantibodies (156).   
In other models of autoimmune disease like the Non-obese diabetes mice (NOD), it was 
shown that the administration of androgen after the onset of insulitis, prevents diabetes in 
these mice, by preventing the further destruction of the islet (157).  In other studies, the 
oral administration of testosterone prior to the induction of EAE in male rats reduced the 
incidence and clinical symptoms of EAE in such rats and, when supplemented in vitro, 
testosterone also inhibited the proliferative response of monocuclear cells to myelin basic 
protein ((158).  Studies in multiple sclerosis patients have also indicated an inverse 
relationship between serum testosterone concentrations and progress of disease, wherein 
lower levels of testosterone were found in women with MS compared with controls 
(159). 
  Together, these data support the hypothesis that physiologic levels of 
endogenous androgens, and not estrogens, are protective against autoimmune disease. 
 
Compartments/targets of the immune system influenced by sex steroids. 
Steroid hormones regulate target genes at the level of transcription (160).  Hence with the 
development of ERα and ERβ knockout mice, αERKO and βERKO, respectively, the 
double knockout mouse αβERKO and the discovery of the androgen receptor mutant 
mouse (testicular feminization mouse; Tfm) it is possible to assess how sex steroids 
regulate certain compartments of the immune system by measuring the expression of 
certain molecules in those compartments.   
Androgens exhibit varying effects on some compartments of the immune system.   
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 Transforming growth factor beta1 (TGFβ1), for example, has been demonstrated to be 
produced by T lymphocytes (161) and to have significant immunoregulatory properties.  
It has been shown that testosterone induces expression of TGFβ1 in the murine thymus 
(151).  Bone marrow chimera experiments have shown that the thymic epithelium 
appears to be the target of both androgens and estrogens, and thereby mediates the effects 
of sex steroids on thymic size and development (127, 146).  Some reports show that 
androgen receptor (AR) gene expression in leucocytes is hormonally regulated, thereby 
influencing the rate of inflammatory diseases (162).  In such studies, it was shown that 
human leucocytes isolated from male cells expressed more (AR) than those from female 
cells.  They investigated whether the gender difference in AR expression was due to 
genetic or hormonal regulation by studying the influence of hormones on AR expression 
in a mouse model of androgen deficiency, which was treated with testosterone, estradiol 
or dihydrotestosterone (DHT).  Blood samples were obtained for leucocyte AR 
expression from females versus males and, using RT-PCR, the investigators found that 
AR mRNA levels were significantly down-regulated in the leucocytes of androgen- 
deficient mice that were treated with exogenous testosterone, estradiol or DHT.  In some 
studies, the castration of male mice to remove physiological levels of testosterone, 
suggests that androgen deprivation results in a decrease in the number of mature 
peripheral T cells, thus altering the function of the peripheral immune system in such 
mice (163).  Other studies show the effect of testosterone on thymocyte proliferation, the 
thymus gland and nonthymic lymphoid organs such as monocyte/macrophage function 
(141, 164, 165).   
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 Studies also show that treatment of male mice with 17-β estradiol induces changes in the 
immune system, but not in reproductive organs (166).  In such studies, the researchers 
used the male outbred-CD-1 mouse which is considered to be less 17-β estradiol -
responsive (in terms of reproductive changes) compared to the inbred mouse.  The CD-1 
mice were treated with 17-β estradiol or vehicle, and the results indicated that the thymic 
organ weight/body ratio and thymocyte cellularity decreased with increasing doses of 17-
β estradiol.  However, although thymocyte numbers were decreased, no differences were 
noted in the relative percentages of major thymocyte subsets.  In contrast to the 
diminished thymocyte numbers, 17-β estradiol increased splenic lymphocyte cellularity, 
indicating that treatment of CD-1 mice with modest doses of 17-β estradiol, altered both 
thymocytes and splenocytes.  Estrogens also tend to inhibit both T and B cell bone 
marrow-derived precursors (128, 167).  Transplantation studies using ER gene-targeted 
animals indicate that ERα expressed by lymphocyte precursors is important for the 
hormone-mediated suppression of lymphopoiesis (128).   
Although androgens and estrogens influence these immune cells, it has not yet been 
ascertained whether or not sex steroids have direct effects on peripheral T cells, or 
whether the effects on peripheral T cell activity are mediated through the thymus or other 
compartments (126).   
 
Possible role of CD4+CD25+ T cells and steroids in SLE disease progression. 
It is thought that autoimmune diseases are more prevalent in females because of 
maternal factors, sex-linked gene inheritance and/or hormonal effects (57, 168, 169).  
Systemic lupus erythematosus (SLE) is more prevalent in women than in men with a 
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corresponding ratio that may be as high as 9:1, respectively. This ratio tends to be more 
prominent just after puberty, suggesting that hormones might play a role in SLE 
susceptibility or exacerbation.  Inherent genetic and environmental heterogeneity within 
human populations hinders comparisons of autoantigen-specific responses between 
females and males with autoimmune disease.  However, inbred animal models of 
autoimmune disease serve as useful tools for the study of gender-related differences in 
immune responses (119).  For example, the (NZB x NZW)F1 mouse is a good model for 
the study of gender-related differences in SLE, since only female and not male mice 
develop SLE-like disease (170).   
SLE is a multigenic disease associated with IgG hypergammaglobulinemia, IgG anti-
nuclear antibodies and immune complex (IC)-type glomerulonephritis.  (NZB x NZW) 
F1 mice are an experimental model for SLE.  Female (NZB x NZW) F1 mice 
spontaneously develop an SLE characterized by the formation of antibodies to nucleic 
acids and the development of a fatal immune complex glomerulonephritis.  Studies have 
shown that sex hormones modulate the expression of autoimmunity in both (NZB x 
NZW) F1 mice and SLE in humans, with androgens exerting a protective effect, while 
estrogens exert an opposing effect (117, 171).   
It has been shown that levels of CD4+CD25+ T cells are decreased in the 
peripheral blood of patients with SLE compared with normal individuals (172).  Other 
functional studies have shown that the abrogation of suppression that is mediated by 
peripheral CD4+CD25+ regulatory T cells is a distinguishing feature of systemic SLE, 
because CD4+CD25- T cells from a polygenic model of SLE (MRL/Mp mouse strain), 
showed reduced sensitivity to suppression by CD4+CD25+ regulatory T cells, and 
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therefore exhibited a defect in CD4+CD25+ T cell regulation (173).  Such studies suggest 
that CD4+CD25+ T cells and sex steroids could play a possible role in the pathogenesis of 
SLE through mechanisms which are currently unknown.  It is therefore reasonable to 
hypothesize that sex steroids could influence SLE through their action on CD4+CD25+ T 
cells that are required for controlling autoimmunity mediated by autoreactive T cells.  It 
is, therefore, worthwhile to assess the influence of sex hormones on SLE, by 
characterizing their effects on regulatory T cell function between the two sexes.  Such 
studies may provide insight into how androgens affect the onset, progression and/or 
abrogation of clinical SLE, leading to a possible therapeutic role for CD4+CD25+ T cells 
and androgens in SLE.  This could lead to development of novel therapies for the 
prevention and/or cure of SLE, as well as other autoimmune diseases.
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MATERIALS AND METHODS 
Mice.   
Female and/or male NZB x NZW F1, C57BL/6 (CD45.2+), estrogen receptor 
knockout, testicular feminization (heterozygous female and wildtype male), B.6SJL-
PtprcaPep3b/BoyJ (CD45.1+) and (NZB x NZW) F1 mice, were purchased from the 
Jackson laboratory (Bar Harbor, ME).  Mice were bred in a specific pathogen-free facility 
at the University of Louisville according to institutional animal care and use committee 
(IACUC) guidelines.  Adult mice were used at either 6-8 weeks of age, or ages described.   
 
Gonadectomy and steroid treatment 
Mice were anesthetized at 21 days of age and skin shaved in the mid-back for 
female, and in the testes area for males.  Ovaries were surgically removed after cutting 
through the skin and peritoneum.  The testes were removed by cutting through the skin 
covering the scrotum, ligation of the testes with surgical sutures, followed by separation 
of the testes from adjoining blood vessels.  Sham surgeries were done in a similar way 
but without the removal of gonads.  For steroid pellet treatment, mice were 
subcutaneously implanted with 60-day testosterone or vehicle-release pellets (Innovative 
Research of America, Sarasota, FL) in the upper back with the aid of a trochar, and the 
incision sealed with a wound clip.  Lymphoid organs were then collected at the 
appropriate time during each experiment and analyzed. 
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Adult thymectomy 
For thymectomy, adult mice were anesthetized by intraperitoneal injection with 
tribromoethanol (Aldrich, Milwaukee, WI).  The skin over the anterior part of the ribcage 
was incised to expose the sternum, and the chest cavity was opened by cutting the first 
two ribs of the sternum.  The two lobes of the thymus were then extracted using forceps 
and the incision sealed with sutures or wound clips.  Mice were kept warm under a heat 
lamp and retuned to their cages when fully awake.  
 
FACS® analysis and antibodies.  
For FACS® analysis of cells, 1 x 106 lymph node, spleen or thymus T-cells were 
labeled for 15 min with various combinations and concentrations of antibodies in staining 
buffer ( Dulbecco's PBS, 0.1% BSA and 0.01% Na2 azide).  Cells were washed and 
analyzed on a FACScan® (Becton, Dickinson, CA) or FACSCalibur® (BD, Palo Alto, 
CA). The following antibody reagents were used:  FITC-, PE- and PerCP-anti-CD4, 
FITC-, PE- and biotinylated anti-CD25, FITC-anti-CD45RB, -CD62L, and -CD45.1, PE-
anti-CD103, and -CD45.1, biotinylated CD45.2 antibodies and FITC-, PE-, PERCP- and 
APC-labeled streptavidin, anti-CD3 antibody (Pharmingen, CA), and PE-anti-GITR, and 
isotype antibodies (R & D Systems, Minneapolis, MN).  Intracellular staining with 
CTLA-4-PE and Foxp3-PE was done as per manufacturer’s instructions. 
 
Harvesting of regulatory (CD4+CD25+) and responder (CD4+CD25-) T cells. 
Spleen and lymph nodes (LN) were collected from adult mice and cells 
dissociated using HBSS media without phenol red, supplemented with 2% heat-
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inactivated charcoal/dextran fetal calf serum (Hyclone, Logan, UT).  LN and spleen cells 
combined and enriched for CD4+ T using a CD4+ T-cell enrichment column (R & D 
systems).  The cells were then labeled with PE-anti-CD25 antibody and incubated with 
anti-PE beads (Miltenyl Biotech, Auburn, CA).  Afterwards, the antibody/bead-treated 
cells were passed through an automagnetic column (Miltenyl Biotech) and the 
CD4+CD25+ T cells separated from the CD4+CD25- T cells.  This procedure yields 
CD4+CD25+ T cells of >90% purity.  To purify CD103+ cells, pre-purified CD4+CD25+ 
cells were stained with fluorochrome-labeled anti-CD103 antibody and 
CD4+CD25+CD103+ cells sorted by high speed cell sorter (Moflow).         
 
Harvesting of bone marrow cells.   
Bone marrow cells were harvested from the tibias and femurs of donors after 
cervical dislocation of the mice.  The cells were then washed by centrifuging (4oC, 
1000rpm, 10 mins) in HBSS without lysing red blood cells.  Mononuclear cells, but not 
red blood cells were then counted, after which 30 x 106 cells were resuspended in 100 ml 
cell sort media (CSM) (1X clear HBSS, 1M HEPES, decomplemented FCS, 50mg/ml 
Pen-Strep) and stained with antibodies from BD Pharmingen).  The antibodies used for 
staining 30 x 106 cells were as follows; 30µl each of biotin anti-CD3, B220, MAC1, Gr-1, 
25µl each of c-KIT APC and SCA-1 PE.  After a 15 min incubation in the dark, the cells 
were washed in CSM and stained in SA-FITC for another 15 mins.  Cells were then 
sorted for stem cells by depleting all the biotin-bound T cells, B cells, macrophages and 
granulocytes, while retaining the stem cells that were double positive for c-KIT and 
SCA1.  The sorted cells were then washed and resuspended in HBSS, ready for injection.  
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  In other cases, T-cell depleted bone marrow cells were used.  After harvesting, 
washing and counting bone marrow cells as described above, a 1:500 (1 ml) dilution of 
ascites (CD90.2) specific for Thy 1.2 on T cells, was added to 10 x 106 cells and 
incubated at 4oC for 60 mins.  Cells were then resuspended in a 1:10 dilution of 
complement and incubated for 37oC for 60 mins to deplete T cells.  After testing for the 
depletion of T cells, cells were washed and resuspended in HBSS, ready for injection.   
 
Adoptive transfer of cells. 
The CD45 isotype was used as a marker to track cells in the recipients. 
Ten thousand bone marrow stem cells or 5 x 106  T-cell depleted bone marrow 
cells from B.6SJL-PtprcaPep3b/BoyJ mice (CD45.1+) were injected i.v. into sub-lethally 
irradiated (550 rads) C57BL/6 or Tfm  (CD45.2+) mice.  For some experiments, adult 
mice (6-8 weeks of age) were manipulated and used as recipients, as detailed in results.  
Lymph node, spleen and thymus (when available) were collected 6-8 weeks after 
injection.  Cells were then either analyzed by FACS® or sorted for use in in vitro assays 
or for analysis of Foxp3 expression.  Absolute cell numbers were determined by direct 
cell counts and flow cytometric analysis.    A dose of 550 rad was used for sublethal 
irradiation of recipient mice, in preparation for adoptive transfer of bone marrow cells. 
 
In vitro proliferation assay 
CD4+CD25+ or CD4+CD25- T cells were either used directly or labeled with either 
anti-CD45.1, anti-CD45.2, anti-CD103 and sorted by a high-speed cell sorter (MoFlo® 
DakoCytomation, Fort Collins, CO).  CD4+CD25+ T cells, CD4+CD25+CD103+, 
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CD4+CD25+CD103-, CD4+CD25+CD45.1+, CD4+CD25+CD45.2+ T cells were evaluated 
for their ability to suppress proliferation by co-culture with CD4+CD25- responder T cells 
(2000, 4000, 12000 or 25000), irradiated spleen cells (1 x 105 or 2 x 105 cells) as antigen 
presenting cells (APC) and anti-CD3 antibody (0.5 mg/ml).  (The regulatory:responder 
ratios that were tested in these assays were dependent on the number of regulatory cells 
recovered, i.e., under some experimental conditions, very few transferred cells were 
recovered).  Cells were cultured in complete media (RPMI 1640, 10% heat-inactivated 
FCS, 2 mM glutamine, 10 mM g/ml strep, HEPES, 100 U/ml penicillin G sodium, 100 
tomycin sulfate, and 1 x 10-5 M 2-mercaptoethanol) at 37°C and 5% CO2 for 3 days.  H3-
thymidine (0.5mCi) was added for the last 18 hrs.  Cells were harvested and H3-
thymidine incorporation measured by scintillation counter. 
 
Direct culturing of cells with steroids. 
Varying doses of 107-1011M dihydrotestosterone (DHT), estradiol (E2) (Sigma 
Aldrich, USA) diluted in 200 proof ethanol (Aaper Chemical Co, Shelbyville, KY) were 
used to treat cocultures of CD4+CD25+/CD4+CD25- cells harvested from adult female or 
male C56BL/6 mice.  The treatment of cocultures with similar dilutions of the 
vehicle(ethanol) served as controls.  APC and 0.5ug antiCD3 were added to the 
cocultures and incubated for 3 days at 370C, 5%CO2.  At the end of three days, 0.5uCi of 
[3H]TdR were added to each well and incubated overnight.  Cells were harvested and H3-
thymidine incorporation measured by scintillation counter. 
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Pretreatment of CD4+CD25+ T cells with dihydrotestosterone or estradiol. 
Regulatory T cells were stained with CFSE by incubatinq with 20µM CFSE, for 
30 mins at 37oC in a dark water-bath. The CFSE-CD4+CD25+ T cells were co-cultured 
overnight in the presence of irradiated spleen cells (APC), 0.5ug antiCD3 and 10-8 M 
steroid (Sigma Aldrich, USA).  At the end of the culture period, the CFSE-CD4+CD25+ 
steroid-treated regulatory T cells were sorted from the APC and washed.  The 
testosterone pretreated regulatory cells were then  cocultured with fresh untreated 
CD4+CD25-, APC and antiCD3 for three days. At the end of the culture period, 3H-
thymidine was added to each well and cells harvested after 18 hrs to evaluate the degree 
of regulation by CD4+CD25+ T cells. 
 
Timed pregnancies and implantation of fetal thymus under the kidney capsule. 
Fetal thymi were harvested at day 14 of gestation of pregnant mice and implanted 
under the kidney capsule of adult mice.  Briefly, mice were anesthesized using 
tribromoethanol and the dorso-lateral portion of the abdomen of the transplant recipient 
was shaved and cut through to view the right kidney.  The right kidney capsule was then 
carefully incised and two fetal thymic lobes carefully inserted under the capsule using a 
micro pipette tip.  The cut over the dorso-lateral portion of the abdomen was then sealed 
with sutures or wound clips.  Mice were kept warm under a heat lamp and retuned to their 
cages when fully awake.  
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Monitoring of the mouse estrous cycle for CD4+CD25+ T cell numbers and function. 
Briefly, 8 week old female mice were monitored daily for diestrus, proestrus and 
estrus stages by staining vaginal smears with J-stain and observing under a phase contrast 
microscope (see Figure 26).  The diestrus stage was identified if the slide contained 
predominantly leukocytes, some nucleated epithelial cells and few/no cornified cells.  
The estrus stage was identified if the slide contained predominantly flat cornified 
epithelial cells, few nucleated epithelial cells but no leucocytes.  The proestrus stage was 
identified if the slide contained predominantly nucleated epithelial cells, some leucocytes 
and few/no cornified epithelial cells.  Once the diestrus, proestrus and estrus stages were 
attained in at least 2 mice/stage, spleen and LN cells from each stage were pooled and 
enriched for CD4+ T cells using a CD4-enrichment column. The CD4+ T cells were 
incubated with anti-CD25-PE antibody, then anti-PE microbeads, followed by the 
separation of CD4+CD25+ and CD4+CD25- T cells on a magnetic column.  Varying 
dilutions of CD4+CD25+ T cells from each stage were co-cultured for 3 days with a 
standard number of CD4+CD25- responder T cells, APC and anti CD3 antibody.  At the 
end of the culture period, 3H-thymidine was added to each well and plates harvested after 
18 hrs.   CD4+CD25+ cell numbers were analyzed by FACs®
 
Induction and evaluation of SLE 
(NZB x NZW) F1 mice were evaluated for SLE disease progression.  Serum 
collected from tail blood was evaluated monthly for anti-dsDNA antibodies by ELISA.  
Briefly, high binding microtitre plates (Corning, Acton, MA) coated with 1µg dsDNA in 
50µl coating buffer (50ml H2O, 0.079g Na2CO3, 0.146g NaHCO3, pH 9.6) were 
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incubated overnight at 40C in the dark.  After being washed with PBS-Tween20 (0.1%, 
pH 7.2), plates were blocked with blocking buffer and incubated at room temperature for 
2 hours.  Plates were then washed and a 1:10 (50µl) dilution of serum in blocking buffer 
added to each well.  Afterwards, plates were incubated at room temperature for 1 hour 
and washed. 50µl of 1:2000 alkaline phosphate-conjugated goat anti-mouse IgG Fc 
(Sigma) was added and incubated for 1 hour.  After washing, 50ul pNPP alkaline 
phosphatase substrate was added and incubated in the dark for 15 minutes. After 
development of color, the optical density (OD) at 405 nm was determined. Urine samples 
were collected and evaluated for proteinuria each month using Albustix® reagent and 
chemistrips (Bayer, IN).   
 
Realtime PCR for Foxp3 
CD4+CD25+ T cells, CD4+CD25+CD103+, CD4+CD25+CD103-, 
CD4+CD25+CD45.1+, CD4+CD25+CD45.2+ T cells were sorted to >98% purity.  Total 
RNA was extracted using the Picopure RNA isolation kit (Arcturus, Mountain View, 
CA), and reverse transcribed using the Taq Man reverse transcriptase kit (Applied 
Biosystems, Foster City, CA).  The cDNA was amplified in duplicate by real-time PCR 
using the SYBR Green PCR kit (Applied Biosystems, Foster City, CA) with primers for 
GAPDH and Foxp3.  Foxp3 mRNA levels were normalized relative to GAPDH mRNA 
expression.  Data were presented as the fold-change relative to CD4+CD25- T cells.  
Primer pairs were designed using software provided by Applied Biosystems, and 
synthesized and purified by HPLC by IDT (Coralville, IA).  Primer pairs were as follows:  
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 Foxp3; 
5'-CCCACCTACAGGCCCTTCTC-3', 5'-GGCATGGGCATCCACAGT-3'  
GAPDH;  
5'-GGAGCGAGACCCCACTAACA-3', 5'-ACATACTCAGCACCGGCCTC-3'. 
 
Statistical analyses 
Data were subjected to analyses by either Student's t test or ANOVA and the 
Tukey-Kramer multiple comparisons test.  All experiments were performed at least three 
times. 
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RESULTS 
 
SPECIFIC AIM I 
Assessing the influence of androgen (dihydrotestosterone) on CD4+CD25+
regulatory T-cell number, phenotype and function. 
The differences in immune function found in females and males are thought to be 
associated with sex-specific sex steroids, e.g., estrogens and progesterone in females, and 
androgens in males (12).  Recent studies have shown that these hormones could have 
opposing effects on the immune system, at physiological levels, i.e., androgens prevent 
autoimmune diseases, while estrogens exacerbate them (106, 174, 175).  Accumulating 
evidence suggests that the CD4+CD25+ regulatory T cells control autoimmunity in 
various animal models and human beings as well.  We propose that the greater levels of 
sex steroids after puberty, could influence CD4+CD25+ regulatory T cell number and 
function, and through this mechanism may influence the differences in autoimmune 
disease prevalence in females and males.  The following study was designed to determine 
the effect that endogenous and exogenous androgens have on regulatory T cell numbers, 
phenotype and function. 
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Analysis of phenotype and function of CD4+CD25+ regulatory T cells from female 
and male mice.  
In the first series of experiments, CD4+CD25+ cells were analyzed in female and 
male mice.  To evaluate the percentage of CD4+CD25+  T cells, spleen and lymph nodes 
(LN) were collected from pre-pubertal (3 weeks) or adult (> 6 weeks) female versus male 
mice of various strains, including C57BL/6, Balb/c, SJL and DO11.10.  Cells from 
spleens and lymph nodes were labeled with PE-anti-CD4 and FITC-anti-CD25 
antibodies.  Flow cytometric analysis was used to determine the percentage of the CD4+ 
T cell population expressing CD25 in females versus males.  In adult C57BL/6 mice, the 
percentages of CD4+CD25+ cells were significantly higher in male than female mice in 5 
of 7 experiments (Table 2, Figure 1A & B).  In 4 of 7 experiments in SJL mice, the 
percentages of CD4+CD25+ cells in males were also significantly higher than in females 
(Table 2, Figure 2A & B).  In the results of experiments with Balb/c mice, 1 of 3 showed 
significant differences, and in the single experiment with D011.10 mice, females also had 
fewer CD4+CD25+ cells (Table 2).  There appears to be a trend, in at least some strains of 
mice, suggesting that males may have significantly more CD4+CD25+ cells than females. 
Mice (and humans) produce higher levels of sex-specific hormones after puberty.  
Therefore, to determine whether sex steroids influence CD4+CD25+ cells, juvenile (pre-
pubertal) female and male mice were evaluated for the presence of CD4+CD25+ cells.  In 
the three strains evaluated, C57BL/6, Balb/c and SJL, there were no differences in the 
percentages of CD4+CD25+ cells between females and males (Figure 3).  The above 
results suggest that sex steroids may influence the levels of CD4+CD25+ in adult mice.                       
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CD4+CD25+ T cells constitutively express high levels of various molecules that 
are associated with regulatory function, such as CTLA-4, GITR and CD103.  CTLA-4 
(CD152) is upregulated in activated T cells, and is generally involved in down-regulating 
T cell activation and maintaining lymphocyte homeostasis.  However, CTLA-4 which is 
constitutively expressed on CD4+CD25+ regulatory T cells, is co-stimulatory for 
CD4+CD25+ regulatory T cells (50).  Microarray analysis of gene expression, has found 
that CD4+CD25+ T cells preferentially express high levels of GITR.  Interestingly, 
ligation of GITR on these cells inhibits immunosuppression mediated by these T cells 
(34, 35).  Similar to CTLA-4, although GITR is thought to be a good marker for 
CD4+CD25+ regulatory T cells, GITR is also upregulated by activated T cells.  The 
intergrin (αEβ7), CD103, identifies a subset of CD4+CD25+ regulatory T cells that are not 
only more suppressive in vitro than the CD103- cells, but have also been shown to be 
more effective at suppressing the inflammatory reaction in inflamed tissues in vivo (95).  
Therefore, with the help of CD103, CD4+CD25+ T cells may be able to traffic to sites of 
inflammation during an ongoing immune response and regulate inflammation directly.                    
CD4+ CD25+ T cells can also be divided into subsets according to the cell-surface 
expression of CD62L (L-selectin).  CD62L is a member of the selectin adhesion molecule 
family, and is required for lymphocyte homing to peripheral lymph nodes via binding to 
sialylated oligosaccharide determinants on high endothelial venules in peripheral lymph 
nodes (176, 177).  CD62L is down-regulated upon       T cell activation, and its level of 
expression, along with other markers, distinguishes naïve T cells, including CD4+CD25+ 
cells, from most effector/memory T cells.   The CD4+CD25+CD62L+ population is more 
potent as it mediates in vitro suppressive function more effectively than the 
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CD4+CD25+CD62L- population (100).  Naïve CD4+ T cells express relatively high levels 
of CD45RB (CD45RBhi), in contrast to memory T cells that express low levels of 
CD45RB (178) and CD45RB is also downregulated upon activation.  Studies have shown 
that the suppression of CD4+CD45RBhi -induced colitis in immunodeficient mice, is 
mediated by CD45RBlo and a sub-set of these cells is composed of the CD4+CD25+ cells 
(55). 
Since CTLA-4, GITR, CD103, CD62L and CD45RB are all associated with the 
CD4+CD25+ regulatory T cell phenotype, we analyzed the expression of these molecules 
in several different strains of adult female and male mice by FACS.  No differences were 
detected in the percentage of CD4+CD25+ cells expressing CD62L, CTLA-4, GITR or 
CD45RB (Figure 4A & B).  However, there was a significant difference in the percentage 
of CD4+CD25+ cells expressing CD103, between females and males (Table 3, Figure 4C 
& D).  In all experiments using adult C57BL/6 and Balb/c mice, the percentages of 
CD4+CD25+CD103+ cells were significantly higher in male than female mice.  In 2 of 4 
experiments using SJL mice, the percentages of CD4+CD25+CD103+ cells in males were 
also significantly higher than in females, while the data from the other two experiments 
exhibited a similar trend, although the differences were not statistically significant.  To 
determine whether sex steroids have an effect on CD103 expression, we compared the 
levels of CD4+CD25+CD103+ cells in pre-pubertal female and male C57BL/6 mice.  Our 
results indicated that there was no significant difference in the percentage of 
CD4+CD25+CD103+ cells in pre-pubertal female versus male mice (Figure 5A & B).  In 
subsequent experiments, we also evaluated the mean intensity of expression of CTLA-4, 
GITR, CD62L, CD45RB and CD103 in female and male C57BL/6 mice, to determine the 
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levels of expression of each marker per cell based on mean fluorescence intensity.  There 
were no consistent differences in the mean fluorescence intensity of CD103, CD62L, 
CD45RB or GITR by female and male CD4+CD25+ T cells (Table 4a, Figure 6A).  
However, in all 3 experiments, there was a significant difference in the mean 
fluorescence intensity of expression of CTLA-4, between females and males; females 
showed a consistently lower mean fluorescence intensity of CTLA-4 by comparison to 
males (Table 4a, Figure 6B).  We also determined the absolute numbers of CD4+CD25+ 
or CD4+CD25+CD103+ T cells in females versus male C57BL/6, Balb/c and SJL mice.  
In the majority of experiments using C57BL/6, Balb/c and SJL, the total numbers of 
CD4+CD25+ T cells in males was significantly higher than that in females (Table 5a).  In 
an even larger majority of experiments, the total numbers of CD4+CD25+CD103+ T cells 
in males was significantly higher than that in females (Table 5b).  Taken together, these 
data suggest that CD103 and CTLA-4 are differentially expressed by CD4+CD25+ cells in 
female and male mice, and their expression may be influenced by sex steroids, which 
could contribute to the differential autoimmune incidence observed in the females and 
males. 
CD4+CD25+ regulatory T cell function can be detected using a classic in vitro 
assay (Figure 7).  In this assay varying numbers of CD4+CD25+ T cells are co-cultured 
with CD4+CD25- responder cells, in the presence of APC and anti-CD3.  Functional 
CD4+CD25+ regulatory cells will inhibit proliferation of CD4+CD25- responder cells 
under these conditions.  The following experiments were designed to determine whether 
there are differences in CD4+CD25+ regulatory cell function between adult female and 
male mice.  For these experiments, spleen and LN cells from 8-week-old female or male 
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mice were pooled and enriched for CD4+CD25+ and CD4+CD25- T cells.  Female and 
male CD4+CD25+ T cells were co-cultured with male CD4+CD25- responder T cells in 
the presence of male irradiated spleen cells (APC) and anti-CD3 antibody.  CD4+CD25+ 
T regulatory cell function was tested at various responder: regulatory cell ratios in order 
to detect any possible subtle but distinct differences in the efficacy of regulatory activity.  
In 3 of 7 experiments in C57BL/6 mice, male CD4+CD25+ cells were significantly better 
than female cells in suppressing responder CD4+CD25- cells typically at ratios of 1:2, 1:4 
and 1:8 (Figure 8A, Table 6a); and in 2 of 5 experiments in SJL mice, male regulatory T 
cells were better than their female counterparts in suppressing in vitro proliferation also 
at ratios of 1:2, 1:4 and 1:8 (Table 6b, Figure 8B).  Frequently, at lower ratios (1:1) 
regulator: effector, there were no significant differences in suppression by CD4+CD25+ 
cells from females versus male mice (Table 6a and 6b).  However, at higher dilution 
ratios, which are comparable to physiological ratios (e.g., 1:8), significant differences 
were observed.  Although not definitive, overall these results suggest that males may 
have more regulatory cells and that male CD4+CD25+ regulatory cells may function 
somewhat better than female cells. 
 
Analysis of phenotype and function of CD4+CD25+CD103+ cells from female and 
male mice.  
Previous studies have found in in vitro proliferation assays using subsets of 
CD4+CD25+ cells, that CD103+ is generally expressed by the most potent subpopulation 
of CD4+CD25+, because at very low responder : regulatory cell ratios (i.e., ratios that are 
comparable to physiological conditions), the CD103+CD25+CD4+ subset exhibits greater 
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suppressive effects (31).  These data suggest that CD103 identifies a more potent subset 
of CD4+CD25+ regulatory cells, in addition to its involvement in trafficking to inflamed 
tissues.    
The following experiments were designed to determine whether there are 
differences in function in the CD4+CD25+CD103+ cell subset between female and male 
C57BL/6 and SJL mice.  Female and male CD4+CD25+CD103+ T cells were co-cultured 
with male CD4+CD25- T cells in the presence of male irradiated spleen cells (APC) and 
anti-CD3 antibody (Figure 7).  In the majority of experiments (4 of 5), male 
CD4+CD25+CD103+ regulatory T cells from C57BL/6 mice were significantly better than 
females in inhibiting the proliferation of CD4+CD25- regulatory T cells at ratios of 1:1, 
1:2, 1:4, 1:8 (Figure 9A, Table 7a).  However, in SJL mice, in only 1 of 3 experiments, 
male CD4+CD25+CD103+ were found to be significantly better than females at 
suppressing CD4+CD25- T cells (Figure 9B; Table 7b).  The differences found in 
CD4+CD25+CD103+ regulatory cell function between females and males were greater 
(i.e., found at ratios as low as 1:1) and more consistent than those found in the 
unfractionated CD4+CD25+ regulatory cell population. 
Another characteristic of CD4+CD25+ regulatory T cells is their high expression 
of the transcription factor, Foxp3, which seems to have a key function in the development 
of CD4+CD25+ regulatory T cells, and there is a direct correlation between CD4+CD25+ 
regulatory cell function and Foxp3 expression (78, 81-83, 179).  To determine whether 
the difference in CD4+CD25+ and CD4+CD25+CD103+ regulatory function between 
females and males correlates with differences in Foxp3 expression, Foxp3 mRNA from 
CD4+CD25+ and CD4+CD25+CD103+ cells was quantified by real-time PCR in C57BL/6 
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mice.  Our results indicated that unlike unfractionated CD4+CD25+ T cells, where little or 
no differences in Foxp3 expression was found between females and males (Figure 10A) 
CD4+CD25+CD103+ from males expressed significantly higher levels of Foxp3, 
compared with females (Figure 10B).  Male CD4+CD25+CD103+ cells expressed 13-fold 
more Foxp3 than female CD4+CD25+CD103+ cells.  Taken together, the above results 
suggest that not only do males produce more CD4+CD25+CD103+  cells which can 
differentially traffic to sites of inflammation, but these cells also appear to exhibit better 
regulatory function than female CD4+CD25+CD103+ cells.  
 
Androgens may modulate CD4+CD25+ regulatory T cell numbers, phenotype and 
function.  
Based on our data showing that adult males may have greater numbers and more 
effective CD4+CD25+ regulatory cells, we hypothesized that sex steroids play a role in 
these differences.  The following experiments were designed to test this hypothesis. 
Castration of mice dramatically decreases levels of circulating estrogens or androgens in 
females or males, respectively (116).  In the following experiments, pre-pubertal (21 days 
of age), female or male mice were castrated and the percentage, function and phenotype 
of CD4+CD25+ determined when the mice reached adulthood.  Briefly, 4 weeks after 
castration, lymph nodes from individual mice were collected, and cells labeled with 
PerCP-anti-CD4, APC-anti-CD25 and PE-CD103 antibodies, then analyzed by FACS®.  
Our results showed that castration of C57BL/6 and SJL males decreased the percentage 
of CD4+CD25+ T cells to levels that were comparable to those found in females (Figure 
11A & B, Table 8a).  The percentage of CD4+CD25+ T cells in SJL females remained 
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unaltered after castration.  We did not find any differences in the percentage of 
CD4+CD25+ T cells after castration of Balb/c male, compared with female mice (Table 
8a).  We also compared the percentages of CD4+CD25+cells from androgen receptor-
deficient male mice (testicular feminization mice; Tfm) with those from wild-type male 
mice.  Interestingly, we found that the percentage of CD4+CD25+ cells was decreased in 
Tfm mice compared with wildtype mice in 3 of 5 experiments and similar to that found in 
castrated mice (Figure 12A & B, Table 8b).  These data, therefore, suggest that 
androgens, and not estrogens may increase the percentage of CD4+CD25+ regulatory cells 
in general. 
Next, we analyzed the effects of androgen on surface marker expression by 
CD4+CD25+ cells.  CD4+CD25+ cells from female, or intact, castrated or Tfm male mice 
were analyzed for the expression of CTLA-4, GITR, CD62L, CD45RB or CD103.  No 
differences were found in the percentage of CD4+CD25+ cells expressing GITR, CD62L 
or CD45RB by CD4+CD25+ in all of the various groups that were compared (Figure 13A 
& B).  However, a significantly higher percentage of CD4+CD25+ T cells from intact 
males expressed CTLA-4 and CD103, compared with female, or castrated or Tfm male 
mice (Figure 13A & B, Table 9).  We also evaluated the mean intensity of expression of 
CTLA-4, GITR, CD62L, CD45RB and CD103 in female, or intact, castrated or Tfm male 
mice, to determine the levels of expression of each marker per cell based on mean 
fluorescence intensity.  There were no consistent differences in the mean fluorescence 
intensity of CD103, CD62L, CD45RB or GITR by female or intact, castrated or Tfm 
male CD4+CD25+ T cells in both experiments (Table 4b, Figure 6C).  However, in both 
experiments, there was a significant difference in the mean fluorescence intensity of 
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expression of CTLA-4, between males and the rest of the groups; intact males showed a 
consistently higher mean fluorescence intensity of CTLA-4 by comparison to females, 
castrated or Tfm males (Table 4b, Figure 6D).  Taken together, these data also suggest 
that both CD103 and CTLA-4 are differentially expressed by CD4+CD25+ cells in intact 
male mice, compared with female or castrated or Tfm male mice, thus reiterating our 
prior findings that their expression may be influenced by sex steroids.                                 
The experiments described above strongly suggested that androgens may 
influence the percentages of CD4+CD25+ regulatory T cells.  To determine whether 
androgens could increase the percentage of CD4+CD25+ regulatory T cells in females, 
sixty-day testosterone (DHT) release pellets or vehicle (control) pellets were implanted 
subcutaneously into the backs of female pre-pubertal (21day old) C57BL/6 mice that 
were then euthanized 4-6 weeks later.  In 2 of 3 experiments, female mice that received 
testosterone-release pellets, had significantly higher levels of CD4+CD25+ regulatory T 
cells, compared with female mice that received only vehicle pellets (Figure 14, Table 8c).  
The levels of CD4+CD25+ in female mice implanted with testosterone pellets were 
comparable to those in male mice (Figure 14).  The CD4+CD25+ cells were also analyzed 
for CD103 expression, but not CTLA-4, GITR, CD62L, CD45RB, since these other 
markers did not appear to be affected by androgens in the castration experiments.  A 
significantly higher percentage of CD4+CD25+ cells from female mice that were treated 
with androgen pellets expressed the CD103 phenotype (Figure 15, Table 9).  These 
results indicated that androgens boost both the percentage of CD4+CD25+ and 
CD4+CD25+CD103+ T cells, further supporting the hypothesis that testosterone may 
augment the potential of these cells in vivo, as well. 
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Having observed that androgens boost both the percentage of CD4+CD25+ and 
CD4+CD25+CD103+ cells, we also investigated whether the presence or absence of 
androgens could affect the function of these cells in vitro.  We therefore harvested 
CD4+CD25+CD103+ from intact female, or intact, castrated or Tfm male mice, or 
CD4+CD25+ cells from androgen pellet-treated female and tested their suppressive 
capacity in in vitro proliferation assays.  In 3 of 3 experiments, proliferation assays 
performed with CD4+CD25+CD103+ cells showed that intact C57BL/6 male mice were 
significantly better than intact female, or castrated or Tfm male mice in suppressing 
CD4+CD25- T cells in vitro (Figure 16, Table 10).  We also performed three different 
proliferation assays with CD4+CD25+ cells from androgen-pellet treated female C57BL/6 
mice versus naive female and male mice.  Our results did not show any significant 
differences in suppression of CD4+CD25- at regulator: effector dilutions of 1:1, 1:2, 1:4, 
1:8, 1:16 and 1:32 (Data not shown). 
Although androgens clearly have an effect on CD103 expression by CD4+CD25+ cells, 
their effect on CD4+CD25+ regulatory cell function is less clear. 
 
Androgens do not have a direct in vitro effect on CD4+CD25+ T cell function. 
Studies have shown that sex steroids can exert their effect on immune cells by 
binding to sex-steroid receptors on these cells.  In order to evaluate the effect of 
androgens on CD4+CD25+ T cells, we first determined by RT-PCR whether these cells 
express androgen receptor (AR) mRNA.  CD4+CD25+ and CD4+CD25- T cells from 
female and male adult mice were sorted to >98% purity, mRNA extracted and the 
androgen receptor mRNA detected by RT-PCR.  Androgen receptor mRNA could be 
42 
  
detected in both CD4+CD25+ as wells as the CD4+CD25- T cells (Figure 17).  These data 
suggest that androgens could possibly act directly on the CD4+CD25+ cells.                                                
The following experiments were designed to determine whether androgens have a 
direct effect on CD4+CD25+ cell function.   We tested the in vitro effect of exogenous 
dihydrotestosterone (DHT) on CD4+CD25+ regulatory T cells, by assessing whether 
direct stimulation with DHT during in vitro proliferation assays has an effect on the 
function of CD4+CD25+ regulatory T cells.  CD4+CD25+ T cells were co-cultured with 
CD4+CD25- T cells in the presence of irradiated spleen cells (antigen presenting cells), 
anti-CD3 and increasing doses of DHT (Figure 18A), or using the highest dose of DHT 
and varying ratios of CD4+CD25+ regulatory cells (Figure 18B).  There was no difference 
in regulatory function of CD4+CD25+ cells treated with either the control vehicle or 
androgen, or for varying ratios of CD4+CD25+ regulatory cells.  This could mean that 
dihydrotestosterone had no direct effect on CD4+CD25+ regulatory T cells in vitro.  
However, since we had co-cultured both CD4+CD25+ and CD4+CD25- cells in the 
presence of dihydrotestosterone, there was a possibility that dihydrotestosterone was also 
acting on the CD4+CD25- cells.  For this reason, we pre-cultured CD4+CD25+ cells with 
dihydrotestosterone before coculturing with CD4+CD25- responders.  Regulatory cells 
were labeled with CFSE, so that they could be distinguished from the APC.  The 
CFSE+CD4+CD25+ T cells were co-cultured overnight in the presence of irradiated 
spleen cells (APC), antiCD3 and 10-8 M DHT (Sigma Aldrich, USA).  At the end of the 
culture period, the CFSE+CD4+CD25+ DHT-treated regulatory T cells were sorted from 
the APC and varying numbers co-cultured with fresh untreated CD4+CD25-cells, APC 
and anti-CD3.  Our results again showed that androgens had no direct effect on 
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CD4+CD25+ regulatory cell function in vitro (Figure 19).  Based on these data, we 
concluded that DHT does not have a direct effect on mature CD4+CD25+ T cells, but may 
exert their effect on regulatory T cells through other compartments such as the thymus or 
at the level of hematopoietic cells.   
Androgens influence CD4+CD25+ regulatory T cells through a direct effect on the 
thymic epithelium. 
As observed in our experiments, androgens do not appear to affect the mature 
peripheral CD4+CD25+ cells directly (at least in vitro), but they may affect the 
development/differentiation of these cells through an effect on the thymic epithelium.  
Alternatively, androgens could directly influence these cells at an early stage in their 
development (i.e., androgens could have an effect on the hematopoietic or bone marrow 
compartment).  Based on the fact that sex steroid receptor mRNA or protein has been 
found in each of these compartments and each can therefore be affected by sex steroids    
(129-137, 180), the following experiments were aimed at determining which 
compartment(s) (i.e, thymic epithelium or hematopoietic) is responsive to sex steroids 
and produces a quantitative and/or qualitative effect on CD4+CD25+ regulatory T cells.  
Castration leads to thymic hypertrophy, which can be reversed by sex steroid 
administration (126).  Moreover, steroid receptors have been identified in both 
thymocytes and thymic epithelium as well as at the level of the bone marrow.  These 
data, coupled with the idea that CD4+CD25+ T cells are thought to originate in the 
thymus and subsequently migrate to the periphery to mediate their function, provide a 
good rationale for performing the following experiments.  By creating bone marrow 
radiation chimeras using wild-type and androgen receptor deficient mice (testicular 
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feminization mice, Tfm), the thymic and the hematopoietic compartments were tested to 
determine whether either or both mediate androgen effects on regulatory T cells. 
The following experiments were designed to determine whether the androgens 
have a direct effect on the hematopoietic (i.e., bone marrow) compartment.  Prepubertal 
(21-day-old) male wild type B6.SJL-ptprca (CD45.1+) mice were gonadectomized, and 
after 4 weeks, the mice were implanted with pellets containing dihydrotestosterone 
(DHT; androgen) or vehicle control (placebo).  One week after implantation of pellets, 
mice were sub-lethally irradiated and bone marrow stem cells (hematopoietic cells) from 
Tfm or C57BL/6 (CD45.2+) mice sorted and transferred into DHT or placebo-treated 
B6.SJL-ptprca (CD45.1+) mice.  The mice were then euthanized 6 weeks after bone 
marrow stem cell transfer.  Cells were collected from lymphoid organs and the CD45 
isotype (CD45.2+) was used as a marker to track transferred cells (see Figure 20 for 
protocol).  The percentage of CD45.2+CD4+CD25+ T cells was determined by FACS®, or 
alternatively, these cells were sorted and analyzed for CD4+CD25+ regulatory T cell 
function in vitro.  We found that although there was a dramatic increase in the percentage 
of CD45.2+CD4+CD25+ cells in all mice receiving the DHT pellets compared to the 
placebo, there were no differences in the percentage of these cells between mice that had 
received bone marrow from wild-type and Tfm mice (Figure 21A).  In these experiments, 
the comparison is between wild-type and Tfm bone marrow.  Therefore, these data 
suggest that the increase in the percentages of CD4+CD25+ cells in response to androgens 
may not be due directly to an effect on  any of the bone marrow (hematopoietic)-derived 
cells since cells from both androgen-sensitive and androgen-insensitive mice were 
equally capable of producing increased numbers of CD4+CD25+ cells.  Interestingly, on 
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the other hand, in the functional assays, the CD45.2+CD4+CD25+ cells from mice injected 
with the wild-type (C57BL/6) bone marrow cells and subcutaneously treated with DHT 
(in vivo), exhibited significantly enhanced regulatory activity in vitro by comparison to 
cells from either the placebo controls or DHT-treated Tfm bone marrow-injected mice 
(Figure 21B).  The inhibitory capacity of the cells from the DHT-treated wild-type bone 
marrow-injected mice was significantly greater at CD4+CD25+ regulatory cell : 
CD4+CD25- responder cell ratios of 1:1, 1:2, 1:4 and 1:8.  These data suggest that 
although androgens may not affect the number of the CD4+CD25+ cells by a direct effect 
on the hematopoietic cells themselves, the androgens do appear to have a positive effect 
on the development of  CD4+CD25+ regulatory cell function.   
The following experiments were designed to determine the effect that androgens 
have on the non-hematopoietic compartment.  Pre-pubertal (21 day old) wildtype 
C57BL/6 (CD45.2+) and Tfm (CD45.2+) mice were subcutaneously implanted with either 
vehicle (placebo) or dihydrotestosterone (DHT) pellets.  After one week, these mice were 
sublethally irradiated and wild type T cell-depleted bone marrow cells from male 
B6.SJL-ptprca (CD45.1) were injected into these mice.  The recipient mice were then 
euthanized 6 weeks after bone marrow transfer (see Figure 22 for protocol).  Cells were 
collected from lymphoid organs and evaluated by FACS® for the percentage of 
CD45.1+CD4+CD25+ T cells.  In this experiment, the non-hematopoietic environment of 
Tfm mice (i.e., thymus and other) will not be responsive to androgens, and since the 
hematopoietic compartment is derived from androgen-sensitive mice, any differences will 
be due to the effect that androgens have on the non-hematopoietic environment.  
Interestingly, under these conditions, there were very large differences in the percentage 
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of CD4+CD25+ cells between wild-type C57BL/6 mice treated with testosterone, and 
either Tfm mice treated with DHT or wild-type C57BL/6 mice treated with placebo 
(Figure 23A).  Wild-type C57BL/6 mice treated with DHT had much greater percentages 
of  both CD4+CD25+ (Figure 23A) and CD4+CD25+CD103+ cells (Figure 23B) than 
either Tfm or placebo-treated wild-type mice.  These data suggest that some component 
of the non-hematopoietic compartment that is responsive to androgens can control the 
percentage of CD4+CD25+ cells.   
Since CD4+CD25+ cells develop primarily in the thymus and the thymic 
epithelium expresses significant levels of androgen receptor, it is highly likely that the 
androgens affect the percentage of CD4+CD25+ cells through the thymic epithelium.  For 
this reason, the following experiments were designed to test whether androgens affect the 
percentages of CD4+CD25+ cells through the thymus.  Pre-pubertal (21-day old) male 
wild-type B6 mice (CD45.2+) were gonadectomized, then 4 weeks later they were 
thymectomized.  Four weeks after thymectomy, these mice were implanted with a fetal 
(Day 14 of gestation) thymus from either the Tfm (androgen receptor-deficient) or 
normal littermates (controls).  After 2 weeks, the mice were implanted with 60-day 
sustained release pellets containing either DHT or placebo.  Mice were sub-lethally 
irradiated then injected with wild-type T cell-depleted bone marrow cells from B6.SJL-
ptprca (CD45.1+) mice.  The recipient mice were then euthanized 6 weeks after bone 
marrow transfer (see Figure 24 for protocol).  Cells were collected from lymphoid organs 
and evaluated by FACS® for the percentage of CD45.1+CD4+CD25+ and CD4+CD25+ 
CD103+ cells.  In this experiment, only the wild-type, and not the Tfm, thymus (i.e., 
lacking a functional androgen receptor), was responsive to the effects of androgen.  Wild-
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type C57BL/6 mice that received the wild-type thymus and were treated with DHT pellet 
exhibited a significant increase in the percentage of CD4+CD25+ and 
CD4+CD25+CD103+  cells compared to mice receiving either the wild-type thymus and 
the placebo, or the Tfm thymus and the placebo or DHT pellet (Figure 25A & B).  Taken 
together, these data suggest that androgens affect the percentage of CD4+CD25+ cells at 
the level of the thymus during CD4+CD25+ development in the thymus.   On the other 
hand, androgens appear to influence the functional development of CD4+CD25+ 
regulatory cells at only a very immature stage in their development (as indicated by the 
results of treatment at the bone marrow level), since they do not appear to directly affect 
the function of mature CD4+CD25+  cells (in the in vitro assays).      
 The overall conclusion is that androgens have a dramatic effect on CD4+CD25+ 
regulatory cell numbers and function in vivo, and it may be through this mechanism that 
males control autoreactive T cells more effectively than females.   
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 Figure 1.  Adult C57BL/6 male mic  have significantly more CD4e
 +CD25+ cells than 
females.  One million lymph node cells from adult female versus male C57BL/6 mice 
 were labeled with anti-CD4 and anti-CD25 antibodies and analyzed by FACS®.   
Stained CD4+ T cells were gated and analyzed for the expression of the CD25 surface  
marker (A).  The percentage of CD4+ T cells that expressed CD25+ (B) were analyzed  
by student’s t test (N=10).  An * indicates a significant difference at p =0.0001. 
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Figure 2.  Adult SJL male mice have significantly more CD4+CD25+ cells than females.   
One million lymph node cells from adult female versus male SJL mice were labeled with  
anti-CD4 and anti-CD25 antibodies and analyzed by FACS®.  Stained CD4+ T cells were  
gated and analyzed for the expression of the CD25 surface marker (A).  The percentage of  
CD4+ T cells that expressed CD25+ (B) were analyzed by student’s t test (N=10).   
An * indicates a significant difference at p <0.0001. 
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Figure 3.  No differences in the percentages of CD4+CD25+ cells between pre-pubertal  
female versus male C57BL/6, SJL and Balb/c mice.  One million lymph node cells from  
pre-pubertal female versus male mice were labeled with anti-CD4 and anti-CD25 antibodies  
and analyzed by FACS®.  Stained CD4+ T cells were gated and analyzed for the expression 
 of the CD25 surface marker (A).  The percentage of CD4+ T cells that expressed CD25+ (B, 
C, D) were analyzed by student’s t test (N=6 or 10).  p >0.05. 
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Figure 4A & B.  No differences in the percentage of CD4 CD25  + + cells expressing  
CD62L, CTLA-4, GITR or CD45RB between adult female and male C57BL/6 mice.   
One million lymph node cells from adult female versus male C57BL/6 mice were 
 labeled with anti-CD4, anti-CD25 and anti-CD62L, CTLA-4 , GITR or CD45RB  
antibodies and analyzed by FACS®.  Labeled CD4+CD25+ T cells were gated and  
analyzed for the expression of these surface markers (A).  The percentage of  
CD4 CD25  + + T cells that expressed CD62L, CTLA-4, GITR or CD45RB (B) 
 were analyzed by student’s t test (N=10).  p >0.05. 
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Figure 4C & D.  There are significant differences in the percentage of CD4 CD25  + + cells 
expressing CD103 between adult female versus male mice.  One million lymph node 
 cells from adult female versus male mice were labeled with anti-CD4, anti-CD25 and a
CD62L or CTLA-4 or GITR or CD45RB or CD103 antibodies and analyzed by FACS®.  
Stained CD4+CD25+ T cells were gated and analyzed for the expression of CD103 (C). 
The percentage of CD4+CD25+ T cells that expressed CD103 (D), were analyzed by  
student’s t test (N=10).  p <0.05. 
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Figure 5.  There is no difference in the levels of CD103 expression by  
pre-pubertal female and male mice.  One million lymph node cells from pre-pubertal  
female versus male mice were labeled with anti-CD4, anti-CD25 and anti-CD103  
antibodies and analyzed by FACS®.  Stained CD4+CD25+  T cells were gated and  
analyzed for the expression of CD103 (A).  The percentage of CD4+CD25+  T cells that 
expressed CD103 (B), were analyzed by student’s t test (N=10).   
 
 
55  
 
 56 
 
A 
0
50
100
150
Me
an
 in
te
ns
ity
 C
D4
+ C
D2
5+
GI
TR
+
Female Male
121.0121.6
0
50
100
150
200
250
300
350
400
M
ea
n 
in
te
ns
ity
 C
D
4+
C
D
25
+ C
D
10
3+
Female Male
309.0 331.1
0
100
200
300
400
500
Me
an
 in
te
ns
ity
 C
D4
+ C
D2
5+
CT
LA
-4
+
Female Male
358.0
258.0
*
0
10
20
30
40
50
Me
an
 in
te
ns
ity
 C
D4
+ C
D2
5+
CD
62
L+
Female Male
38.1 39.0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
1 6 0
M
ea
n 
in
te
ns
ity
 C
D
4+
C
D
25
+ C
D
45
R
B
+
F e m a le M a le
9 5 .2
1 1 6 .3
           CD62L 
 
CD103 CD45RB 
      GITR 
    CTLA-4 
Figure 6A & B.  CD4+CD25+ T cells from adult female and male mice do not exhibit 
 significant differences in the mean intensity of expression of CD62L, GITR, CD45RB,  
or CD103(A), but do exhibit differences in the expression of CTLA-4 (B).  One million 
 lymph node cells from adult female versus male mice were labeled with anti-CD4,  
anti-CD25 and anti-CD62L, CD103, CTLA-4 , GITR or CD45RB antibodies and analyzed 
 by FACS®.  Labeled CD4+CD25+ T cells were gated and analyzed for the mean intensity 
 of expression of CD62L, CD103, CTLA-4, GITR or CD45RB. (N=10).  An * indicates 
 a significant difference at p <0.05. 
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Figure 6C & D.  CD4+CD25+ T cells from adult female, intact or castrated or Tfm 
  male mice do not exhibit significant differences in the mean intensity of  
expression of CD62L, GITR, CD45RB, or CD103 (A), but do exhibit differences 
  in the expression of CTLA-4 (B).  One million lymph node cells from adult female,
 intact or castrated or Tfm male mice were labeled with anti-CD4, anti-CD25 and  
 anti-CD62L, CD103, CTLA-4 , GITR or CD45RB antibodies and analyzed by  
FACS®.  Labeled CD4+CD25+ T cells were gated and analyzed for the mean  
 intensity of expression of CD62L, CD103, CTLA-4, GITR or CD45RB. (N=10).  
 An * indicates a significant difference at p <0.05. 
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Figure 7.  Standard in vitro assay for regulatory T cell function (proliferation assay). 
Varying numbers of CD4+CD25+ cells are co-cultured with a constant number of  
CD4+CD25- responder T cells , irradiated spleen cells (1 x 105 or 2 x 105 cells) as 
antigen presenting cells (APC) and anti-CD3 antibody (0.5 mg/ml) for 3 days.  H3-
thymidine (0.5mCi) is added for the last 18 hrs.  Cells are then harvested and H3-
thymidine incorporation measured by β-scintillation counter. 
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Figure 8.  Male CD4+CD25+ cells suppress significantly better than female 
CD4+CD25+ cells.  Female and male CD4+CD25+ T cells were harvested from adult 
C57BL/6 or SJL mice, and co-cultured with male CD4+CD25- responder T cells in the 
presence of male irradiated spleen cells (APC) and anti-CD3 antibody.  CD4 CD25+ + 
regulatory T cell function was tested at various responder : regulatory cell ratios in 
C57BL/6 mice  (A) or in SJL (B) mice.  An * indicates a significant difference at p 
<0.05.   
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Figure 9.  Male CD4+CD25+CD103+ cells suppress significantly better than female CD4+CD25+ 
cells.  Female and male CD4+CD25+CD103+  T cells were harvested from adult C57BL/6 or SJL 
mice, and co-cultured with male CD4+CD25- responder T cells in the presence of male irradiated 
spleen cells (APC) and anti-CD3 antibody.  CD4+CD25+CD103+ regulatory T cell function was 
tested at various responder : regulatory cell ratios in C57BL/6 mice  (A) or in SJL (B) mice.  An * 
indicates a significant difference at p <0.05.   
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Figure 10.  CD4+CD25+CD103+, but not CD4+CD25+ cells,  from males express 
significantly higher levels of Foxp3 compared with females.  Foxp3 mRNA from 
CD4+CD25+ (A) and CD4+CD25+CD103+ (B) cells, harvested from female or male 
C57BL/6 mice were quantified by real-time PCR and analyzed for the fold 
difference in Foxp3 expression, normalized relative to GAPDH mRNA expression.  
An * indicates a significant difference at p <0.05 between female and male 
expression of Foxp3.   
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Figure 11.  Castration in C57BL/6 and SJL males decreases the percentage of CD4+CD25+ T 
cells to levels comparable to those found in females.  Pre-pubertal female or male mice were 
either sham castrated or castrated and the percentage of CD4+CD25+ cells determined at 
adulthood.  Lymph nodes from individual mice were collected, and cells labeled with anti-CD4 
and anti-CD25 antibodies, then analyzed by FACS®.    The percentage of CD4+CD25+ T cells 
in castrated male C57BL/6 (A) or castrated female and male SJL (B) mice was determined.  
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Figure 12.  Testicular feminization mice (Tfm) have a lower percentage of CD4+CD25+  
cells compared with wild-type male mice.  Individual lymph node cells from adult Tfm,  
castrated or intact wild-type C57BL/6 male mice were collected, and labeled with anti-CD4 
 and anti-CD25 antibodies, then analyzed by FACS®.   Stained CD4+ T cells were gated and  
analyzed for the expression of the CD25 surface marker (A).  An * indicates a significant  
difference at p <0.05.   
65 
 66 
 
 
GITR or CD45RB (B) was determined.  An * indicates a significant difference at p <0.05.   
markers (A).  The percentage of CD4+CD25+ T cells that expressed CD103, CD62L, CTLA-4, 
Stained  CD4+CD25+ T cells were gated and analyzed for the expression of these surface  
 and anti-CD62L, CTLA-4, GITR, CD45RB, or CD103 antibodies and analyzed by FACS®.    
 intact wild-type male or castrated or Tfm male mice were labeled with anti-CD4, anti-CD25 
castrated or Tfm male mice. One million lymph node cells from adult wild-type female, 
 CD103, but not CD62L, CTLA-4, GITR or CD45RB compared with wild-type female, or  
Figure 13.  CD4+CD25+ cells from intact wild-type male mice express significantly more 
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Figure 14.  Androgens increase the percentage of CD4+CD25+ regulatory T cells in 
 females.  Sixty-day testosterone (DHT) release pellets or vehicle (control) pellets were w
implanted subcutaneously into the backs of female pre-pubertal C57BL/6 mice that were 
 then  euthanized 4-6 weeks later.  Stained CD4+ T cells from normal male or female  
mice implanted with DHT or vehicle release pellets were gated and analyzed for the  
expression of CD25 (A).  The percentages of CD4+CD25+ in female mice implanted 
 with DHT or vehicle release pellets were compared to those from male mice (B).  
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Figure 15.  Treatment with androgens results in an increase in the percentage of  
CD4+CD25+CD103+ regulatory T cells in females.  Sixty-day testosterone (DHT) release 
 pellets or vehicle (control) pellets were implanted subcutaneously into the backs of 
 female pre-pubertal C57BL/6 mice that were then euthanized 4-6 weeks later.  Stained 
 CD4+CD25+ T cells from normal female or female mice implanted with DHT or vehicle 
 release pellets were gated and analyzed for the expression of CD103 (A).   
The percentages of CD4+CD25+CD103+ in female mice implanted with DHT or vehicle 
 release pellets were compared to those from normal female mice (B).  An * indicates a  
significant difference at p <0.05.   
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Figure 16.   Intact C57BL/6 male CD4+CD25+CD103+ cells suppress significantly better than 
intact female, or castrated or Tfm male CD4+CD25+CD103+ cells.  Intact female or male, or 
castrated or Tfm male CD4+CD25+CD103+ cells were harvested from adult mice, and co-
cultured with male CD4+CD25- responder T cells in the presence of male irradiated spleen 
cells (APC) and anti-CD3 antibody.  CD4+CD25+CD103+ regulatory T cell function was 
tested at various responder : regulatory cell ratios.  An * indicates a significant difference at p 
<0.05.   
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Figure 17.  Androgen receptor mRNA is expressed by both CD4+CD25+  and 
CD4+CD25-   T cells.  CD4+CD25+ and CD4+CD25- T cells from female and male 
adult mice were sorted to >98% purity, mRNA extracted and the androgen receptor 
mRNA detected by RT-PCR.  mRNA from mouse testes was used as positive control. 
Rg = regulatory cells, Ef = effector cells, Tst = testes 
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Figure 18.  Treatment of CD4+CD25+ cells with androgens in vitro does not affect their 
regulatory function.   A constant number of CD4+CD25+  T cells was co-cultured with 
CD4+CD25- T cells in the presence of irradiated spleen cells (APC), anti-CD3 and increasing 
doses of DHT (A), or using the highest dose of DHT (10-8) and varying ratios of CD4+CD25+ 
regulatory cells (B).   
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Figure 19.   Pretreatment of CD4+CD25+ with androgens has no direct effect on 
regulatory function of CD4+CD25+ cells.  CFSE+CD4+CD25+ T cells were co-cultured 
overnight in the presence of irradiated spleen cells (APC), antiCD3 and 10-8 M DHT 
(Sigma Aldrich, USA).  At the end of the culture period, the CFSE+CD4+CD25+ DHT-
treated regulatory T cells were sorted from the APC and varying numbers co-cultured 
with fresh untreated CD4+CD25-cells, APC and anti-CD3.   
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igure 21.  Androgens influence the function but not the percentage of CD4 CD25+ cells 
through an effect on bone marrow-derived cells.  Bone marrow stem cells (hematopoietic 
cells) from Tfm (androgen receptor deficient) or wildtype C57BL/6 mice (CD45.2 ) were 
sorted and transferred into castrated dihydrotestosterone (DHT) or placebo-treated 
B6.SJL-ptprca (CD45.1 ) mice.  The mice were then euthanized 6 weeks after bone 
marrow transfer.  Cells were collected from lymphoid organs and the CD45 isotype 
(CD45.2 ) was used as a marker to track transferred cells.  The percentage of 
CD45.2 CD4 CD25   T cells was determined by FACS  (A), or alternatively, these cells 
were sorted for CD45.2 CD4 CD25  cells and analyzed for regulatory T cell function in 
vitro (B).    An * indicates a significant difference at p <0.05.  WT = wildtype, BM = 
bone marrow, DHT =dihydrotestosterone.   
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 Figure 22.   Protocol to test for the influence of androgens on the numbers and 
phenotype of CD4+CD25+ cells through an effect on the non-bone marrow-derived 
compartment.   
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Figure 23.  Androgens influence the percentages of CD4+CD25+ and 
CD4+CD25+CD103+ cells through an effect on the non-bone marrow-derived 
compartment.  T cell-depleted bone marrow cells (hematopoietic cells) from male 
B6.SJL-ptprca (CD45.1+) mice were sorted and transferred into placebo or DHT-treated, 
Tfm (androgen receptor deficient) or wildtype C57BL/6 mice (CD45.2+).  Mice were 
then euthanized 6 weeks after bone marrow transfer.  Cells were collected from lymphoid 
organs and the CD45 isotype (CD45.1+) was used as a marker to track transferred cells.  
The percentage of CD4+CD25+CD45.1+ (A) or CD25+CD45.1+CD103+ (B) T cells was 
determined by FACS®.  An * indicates a significant difference at p <0.05.  WT = 
wildtype, BM = bone marrow, PLA = placebo, DHT = Dihydrotestosterone   
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 Figure 24.  Protocol to test for the influence of androgens on the numbers and 
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Figure 25.  Androgens influence the percentages of CD4+CD25+ and CD4+CD25+CD103+ 
cells through an effect on the thymus.  T cell-depleted bone marrow cells (hematopoietic 
cells) from male B6.SJL-ptprca (CD45.1+) mice were sorted and transferred into placebo 
or DHT-treated wild-type C57BL/6 mice that had been castrated and thymectomized and 
implanted with Tfm or wildtype C57BL/6 (CD45.2+) donor thymus.   Mice were then 
euthanized 6 weeks after bone marrow transfer.  Cells were collected from lymphoid 
organs and the CD45 isotype (CD45.1+) was used as a marker to track transferred cells.  
The percentage of CD4+CD25+CD45.1+ (A) or CD25+CD45.1+CD103+ (B) T cells was 
determined by FACS®.   An * indicates a significant difference at p < 0.05.                       
WT = wildtype, BM = bone marrow, T = transplant, PLA = placebo,                                  
DHT = Dihydrotestosterone   
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Table 1.  Female/Male Ratios in Autoimmune Diseases  
 
Autoimmune disease                                    Female to male ratio 
Hashimoto’s disease     50-to-1 
Sjogren's syndrome       9-to-1 
Systemic lupus erythematosus         9-to-1 
Antiphospholipid syndrome      9-to-1 
Primary biliary cirrhosis         9-to-1 
Mixed connective tissue disease        8-to-1 
Chronic active hepatitis       8-to-1 
Graves' disease      7-to-1 
Rheumatoid arthritis        4-to-1 
Scleroderma       3-to-1 
Chronic idiopathic thrombocytopenic purpura      2-to-1 
Multiple sclerosis       4-to-1 
From the American Autoimmune Related Diseases Association, Michigan 
National Bank Building, 15475 Granot Ave, Detroit, MI 48205, (313) 371-8600.  
http://www.womenshealth.gov/OWH/pub/autoimmune/index.htm 
 
 
  
Table 2.  Analysis of the percentage of CD4+CD25+ T cells in female and male mice. 
 
                                    Exp#1                             Exp#2                              Exp#3                             Exp#4                               Exp#5                                Exp#6                              Exp#7 
 ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ 
C57BL/6 19.83±      
0.63(3) 
(9 wks)   
26.40*±     
0.63(3) 
(9 wks) 
*P<0.0001 
16.49±      
0.35(3) 
(10 wks)  
20.58*±     
0.23(3) 
(10 wks 
*P=0.006   
10.96±      
0.65(10) 
(9 wks) 
13.30*±     
0.50(9) 
(9 wks)  
*P=0.03     
12.89±      
0.60(5) 
(10 wks)   
15.80*±     
0.97(5) 
(10 wks) 
*P=0.034   
13.10± 
0.23(10) 
(9 wks)     
15.78*±     
0.51(10) 
(9 wks) 
*P=0.0001 
15.27±      
1.61(5) 
(8 wks) 
14.66±    
1.19(5) 
(8 wks) 
P=0.765    
9.60±        
0.44(10) 
(9 wks)     
11.60±      
0.55(10)  
(9 wks)  
P=0.063    
BALB/C  16.78±      
0.95(6) 
(10 wks)   
17.10±      
0.85(6) 
(10 wks)  
P=0.412    
12.00±      
1.39(5) 
(12 wks)   
11.90±      
0.28(4) 
(12 wks) 
P=0.555    
9.70±        
0.48(5)  
(8 wks)     
11.70*±     
0.40(8)  
(8 wks) 
*P=0.041   
        
SJL 10.20± 
0.90(8) 
(8 wks)     
11.36± 
0.78(10) 
(8 wks)    
P=0.081    
12.58± 
0.27(5) 
(9 wks)     
15.93*± 
1.12(5) 
(9 wks)  
*P=0.035   
 9.72± 
0.41(9) 
(9 wks)     
10.70± 
 0.32(9) 
(9 wks)   
P=0.312    
16.12± 
0.64 (10) 
(10 wks)   
16.98± 
0.54(9) 
(10 wks)  
P=0.786    
15.30± 
1.31(5) 
(8 wks)     
24.18*± 
1.71(5) 
(8 wks) 
*P=0.003  
6.60± 
0.35(10) 
(6 wks)     
11.45*± 
1.10(10) 
(6 wks)  
*P=0.005   
7.56± 
0.23(10) 
 (5 wks)    
10.30*±     
0.34(10) 
(5 wks) 
*P<0.0001 
D011.10  3.50± 
0.23(10) 
(6-8wks)   
6.40*± 
0.37(9) 
(6-8wks)  
*P=0.040   
            
 
 
One million lymph node cells from adult female versus male mice of varying strains, were labeled with 
anti-CD4 and anti-CD25 antibodies and analyzed by FACS®.  The percentage of CD4+ T cells that 
expressed CD25+ is presented as Mean ± SEM.  Data were analyzed by student’s t test. * = p < 0.05.  
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Table 3.  Analysis of the percentage of CD4+CD25+CD103+ T cells in female and male 
                mice. 
 
                                           Exp#1                                Exp#2                                  Exp#3                                  Exp#4                                   Exp#5                              Exp#6                        
 
 
♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ ♀ ♂ 
C57BL/6   31.95±       
1.91(3) 
( 9 wks)     
51.40*± 
1.63 (3) 
(9 wks) 
*P<0.0003  
14.90± 
0.69(3) 
(10 wks)     
22.04*± 
1.58 (3) 
(10 wks)  
*P=0.014    
13.78± 
0.79(10) 
(9 wks)       
21.03*± 
1.56(10) 
(9 wks)    
*P=0.0007  
21.43± 
2.13(5) 
(8 wks)       
28.69*± 
2.62(5) 
(8 wks)    
*P=0.0054  
24.99± 
0.55(10) 
(9 wks)       
28.44*± 
1.27(10) 
(9 wks)    
*P=0.023    
24.95± 
0.46(13) 
(8-9wks)     
29.61*± 
1.01(13) 
(8-9wks)  
*P=0.008    
BALB/C     13.34± 
0.57(6) 
(8 wks)      
18.65*± 
0.94(8) 
(8 wks) 
*P=0.0041  
          
SJL 13.14±        
1.24(8) 
(8 wks)       
17.70*± 
1.35(10) 
(8 wks)     
*P=0.0005  
13.29± 
1.12(5) 
(8 wks)       
15.40± 
1.20(5) 
(8 wks)     
P=0.055      
16.57± 
0.90(10) 
(10 wks)     
17.95± 
0.81(9) 
(10 wks)  
P=0.324      
15.0± 
0.71(5) 
(9 wks) 
18.4* ± 
0.18(5) 
(9 wks) 
*p=0.0003 
    
anti-CD25 and anti-CD103 antibodies and analyzed by FACS®.  The percentage of CD4+CD25+
 
One million lymph node cells from adult mice of varying strains were labeled with anti-CD4, 
T cells expressing CD103+ is presented as Mean ± SEM.  Data were analyzed by student’s t 
 test. * = p < 0.05. 
 
 
  
Table 4a.  Mean intensity of expression of CD103, CD45RB, CTLA-4, GITR, and 
       CD62L by female versus male CD4+CD25+ T cells.   
 
                                             Exp#1                                Exp#2                         Exp#3                                          
 
 
♀ ♂ ♀ ♂ ♀ ♂ 
CD62L 38.1 ±  
0.92 (10) 
( 9 wks)     
39.0 ±  
1.2 (10) 
( 9 wks)   
54.3 ±  
1.7(3) 
( 9 wks)     
50.4 ±  
1.7(3) 
( 9 wks)  
43.6 ±  
0.68 (10) 
( 9 wks)     
49.0 ±  
0.34 (10) 
( 9 wks)   
 
GITR 186.4 ±  
8.0 (10) 
( 9 wks)     
223.2*±  
10.7 (10) 
( 9 wks) 
 p=0.013    
121.6 ±  
2.6 (10) 
( 9 wks)     
121.0 ±  
5.1 (10) 
( 9 wks)  
 
112.8 ±  
1.73 (10) 
( 9 wks)    
 
100.6 ±  
1.23 (10) 
( 9 wks)    
 
CD45RB 95.2 ±  
3.0 (10) 
( 9 wks)     
116.3* ±  
7.5 (10) 
( 9 wks)  
p=0.018 
640.5 ±  
11.2 (3) 
( 9 wks)     
605.0 ±  
16.0 (3) 
( 9 wks) 
 
789.0 ±  
9.7 (10) 
( 9 wks)     
796.9 ±  
11.5 (10) 
( 9 wks) 
 
CTLA-4 235.3 ±  
9.3 (10) 
( 9 wks)     
273.0*±  
15.3 (10) 
( 9 wks)  
p=0.04      
272.0 ±  
0.4 (3) 
( 9 wks)     
336.2*±  
1.8 (3) 
( 9 wks) 
p=0.035      
258.0 ±  
8.4 (10) 
( 9 wks)     
358.0*±  
18.9 (10) 
( 9 wks)    
p=0.00032 
CD103 308.9 ±  
6.4 (10) 
( 9 wks)     
331.1 ±  
9.6 (10) 
( 9 wks) 
 
651.2 ±  
51.1 (3) 
( 9 wks)     
811.4* ±  
2.4 (3) 
( 9 wks)  
p=0.035    
863.3 ±  
55.3 (10) 
( 9 wks)     
911.0 ±  
20.5 (10) 
( 9 wks) 
 
 
One million lymph node cells from adult female versus male mice were labeled with 
 anti-CD4, anti-CD25 and anti-CD62L, CD103, CTLA-4 , GITR or CD45RB antibodies 
 and analyzed by FACS®.  Labeled CD4+CD25+  T cells were gated and analyzed for the 
 mean intensity of expression of CD62L, CD103, CTLA-4, GITR or CD45RB.  
 An * indicates a significant difference at p <0.05. 
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Table 4b.  Mean intensity of expression of CD103, CD45RB, CTLA-4, GITR, and CD62L 
                   by intact male versus female, castrated or Tfm male CD4+CD25+ T cells.   
 
 
    ♀ 
 
 Exp#1         
  ♂ 
 
 Exp#1         
Castrated ♂ 
 
 Exp#1         
 Tfm ♂ 
 
 Exp#1         
  ♀ 
 
 Exp#2         
  ♂ 
 
 Exp#2         
Tfm ♂ 
 
 Exp#2         
CD62L 38.1 ±  
0.92 (10) 
( 9 wks)     
39.0 ±  
1.2 (10) 
( 9 wks)   
 
43.0 ±  
0.75 (10) 
( 9 wks)     
41.3 ±  
0.85 (10) 
( 9 wks)   
      
54.3 ±  
1.7(3) 
( 9 wks)     
50.4 ±  
1.7(3) 
( 9 wks)  
   
64.6 ±  
3.1 (3) 
( 9 wks)  
  
GITR 186.4 ±  
8.0 (10) 
( 9 wks)     
223.2*±  
10.7 (10) 
( 9 wks) 
p=0.022   
133.6 ±  
5.1 (10) 
( 9 wks)     
160.4 ±  
3.5 (10) 
( 9 wks)   
      
121.6 ±  
2.6 (10) 
( 9 wks)     
121.0 ±  
5.1 (10) 
( 9 wks)  
 
118.0 ±  
3.5 (10) 
( 9 wks)  
 
CD45RB 95.2 ±  
3.0 (10) 
( 9 wks)     
116.3* ±  
7.5 (10) 
( 9 wks) 
p=0.020 
95.7 ±  
3.9 (10) 
( 9 wks)     
81.5 ±  
3.0 (10) 
( 9 wks)  
    
640.5 ±  
11.2 (3) 
( 9 wks)     
605.0 ±  
16.0 (3) 
( 9 wks) 
 
596.2 ±  
19.1 (3) 
( 9 wks 
CTLA-4 235.3 ±  
9.3 (10) 
( 9 wks)     
273.0*±  
15.3 (10) 
( 9 wks) 
p=0.031      
216.5 ±  
8.0 (10) 
( 9 wks)     
225.3 ±  
8.8 (10) 
( 9 wks)  
        
272.0 ±  
0.4 (3) 
( 9 wks)     
336.2*±  
1.8 (3) 
( 9 wks) 
p=0.040      
203.7±  
1.8 (3) 
( 9 wks)   
     
CD103 308.9 ±  
6.4 (10) 
( 9 wks)     
331.1 ±  
9.6 (10) 
( 9 wks) 
     
326.6 ±  
7.4 (10) 
( 9 wks)     
301.4 ±  
6.1 (10) 
( 9 wks) 
     
651.2 ±  
51.1 (3) 
( 9 wks)     
811.4* ±  
2.4 (3) 
( 9 wks)  
p=0.024    
483.0 ±  
15.2 (3) 
( 9 wks)  
    
 
One million lymph node cells from intact male versus female, castrated or Tfm male mice 
 were labeled with anti-CD4, anti-CD25 and anti-CD62L, CD103, CTLA-4 , GITR or 
 CD45RB antibodies and analyzed by FACS®.  Labeled CD4+CD25+ T cells were gated 
 and analyzed for the mean intensity of expression of CD62L, CD103, CTLA-4, GITR or 
CD45RB.  An * indicates a significant difference at p <0.05, with males being significantly 
higher than female and castrated male (Exp#1) or female and Tfm male (Exp#2).
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      Table 5a.  Absolute numbers of CD4+CD25+ T cells in female and male mice. 
 
                                                                                 Exp#1                                                   Exp#2                                                    Exp#3                                      
 
 ♀  ♂ ♀ ♂ ♀ ♂ 
C57BL/6  5.0 x 105± 
41238(10) 
*6.6 x 105± 
58711(10) 
p = 0.035 
8.3 x 105± 
149470(4) 
*1.3  x 106± 
154520(5) 
p = 0.044 
1.1 x 106± 
168880(5) 
1.4 x 106± 
237710(5) 
 
BALB/C     4.4 x 105± 
90035(6) 
*1.1 x 106± 
101410(6) 
p = 0.002 
2.14 x 106± 
92502 (8) 
2.5 x 106± 
221140(8) 
 
 
 
 
 
SJL 7.7 x 106± 
493930(9) 
9.1 x 106± 
437760(9) 
 
4.4 x 106± 
248990(9) 
 
*5.1 x 106± 
158470(9) 
p = 0.029 
3.0 x 106± 
173040(10) 
 
*3.7 x 106± 
181800(10) 
 p = 0.008 
 
 
 
 
 
 
 
 
 
 
 
 
       Table 5b.  Absolute numbers of CD4+CD25+CD103+ T cells in female and male mice. 
 
                                        Exp#1                                     Exp#2                                        Exp#3                                    Exp#4                                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ♀  ♂ ♀ ♂ ♀ ♂ ♀ ♂ 
C57BL/6  1.2 x 105± 
3820 (9) 
*1.9 x 105± 
11715(9) 
p<0.0001 
3.5 x 105± 
11761(4) 
3.9 x 105± 
23296(5) 
 
4.7 x 105± 
13655(5) 
*6.1 x 105± 
10563(5) 
p =0001 
1.1 x 105± 
76541(6) 
*1.8 x 105± 
65432(6) 
p<0.0001 
BALB/C     7.7 x 104± 
15364 
*2.1 x 105± 
14687 
p<0.0001 
5.0 x 105± 
51436 (10) 
*6.8 x 105± 
56608(10) 
p =0.031 
    
SJL 5.5x 105± 
55930 (8) 
6.4 x 105± 
48633 (9) 
 
7.6 x 105± 
47922 (10) 
*9.3 x 105± 
51548 (10) 
p =0.025 
5.7 x 105± 
30159 (7) 
*6.8x 105± 
36214 (8) 
p =0.041 
5.8 x 105± 
82450 (5) 
6.9 x 105± 
72415 (5) 
 
One million lymph node cells from adult mice of varying strains were labeled with 
 anti-CD4, anti-CD25(a) and anti-CD103(b) antibodies and analyzed by FACS®.  Total  
numbers were then calculated using total cell counts and the results of FACS® analysis. 
Data are represented as Mean ± SEM.  Data were analyzed by student’s t test.   
An * indicates a significant difference at p <0.05. 
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Table 6a.  Comparison of CD4+CD25+ T cell regulatory function between adult 
                   female and male C57BL/6 mice. 
 
Experiment Sex / inhibition           1:1          1:2          1:4          1:8          1:16 
♀ (9 wks) 
    ―  
14572.3± 
2500.0 
36145.8± 
1320.9 
53698.8± 
4491.0 
67401± 
5554.2 
84540± 
3104.9 
 
 
Exp # 1 
♂ (9wks) 
    ― 
10831.3± 
552.8 
26274.8± 
1831.9 
48461.8± 
2951.6 
49082.0± 
4836.2 
63060.3± 
4399.0 
♀ (10wks) 
    ― 
48624.5± 
2135.7 
45010.8± 
2967.9 
49141.0± 
2036.2 
63541.3± 
1977.7 
50430.3± 
4524.3 
 
 
Exp # 2 
 ♂ (10wks) 
    ― 
47430.7± 
639.6 
45971.0± 
2896.6 
47372.8± 
1236.9 
52883.8± 
4382.0 
45085.3± 
7416.5 
♀ (9 wks) 
    ―  
27953.5± 
2495.9 
39369.8± 
3316.3 
60868.7± 
2508.2 
73847.7± 
686.6 
75616.5± 
695.5 
 
 
Exp #3 
♂ (9wks) 
    ― 
39825.8± 
6009.7 
42554.8± 
3662.6 
45765.7± 
3359.0 
77239.3± 
7340.6 
71425.0± 
6793.0 
♀ (10wks) 
     ↓  
16609.0± 
2335.5 
19423.0± 
1295.8 
23104.0± 
1046.3 
26403.8± 
1912.8 
33724.0± 
1316.1 
 
 
Exp #4 
 ♂ (10wks) 
    ― 
*7439.2± 
656.3 
*11353.8± 
943.4 
*14740.8± 
937.2 
*20822.0± 
1926.6 
33049.2± 
2199.9 
♀ (9 wks) 
     ↓  
17887.0± 
1633.0 
30733.5± 
4327.3 
34856.3± 
3184.2 
45629.5± 
2972.3 
58450.2± 
5484.7 
 
 
Exp# 5 
 ♂ (9wks) 
    ― 
*8787.5± 
687.8 
*15743.2± 
1421.5 
*29981.7± 
3013.4 
*37531.5± 
2284.3 
*46227.5± 
8891.5 
♀ (8 wks) 
    ―  
4105.8± 
249.7 
11102.0± 
2451.1 
27744.7± 
2312.0 
44579.3± 
4263.4 
54440.0± 
1401.2 
 
 
Exp # 6 
 ♂ (8 wks) 
    ― 
3631.7± 
389.1 
6471.0± 
729.2 
20020.8± 
1261.8 
44800.3± 
2933.3 
55991.5± 
3653.8 
♀ (9 wks) 
     ↓  
2702.0± 
295.0 
9547.5± 
798.6 
26602.3± 
713.9 
42807.7± 
3933.8 
62084.2± 
3964.2 
 
 
Exp # 7 
 ♂ (9wks) 
    ― 
*1789.5± 
195.6 
*4240.2± 
243.3 
*9438.0± 
1407.3 
*19332.0± 
2195.6 
*32101.8± 
2235.4 
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Table 6b.  Comparison of CD4+CD25+ T cell regulatory function between adult 
                   female and male SJL mice. 
 
Experiment Sex / inhibition           1:1          1:2          1:4          1:8          1:16 
♀ (8 wks) 
    ― 
47710 ± 585 77378 ± 3519 104669 ± 4920 
 
116186 ± 6298 127992 ± 3133  
 
Exp # 1 
♂ (8 wks) 
    ― 
40939 ± 1763 53008 ± 2658 95212 ± 5496 102979 ±4603 113525 ±7131 
♀ (9 wks) 
     ↓ 
10456 ±1000 23791 ± 1269 27301 ± 2464 44787 ±10154 53657 ± 5059  
 
Exp # 2 
 ♂ (9 wks)     ― 
9823 ±1030 *10858 ± 2193 *20715 ± 4302 *30895 ± 2184 *35758 ± 5516 
♀ (9 wks) 
     ↓ 
7500 ±1120 
 
24700 ± 3330 
 
30800 ± 3460 
 
41200 ± 1290 
 
51200 ± 5850 
 
 
 
Exp #3 
♂ (9wks) 
    ― 
6240 ± 1050 
 
*15400 ±1670 
 
*21800 ± 3490 
 
*38000 ± 2340 
 
51100 ± 3640 
 
♀ (10wks) 
    ― 
48934 ± 2013 70421 ± 4816 78583 ± 4970 93743 ± 4520 104246 ± 4270  
 
Exp #4 
 ♂ (10wks)     ― 
49894 ±1268 67411 ± 1309 76287 ± 3000 99949 ± 7000 101658 ± 4044 
♀ (8 wks) 
    ― 
29735 ± 2499 40370 ± 2322 67869 ±3345 103446 ± 3421 107567 ± 4356  
 
Exp# 5 
 ♂ (8wks)     ― 
28549 ±1197 37831 ±1309 61982 ± 2939 94658.5± 5432 101658 ± 6754 
 
CD4+CD25- responder cells were co-cultured with varying numbers of adult female versus 
 male CD4+CD25+ regulatory T cells, APCs, and 0.5 mg/ml anti-CD3 for three days, and 
 subsequently pulsed with 3H-Thymidine for 18 hours.  Cells were harvested and analyzed 
 for 3H-Thymidine uptake (counts per minute, CPM).   ―  = no difference; ↓=  inhibition 
by females < males.  Data are represented as Mean CPM ± SEM. 
Data were analyzed by student’s t test.  An * indicates a significant difference at p <0.05. 
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Table 7a.  Comparison of CD4+CD25+CD103+ T cell regulatory function between 
                  female and male C57BL/6  mice. 
 
                                                    Exp#1                                Exp#2                             Exp#3                              Exp#4                                Exp#5                            
 
Experiment Sex / inhibition           1:1          1:2          1:4          1:8          1:16 
♀ (9 wks) 
    ↓ 
42204 ± 3080 73579 ±4646 99767 ±3620 102436 ± 5390 121766 ± 1723  
 
Exp # 1 
♂ (9 wks) 
    ― 
*13736 ± 766 *43694 ± 716 *65387 ± 2056 95309 ± 1766 *100302 ±4264 
♀ (10 wks) 
     ↓ 
4426 ± 1579 8842 ± 1525 19752 ± 1314 28007 ± 5262 40073 ± 1496  
 
Exp # 2 
 ♂ (10 wks)     ― 
*675 ± 58 *3731 ±884 *10934 ± 1591 *17697 ± 1836 35815 ± 4878 
♀ (9 wks) 
    ― 
 12418 ± 876 28420 ± 2506 48087 ± 5278 60949 ± 5322  
 
Exp #3 
♂ (9 wks) 
    ― 
 13353 ± 709 31139 ± 5176 45781 ± 5581 64992 ± 8833 
♀ (8 wks) 
     ↓ 
6700 ± 1017 14864 ± 1362 38207 ± 9175 81501 ± 9164   
 
Exp #4 
 ♂ (8 wks)     ― 
*3025 ± 521 *9967 ± 761 *18886 ± 1876 *38660 ± 2000  
♀ (9 wks) 
     ↓ 
13183 ±2537 20071 ± 5337 26712 ± 3426 49560 ± 1523 48136 ± 6672  
 
Exp# 5 
 ♂ (9 wks)     ― 
*5229 ± 256 *14080 ± 914 24809 ± 2545 47035 ±4467 *37716 ± 4692 
 
CD4+CD25- responder cells were co-cultured with varying numbers of adult female versus 
 male CD4+CD25+CD103+ regulatory T cells, APCs, and 0.5 mg/ml anti-CD3 for three 
 days, and subsequently pulsed with 3H-Thymidine for 18 hours.  Cells were harvested 
 and analyzed for 3H-Thymidine uptake (counts per minute, CPM).   ―  = no difference; 
 ↓=  inhibition by females < males.  Data are represented as Mean CPM ± SEM. 
Data were analyzed by student’s t test.  An * indicates a significant difference at p <0.05. 
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Table 7b.  Comparison of CD4+CD25+CD103+ T cell regulatory function between 
                  female and male SJL mice. 
 
 
 
Experiment Sex / inhibition            1:1          1:2          1:4          1:8          1:16 
♀ (8 wks) 
    ― 
2879 ± 195 5559 ± 1006 12335 ± 2206 11262 ± 669 15619 ± 1824  
 
Exp # 1 
♂ (8 wks) 
    ― 
1589 ± 216 3425 ± 233 10815 ± 1649 12558 ± 1354 15768 ± 1006 
♀ (9 wks) 
     ↓ 
7570 ± 758 9220 ± 282 14000 ± 1760 24900 ± 3250 26700 ± 1580  
 
Exp #2  
♂ (9 wks) 
    ― 
*3810 ± 594 *5790 ± 916 *10100 ± 700 *11500 ± 1710 25400  ± 1570 
♀ (8 wks) 
    ― 
1042 ± 114 1779 ± 258 3430 ± 761 5401 ± 693 9290 ± 1221  
 
Exp #3 
♂ (8 wks) 
    ― 
866 ± 69 1104 ± 119 3107 ± 348 4884 ± 699 8196 ± 958 
 
CD4+CD25- responder cells were co-cultured with varying numbers of adult female versus 
 male CD4+CD25+CD103+ regulatory T cells, APCs, and 0.5 mg/ml anti-CD3 for three 
 days, and subsequently pulsed with 3H-Thymidine for 18 hours.  Cells were harvested 
 and analyzed for 3H-Thymidine uptake (counts per minute, CPM).   ―  = no difference; 
 ↓=  inhibition by females < males.  Data are represented as Mean CPM ± SEM. 
Data were analyzed by student’s t test.  An * indicates a significant difference at p <0.05. 
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Table 8a.  Analysis of the percentage of CD4+CD25+                             Table 8b.  Analysis of the percentage of CD4+CD25+  
                 T cells in castrated mice.                                                                              T cells in Tfm male mice. 
       Sham  castrated 
    or naive wild-type. 
              Castrated 
Sex 
treated 
♀ ♂ ♀ ♂ 
Exp#1 
(C57BL/6) 
10.96±0.65(10) 
(9 wks) 
13.30*± 0.50(9) 
(9 wks)         
10.16 ±0.13(9) 8.20 ±0.48 (9) 
(9 wks) 
Exp#2 
(SJL) 
8.46±0.18(10) 
(7 wks) 
10.51*±0.58(9) 
(7 wks) 
7.93±0.13(9) 
(7 wks) 
8.76±0.26(9) 
(10 wks) 
Exp#3 
(Balb/c) 
6.23±0.88(3) 
(7 wks) 
7.91±0.26(3) 
(10 wks) 
6.70±0.43(3) 
(7 wks) 
6.34±0.23(8) 
(7 wks) 
 Wild- type male Tfm male 
Exp#1 
(B6, Tfm) 
26.40*±0.63(3) 
(9 wks) 
22.10±0.59(3) 
(9 wks) 
Exp#2 
(B6, Tfm) 
20.58*± 0.23(3) 
(10 wks) 
13.50±1.66(3) 
(10 wks) 
Exp#3 
(B6, Tfm) 
13.30*± 0.50(9) 
(9 wks) 
8.19±0.68(9) 
(9 wks) 
Exp#4 
(B6, Tfm 
10.45±0.46 (9) 
(9 wks) 
9.80±0.29(8) 
(9 wks) 
Exp#5 
(B6, Tfm 
12.00±0.37(6) 
(9 wks) 
14.70±0.48(5) 
(9 wks) 
             
                                                      Table 8c.  Analysis of the percentage of CD4+CD25+ T cells in androgen  
                                                                       pellet-treated female mice. 
 
 
 
 
 
 
 
 
 
One million lymph node cells from adult castrated or sham castrated female or male, Tfm male or vehicle or androgen pellet-treated 
female mice of varying strains, were labeled with anti-CD4 and anti-CD25 antibodies and analyzed by FACS®. 
The percentage of CD4+ T cells that expressed CD25+ is presented as Mean ± SEM.  Data were analyzed by student’s t test. 
An * indicates a significant difference at p <0.05. 
 Vehicle 
pellet-treated female 
Androgen 
pellet-treated female 
Exp#1 
(B6) 
9.23±0.42(5) 
 
10.44±0.63(5) 
Exp#2 
(B6) 
8.75±0.23(6)   10.61*± 0.32(9)
Exp#3 
(B6) 
6.53±0.19(8)  9.49*±0.50(9)
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Table 9.   Percentage of CD4+CD25+CD103+ T cells in intact female or intact or castrated or Tfm male 
                and androgen pellet-treated female. 
One million lymph node cells from intact female, or intact or castrated or Tfm male, or vehicle or androgen 
 pellet-treated mice were labeled with anti-CD4, anti-CD25 and anti-CD103 antibodies and analyzed by FACS®. 
 The percentage of CD4+CD25+ T cells expressing CD103+ is presented as Mean ± SEM.  Data were analyzed 
 by student’s t test.  An * indicates a significant difference at p <0.05.
 
                Wild- type                         Castrated  
male                     
Tfm male  Vehicle 
pellet 
Androgen  
pellet 
 ♀ ♂ ♂ ♂ ♀ ♀ 
Exp#1 
(B6, Tfm) 
 31.95±1.91(3) 
( 9 wks)     
51.40*±1.63(3) 
(9 wks)          
    31.00±1.13(3)
Exp#2 
(B6, Tfm) 
14.90±0.69(3) 
(10 wks)           
22.04*±1.58(3) 
(10 wks)         
    15.00±1.09(3)
(10 wks) 
Exp#3 
(B6, Tfm) 
13.78±0.79(10) 
(9 wks)         
21.03*±1.56(10) 
(9 wks)      
15.82±0.83(10) 
(9 wks) 
13.48±1.06(10) 
(9 wks) 
  
Exp#4 
(B6) 
22.70±0.93(10)     20.50±0.76(5) 28.80*±1.64(5)
Exp#5 
(B6, Tfm) 
      25.13*±1.26(9) 18.44±0.42(8) 16.85±0.41(8)
 
 
  
Table 10.  Comparison of suppression by regulatory CD4+CD25+CD103+ T cells 
                  from intact female or intact or castrated or Tfm male mice. 
 
Experiment  Treatment & 
  inhibition   
         1:1          1:2          1:4          1:8          1:16 
   Castrated ♂ 
          ↓ 
2260 ± 1417 3374 ± 325 10237 ± 1468 27752 ± 2624 53830 ± 2005 
Wild-type ♀ 
         ↓  
4426 ± 1579 8842± 1321 19752 ± 1314 28007 ± 5262 40073 ± 1496 
Wild-type ♂ 
        ― 
*675 ± 58 *3731 ± 884 *10934 ± 1591 *17697± 1836 35815 ± 4878 
 
 
 
      Exp #1  
(B6, Tfm) 
 
 
      Tfm ♂ 
         ↓ 
2934 ± 606 8147 ± 949 21433 ± 5183 29405 ± 10424 32806 ± 4259 
   Castrated ♂ 
          ↓ 
2142 ± 119 2794  ± 555 3887 ± 725 5521 ± 386 3837 ± 469 
Wild-type ♀ 
         ↓  
2913 ± 809 4764 ± 717 4392 ± 557 6652 ± 216 7798 ± 592 
Wild-type ♂ 
        ― 
*553 ± 81 *952 ± 185 *1953 ± 337 *3467 ± 2037 5309 ± 632 
 
 
 
      Exp # 2 
(B6, Tfm) 
 
 
Tfm ♂ 
         ↓ 
2417 ± 447 3876 ± 202 3839 ± 529 16482 ± 1270 13781 ± 1039 
   Castrated ♂ 
          ↓ 
16816± 3178 37140 ± 4233 53738 ± 3820 59061 ± 4690 59957 ± 5352 
Wild-type ♀ 
         ↓  
14572± 2500 36146 ± 1321 53700 ± 4491 67401 ± 5554 84540 ± 3105 
Wild-type ♂ 
        ― 
*10831± 276 *26275 ± 1832 *48462 ± 2952 56844 ± 2124 61432 ± 3245 
 
 
 
 
 
      Exp # 3 
(B6, Tfm) 
Tfm ♂ 
         ↓ 
18599 ± 2016 36726 ± 2271 44947 ± 846 56470 ± 1389 62639 ± 5425 
 
 
 
 
 
 
 
 
 
 
 
CD4+CD25- responder cells were co-cultured with CD4+CD25+CD2103+ regulatory T cells from 
 intact female, or intact or castrated or Tfm male mice, APCs, and 0.5 mg/ml anti-CD3 for three 
 days, and subsequently pulsed with 3H-Thymidine for 18 hours.  Cells were harvested and 
 analyzed for 3H-Thymidine uptake (counts per minute, CPM).   ―  = no difference; ↓=  inhibition
by females < males.  Data are represented as Mean CPM ± SEM. 
Data were analyzed by student’s t test.  An * indicates a significant difference at p <0.05. 
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SPECIFIC AIM II 
Assessing the influence of estrogens (estradiol) on CD4+CD25+ regulatory T cell 
number and function. 
Within the past two decades, there has been extensive study on the reasons why 
autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus 
erythematosus are more prevalent in women than men.  In general, females exhibit a 
more potent immune response than males, for example; females mount higher antibody 
responses to many microorganisms and elicit more vigorous T cell activation than males, 
reject allografts more readily, and display a reduced incidence of certain tumors.  
Furthermore, the proinflammatory (IL-1 secretion) and TH1-mediated (e.g., IFN-γ 
secretion) responses observed in females are also greater than those observed in males 
(106, 107).  Studies have shown that this phenomenon of enhanced immunity in female 
mice is reminiscent of a similar situation in female humans, and may be mediated by the 
predominantly female sex steroid, estrogen through mechanism(s) which are currently 
unknown (114-119, 181).  In the following experiments, we evaluated the effect of 
estrogens on CD4+CD25+ regulatory cell numbers, phenotype and function. 
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Estrus cycle has a small influence on the numbers and function of CD4+CD25+ 
regulatory cells. 
The reproductive process in the female mouse is characterized by cyclic hormonal 
fluctuations which correspond to the emergence or disappearance of characteristic cells in 
the reproductive tract, in a process known as the estrous cycle.  The different stages of the 
estrous cycle which occur in the whole of the reproductive tract (ovary, uterus and 
vagina) are morphologically distinct, and the changes which occur during these stages 
can be observed in stained smears prepared from the vaginal fluid.  By microscopic 
examination of smears, the diestrus, estrus and proestrus stages of the estrous cycle in 
mice can be distinguished (Figure 26A).  During the diestrus stage of the estrous cycle, 
blood estrogen levels are low, then suddenly peak during proestrus, and then drop again 
during the estrous stage (Figure 26B).                                                                                                   
In the following experiments, we evaluated the effects of normal changes in 
physiological levels of estrogen on the number and regulatory function of CD4+CD25+ T 
cells by comparing these parameters in mice during the proestrus (high estrogen levels), 
diestrus or estrus (low estrogen levels) stages of the estrous cycle.  Briefly, 8 week old 
female mice were monitored for the stage of estrous cycle by evaluating vaginal smears 
daily for a period of 2-3 weeks.  Cells from individual mice at various stages of the 
estrous cycle, were labeled to determine the percentage of CD4+CD25+ and 
CD4+CD25+CD103+ regulatory T cells.  We found that the percentages of CD4+CD25+ 
and CD4+CD25+CD103+ cells from each stage were not significantly different between 
diestrus, proestrus and estrus (Figure 27A & B).  However, the percentage of 
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CD4+CD25+ and CD4+CD25+CD103+ cells from male mice were significantly higher 
than those from female (and Tfm) mice at all stages of estrous (Figure 27A & B).   
The following experiments were performed to determine whether different stages 
of the estrous cycle can affect regulatory cell function.  For in vitro proliferation assays, 
the suppressive ability of CD4+CD25+ cells harvested from mice at each stage of the 
estrous cycle was tested.  Varying ratios of CD4+CD25+ regulatory T cells : CD4+CD25-  
responder cells from mice at each stage were co-cultured with CD4+CD25- responder T 
cells, APCs and anti CD3 antibody.  Our results indicated that CD4+CD25+ regulatory T 
cells from C57BL/6 female mice in proestrus (i.e., stage with higher levels of estrogen)  
were slightly less effective than male mice in regulating proliferation of responder cells 
(Figure 28A & B).  The diestrus CD4+CD25+ regulatory T cells were also slightly better 
than the proestrus in regulating the proliferation of responder cells, but were not different 
from either the male or female at estrus (Figure 28A & B).  In subsequent experiments, 
we also determined whether there were differences in the expression of Foxp3 by 
CD4+CD25+ cells from different stages of the estrus cycle.  Foxp3 mRNA from 
CD4+CD25+ cells was quantified by real-time PCR in wild-type C57BL/6 mice.  Our 
results indicated that there were no significant differences in Foxp3 expression by 
CD4+CD25+ T cells from diestrus, estrus or proestrus (Figure 29).  Moreover, male 
CD4+CD25+ cells did not express higher levels of Foxp3 than females at any stage of the 
estrous cycle.  Our results indicated that the numbers and function of regulatory T cells in 
male mice with high testosterone levels were somewhat greater than female mice at 
proestrus with high estrogen levels.  Moreover, CD4+CD25+ regulatory T cells from 
female mice in diestrus with low estrogen levels, were slightly better in inhibiting the 
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proliferation of responder T cells, compared with CD4+CD25+ from female mice in 
proestrus with high estrogen levels.  Based on these results, we concluded that 
physiological levels of estrogens may have little or no effects on CD4+CD25+ regulatory 
cells. 
Estrogens do not have a direct effect on CD4+CD25+ T cell function in vitro.    
The following experiments were performed to determine whether estrogen has a 
direct effect on regulatory T cells function in vitro.  For these experiments, purified 
female wild-type C57BL/6 or estrogen receptor (α & β) knockout (ERKO) CD4+CD25+  
T cells were analyzed for their ability to regulate in the presence of varying 
concentrations of estradiol.  Our results showed that there were no differences in 
proliferation between CD4+CD25+ T cells treated with increasing doses of estradiol or 
vehicle (ethanol) control (Figure 30).  These results suggested that estradiol may not have 
a direct effect on CD4+CD25+ T cells.  With the above results in mind, we came to the 
conclusion that unlike androgens, the effect of estrogens on regulatory T cells was less 
clearly defined.  
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 Diestrus                                                   
Ç Leucocytes.                                     
È Cornified epithelial cells.                                               
 
Figure 26.  Diestrus, estrus and proestrus stages of the estrous cycle as observed under the microscope (A) and reflect changes in 
estrogen levels that occur during each stage (B).  During the diestrus stage, estrogen levels are low, then the levels increase and peak 
during the proestrus stage, then decrease to low levels during the estrus stage (B).  These fluctuations in estrogen hormone levels 
correspond to the emergence or disappearance of characteristic cells as observed in (A).   
 A                                                                                    B                           
     Moderate nucleated 
     epithelial cells. 
 
Proestrus     
Ç Nucleated epithelial cells. 
È Leucocytes.                                        
    Moderate cornified 
    epithelial cells. 
 
Estrus 
Ç Nucleated cornified 
    epithelial cells. 
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Figure 27.  The percentages of CD4+CD25+ and CD4+CD25+CD103+ regulatory  
T cells are not significantly different between the diestrus, proestrus and estrus stages.    
Lymph node cells from individual female mice at various stages of the estrous cycle  
or male mice, were labeled with anti-CD4, anti-CD25 and anti-CD103 antibodies, 
 then analyzed by FACS® to determine the percentage of CD4+CD25+ (A) and  
CD4+CD25+CD103+ (B) regulatory T cells.  An * indicates a significant difference 
 at p <0.05.   
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Figure 28.  CD4+CD25+ regulatory T cells from C57BL/6 female mice in proestrus are 
slightly less effective than those from male mice at regulating proliferation of responder 
cells.  The suppressive ability of varying ratios of CD4+CD25+ cells harvested from mice 
at each stage of the estrous cycle was tested in vitro (A) and the percentage inhibition of 
suppression calculated (B).  CD4+CD25+  T cells  harvested from female mice at the 
diestrus, estrus and proestrus stages, or from male mice were cocultured with CD4+CD25- 
responder T cells, irradiated spleen cells (APC) and anti-CD3 antibody for 3 days, and 
tested for  their suppressive ability.    
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Figure 29.  There were no significant differences in Foxp3 expression by CD4+CD25+ T 
cells from diestrus, estrus or proestrus females, or males.  CD4+CD25+  T cells from 
C57BL/6  females at various stages of the estrous cycle, and male adult mice were sorted 
to >98% purity, mRNA extracted and the androgen receptor mRNA detected by real 
time-PCR.  mRNA from CD4+CD25-  T cells was used as negative control. 
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Figure 30.  Estradiol does not have a direct effect on CD4+CD25+ T cells in vitro.  Purified 
female wild-type or estrogen receptor knockout CD4+CD25+  T cells were analyzed for 
their ability to regulate CD4+CD25-  T cells in the presence of varying concentrations of 
estradiol or vehicle (ethanol) control (A) and the percentage inhibition of suppression 
calculated (B).  A constant number of CD4+CD25+  T cells from female wild-type or 
estrogen receptor knockout mice was co-cultured with CD4+CD25- T cells in the presence 
of irradiated spleen cells (APC), anti-CD3 and increasing doses of estradiol, and evaluated 
for the degree of proliferation 
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SPECIFIC AIM III 
Assessment of CD4+CD25+ T cells and the effects of androgens in systemic lupus 
erythematosus. 
The NZB x NZW mouse model develops a spontaneous SLE that is characterized 
by accelerated glomerulonephritis that is due to the deposition of immune complexes, 
including anti-DNA immunoglobulin.  Since the disease in NZB x NZW mice resembles 
human lupus very closely, in both the immunological features of the disease as well as 
the increased incidence of disease in females, this model may be useful for the 
identification of the critical factors that contribute to the development of human SLE.    
Interestingly, treatment with androgens has been found to decrease SLE in 
experimental models, while pregnancy and estrogens exacerbate disease (182-185).  
These data strongly suggest that steroids have a direct effect on disease incidence and 
severity.  Studies have shown that the levels of CD4+CD25+ T cells in the peripheral 
blood of SLE patients are decreased compared to normal individuals (172).  Such studies 
suggest that CD4+CD25+ cells may play a role in the pathogenesis of SLE.  The 
following study was designed to determine the relationship between CD4+CD25+ 
regulatory T cells and androgens in NZB x NZW mice and the development of SLE.   
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Analysis of numbers, function and phenotype of CD4+CD25+ regulatory T 
cells from female and male NZB x NZW mice.  
Despite the number of studies performed, there still remains a paucity of 
information about the role of CD4+CD25+ regulatory T cells in the etiology of 
autoimmune diseases like SLE.   In the following experiments, we aimed to compare the 
percentage, function and phenotype of CD4+CD25+ regulatory T cells in the lymphoid 
tissues of female NZB x NZW mice that spontaneously develop lupus-like disease, and 
disease-resistant male NZB x NZW mice.  We examined female versus male NZB x 
NZW mice between the ages of 8-28 weeks for the percentage of CD4+CD25+ T cells.  
First, we evaluated CD4+CD25+ cells in blood at 8 and 12 weeks of age and found no 
differences between female and male NZB x NZW mice (Table 11b).    However, at 9, 16 
or 18 weeks of age, the percentages of CD4+CD25+ cells in the lymph node of female 
mice were significantly lower (or tended to be lower) than that found in males, while at 
28 weeks, there were no significant differences in the percentage of CD4+CD25+ T cells 
between females and males (Figure 31, Table 11a).   
The integrin, CD103 is highly expressed by a significant percentage of 
CD4+CD25+  T cells and appears to identify a sub-population of CD4+CD25+  regulatory 
cells that exhibit more potent regulatory function in vitro, and aids in preferential 
trafficking to sites of inflammation (186, 187).  In the following experiments, we 
investigated the expression of CD103 by CD4+CD25+ T cells in female and male NZB x 
NZW mice.  In the blood, we found at 8 and 12 weeks that female mice already had 
significantly fewer CD4+CD25+ cells that expressed CD103 (Figure 32, Table 12b).  At 9, 
16 and 18 weeks, a significantly lower percentage (or a similar trend) of lymph node 
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CD4+CD25+ cells from non-sick female mice expressed CD103 compared with non-sick 
male mice (Figure 33A,  Table 12a).  At 28 weeks, non-sick female CD4+CD25+ cells 
expressed  a significantly lower  percentage of CD103, than non-sick male mice, and sick 
female CD4+CD25+  cells were observed to express a significantly higher percentage of 
CD103 compared with non-sick female or male mice (Figure 33A, Table 12a).  At 28 
weeks, both sick and non-sick female CD4+CD25+ cells generally expressed a 
significantly lower percentage of CD62L, than non-sick male mice (Figure 33B, Table 
13).  Lower levels of CD62L expression by CD4+CD25+ cells from 28 week-old female 
NZB x NZW mice suggest that these cells may actually be activated T cells, and not 
regulatory T cells.   Regarding the expression of CTLA-4 and Foxp3 by CD4+CD25+ 
cells at 28 weeks, we did not find any significant differences in the percentage of 
expression of either of these molecules between females and males (Table 13).  We also 
did not find any significant differences in the mean intensity of expression of CD62L, 
CD103, CTLA-4 and Foxp3 by CD4+CD25+ cells from female and male mice (data not 
shown). 
Paradoxically, in general, the percentage of CD4+CD25+ in the thymus, was 
significantly higher in the females than in the male mice; likewise, the percentage of 
CD4+CD25+CD103+  T cells was higher in the thymus in females than in males (Table 
14).  These data suggest that the decrease in CD4+CD25+ cells found in the periphery may 
not be due to failure of the thymus to produce CD4+CD25+ cells.   
 In these experiments, we also assessed the absolute numbers of CD4+CD25+ or 
CD4+CD25+CD103+  T cells in NZB x NZW female versus male mice.  In correlation 
with the percentages, in the majority of experiments at 9, 16, or 18 weeks, the absolute 
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number of lymph node CD4+CD25+ from non-sick females was significantly lower than 
that in non-sick male mice, while at 28 weeks, the absolute number of lymph node 
CD4+CD25+ from sick females was significantly higher than that found in non-sick 
female or male mice (Table 15a).  Similarly, in the majority of experiments at 9, 16, or 18 
weeks, the absolute number of lymph node CD4+CD25+CD103+ from non-sick females 
was significantly lower than that in non-sick male mice, while at 28 weeks, the absolute 
number of lymph node CD4+CD25+ from sick females was significantly higher than that 
found in non-sick female or male mice (Table 15b).   
Assays to compare regulatory function of CD4+CD25+ and CD4+CD25+CD103+ cells 
from female versus male NZB x NZW mice were also performed to determine whether 
there are differences in regulatory activity.  In both experiments at 9 weeks, male 
CD4+CD25+ cells were not significantly better than female cells in suppressing responder 
CD4+CD25- (Fig 34A, Table 16a).  However, in the majority of experiments at 9, 16 or 
28 weeks, male CD4+CD25+CD103+  regulatory T cells were better than their female 
counterparts in suppressing in vitro proliferation at ratios of 1:1, 1:2, 1:4 and 1:8 (Figure 
34B, Table 16b).  These results indicated that unlike CD4+CD25+ T cells, male NZB x 
NZW CD4+CD25+CD103+ T cells were better than females in suppressing responder 
CD4+CD25- T cells.   
Overall, the data described above were generally indicative of the fact that female 
NZB x NZW mice had significantly lower levels of CD4+CD25+ T cells, compared with 
male mice.  Similarly, a smaller percentage of CD4+CD25+ T cells from female mice 
expressed the CD103 phenotype, compared with male mice.  Furthermore, although sick 
female mice at 28 weeks generally had significantly more CD4+CD25+ or 
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CD4+CD25+CD103+ cells in the lymph nodes, the CD4+CD25+ cells generally expressed 
lower levels of CD62L, suggesting that these cells may represent an activated phenotype.   
The results of the proliferation assays indicated that unlike unfractionated CD4+CD25+ T 
cells, where little or no differences in suppression were found between NZB x NZW 
females and males, the CD4+CD25+CD103+ from males suppressed better than those 
from females, suggesting that males have more potent and greater numbers of 
CD4+CD25+CD103+ cells which by virtue of the CD103 surface marker can differentially 
traffic to sites of inflammation.  Taken together, these data suggest a defect in the 
CD103+ subset of CD4+CD25+ regulatory cells in female NZB x NZW mice could 
contribute to the increased incidence of disease in females.   
 
Assess the effects of androgens on CD4+CD25+ T cells in NZB x NZW mice and 
correlate these effects with SLE disease regression or progression.  
In recent years, the potential role of androgens in the prevention/cure of SLE has 
been investigated with results that generally suggest that androgens may protect the 
disease.  In some of such studies the role of testosterone in the treatment of SLE was 
emphasized, wherein the administration of various forms of the steroid alleviated or 
modified the course of SLE in both females and males (87, 117, 153-155, 188).   
a).  Effect of the absence of androgens in male NZB x NZW mice. 
In these experiments, male mice were castrated at 3 weeks of age to determine the effects 
of the absence of androgens on CD4+CD25+ numbers and function.  At 8 and 12 weeks, 
blood from the castrated and intact male mice was evaluated by FACS®, to quantify the 
levels of CD4+CD25+ and CD4+CD25+ CD103+ cells.  Significant differences in the 
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levels of CD4+CD25+CD103+, but not CD4+CD25+ cells were generally found in the 
blood of castrated males compared with intact male mice (Tables 17a and 17b).  We also 
did not find any significant differences in the levels of CD4+CD25+ and 
CD4+CD25+CD103+ cells by castrated males versus intact females treated with vehicle-
pellet (Tables 17a and 17b).  The levels of CD4+CD25+CD103+, but not CD4+CD25+ 
cells in intact male mice were generally significantly higher than those in intact females 
treated with vehicle pellet (Tables 17a and 17b).  We also performed proliferation assays 
to compare the regulatory function of CD4+CD25+CD103+ cells from intact versus 
castrated males.  Our results indicated that CD4+CD25+CD103+ cells from intact male 
mice did not suppress the proliferation of CD4+CD25- responder cells significantly better 
than those from castrated mice (Figure 35A, Table 18).   
After a period of 24 weeks, lymph nodes from the mice were collected and 
analyzed for CD4+CD25+ regulatory cell numbers, phenotype and function.  Our results 
in one experiment indicated that although there were no differences between the 
percentage of CD4+CD25+ cells in castrated and intact males (Figure 36A, Table 19a), on 
the other hand, castrated males had significantly decreased percentages of 
CD4+CD25+CD103+  cells compared to intact males (Figure 36 B, Table 19b).   The 
absolute numbers of both CD4+CD25+ and CD4+CD25+CD103+ cells in castrated males 
and females treated with placebo pellet were significantly decreased compared to intact 
males (Table 20).   
  The overall summary of these results is that the absence of androgens could lead 
to a reduction in the percentages of CD4+CD25+CD103+ cells in male mice, as was 
observed when levels in castrated mice either dropped to lower levels compared to those 
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in intact male mice, or were comparable to levels in intact females that were treated with 
vehicle pellet.   
To correlate number of CD4+CD25+ cells and disease development at 12-20 
weeks of age, serum samples from castrated or intact NZB x NZW male mice were 
collected monthly and evaluated by ELISA for the appearance of IgG antibodies to 
dsDNA in serum in order to evaluate the progress of disease.  In general, the anti-dsDNA 
levels were higher in females than males for all ages evaluated.    Interestingly, our 
results indicated that castrated male mice had higher levels of serum antibodies to 
dsDNA than intact male controls that were comparable to those found in females (Figure 
37).                                                                                                                
b). Effect of androgen treatment of female NZB x NZW mice. 
In the following experiments, female NZB x NZW mice were treated with androgen 
pellets or vehicle pellets as control and tested for the influence of androgens CD4+CD25+ 
cells in female mice.  At 8 and 12 weeks of age, blood from these mice was evaluated by 
FACS for the levels of CD4+CD25+ and CD4+CD25+ CD103+ cells.  Androgen pellet-
treated females exhibited significantly higher levels of CD4+CD25+ cells compared with 
vehicle-treated female controls, and the levels of CD4+CD25+ cells in androgen pellet-
treated females was generally comparable to levels in intact male controls (Table 17a).  
The percentage of CD4+CD25+ cells in androgen-treated females that expressed CD103+ 
was generally comparable to the percentage in intact males, but was generally not 
significantly higher than the percentage in placebo-treated control females (Table 17b).   
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At 24 weeks of age, lymph nodes from the mice were collected and analyzed for 
CD4+CD25+ regulatory cell numbers, phenotype and function.  In both experiments, the 
results indicated that although the percentages of CD4+CD25+ and CD4+CD25+CD103+ 
cells in androgen-treated female mice was not significantly greater than in placebo-
treated females, they were generally comparable to the  percentages in intact male mice 
(Table 19a & b).   In both experiments, the results also indicated that absolute numbers of 
CD4+CD25+ and CD4+CD25+CD103+ cells in androgen-treated female mice were 
significantly greater than in placebo-treated females, and were generally comparable to 
the  percentages in intact male mice (Table 20a & b).   Moreover, CD4+CD25+CD103+ 
cells from intact male or androgen-treated female mice significantly suppressed the 
proliferation of CD4+CD25- responder cells compared with placebo-treated females 
(Figure 37B, Table 18).  In summary, these results indicate that the administration of 
androgens to females could lead to an increase in the percentages of CD4+CD25+ and 
CD4+CD25+CD103+ cells in female mice.    
To correlate number of CD4+CD25+ cells and disease development, serum samples from 
male, or androgen or placebo-treated female mice were evaluated monthly from 12-24 
weeks of age by ELISA for the appearance of IgG antibodies to dsDNA in serum.  Our 
results indicated that androgen-treated female mice had levels of serum antibodies to 
dsDNA that were comparable to intact male mice, but were significantly lower than in 
placebo-treated female controls (Figure 38).   
In summary, the data obtained with the NZB x NZW mice indicate that female mice may 
be more susceptible to disease because of a possible defect in the numbers and function 
of both CD4+CD25+ and CD4+CD25+CD103+ cells.  CD4+CD25+ cells in male mice 
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appear to be generally more numerous and/or more potent in vitro, indicating their 
potential ability to more effectively prevent SLE in mice.  The removal of androgens 
from males led to an increase in disease as indicated by the increase in antibodies to 
dsDNA and a coincident reduction in CD4+CD25+ cell numbers.  On the other hand, the 
administration of androgens to females inhibited disease progression while at the same 
time increasing regulatory cell numbers and function.  Taken together, these data strongly 
suggest that sex steroids could affect the incidence and/or severity of disease by affecting 
the numbers and/or function of regulatory T cells.     
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Figure 31.  NZB x NZW female mice have significantly fewer CD4+CD25+ cells than 
 males at 9, 16 and 18, but not, 28  weeks of age.  One million lymph node cells 
 from 9, 16, 18 or 28 week-old female versus male NZB x NZW mice were labeled with
 anti-CD4 and anti-CD25 antibodies and analyzed by FACS®.  Stained CD4+ T cells 
 were gated and analyzed for the expression of the CD25 surface marker, and the 
 percentage of CD4+ T cells that expressed CD25+ were analyzed by student’s 
 t test (N=10).  An * indicates a significant difference at p < 0.05. 
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Figure 32.  Blood CD4+CD25+ cells from female mice express significantly lower 
 CD103 compared with male mice.  Blood cells from 8 and 12 week old female versus 
 male NZB x NZW mice were labeled with anti-CD4, anti-CD25 and anti-CD103 
 antibodies and analyzed by FACS®.  Stained CD4+CD25+ T cells were gated and 
 analyzed for the expression of the CD103 surface marker, and the percentage of 
CD4+CD25+ T cells that expressedstudent’s t test.  An * indicates a significant difference
 at p < 0.05. 
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Figure 33.  Males have significantly more CD4+CD25+CD103+ cells at 9 and 16, but not       
28 weeks of age, while females have fewer CD4+CD25+CD62Lhi cells than males at 28       
weeks of age.  One million lymph node cells from 9, 16, 18 or 28 week female versus male 
NZB x NZW mice were labeled with anti-CD4, anti-CD25, anti-CD62L and anti-CD103 
antibodies and analyzed by FACS®.  Stained CD4+CD25+ T cells were gated and analyzed    
for the expression of CD103 or CD62L surface markers, and the percentage of                     
CD4+CD25+ T cells that expressed CD103 (A) or CD62L (B), were analyzed by student’s t 
 test.  An * indicates a significant difference at p < 0.05. 
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Figure 34.  Male NZB x NZW CD4+CD25+CD103+ , but not CD4+CD25+, cells suppress 
CD4+CD25- responder cells significantly better than female CD4+CD25+CD103+  cells.  
Female and male CD4+CD25+ or CD4+CD25+CD103+  T cells were harvested from NZB 
x NZW mice of varying ages, and co-cultured with CD4+CD25- responder T cells in the 
presence of irradiated spleen cells (APC) and anti-CD3 antibody.  CD4+CD25+ (A) or 
CD4+CD25+CD103+ (B) regulatory T cell function was tested at various responder : 
regulatory cell ratios.  An * indicates a significant difference at p <0.05.   
116 
  
117  
0
5 104
1 105
1.5 105
2 105
Pr
ol
ife
ra
tio
n 
(C
PM
)
1:
2
1:
4
1:
8
1:
2
1:
4
1:
11:
1 * *
*
1:
8
Female Male
9 Weeks
1:
0
0
1 104
2 104
3 104
4 104
5 104
Pr
ol
ife
ra
tio
n 
(C
PM
)
Female
1:
0
1:
2
1:
4
1:
8
1:
2
1:
4
1:
8
Male
1:
11:
1 *
*
*
*
28 Weeks
0
5 104
1 105
1.5 105
2 105
Pr
ol
ife
ra
tio
n 
(C
PM
)
1:
2 1:
4
1:
8 1:
16
1:
2
1:
4
1:
8
* *
* *
Female Male
16 Weeks
1:
0
1:
16
B 
  
0
2 104
4 104
6 104
8 104
1 105
1.2 105
Castrated male Intact male
Pr
ol
ife
ra
tio
n 
(C
PM
)
1:
0
1:
2 1
:4
1:
8
1:
16
1:
2
1:
4 1
:8
1:
16
A
 
0
2 104
4 104
6 104
8 104
1 105
1.2 105
Pr
ol
ife
ra
tio
n 
(C
PM
)
1:
2 1
:4 1
:8
1:
16
1:
0
1:
2
1:
4
1:
8
*
* *
*
     Female
+ vehicle pellet
     Female
+ androgen pellet
1:
16
B
 
Figure 35.  CD4+CD25+CD103+ cells from androgen pellet-treated female but not those 
from intact male mice, suppressed CD4+CD25- cells significantly better than 
CD4+CD25+CD103+  cells from female vehicle-pellet treated  or castrated male mice, 
respectively.  CD4+CD25+CD103+  T cells were harvested from (A) intact or castrated 
male or  (B) vehicle or androgen-treated female NZB x NZW mice, and co-cultured with 
CD4+CD25- responder T cells in the presence of irradiated spleen cells (APC) and anti-
CD3 antibody.  CD4+CD25+CD103+ cell function was tested at various responder : 
regulatory cell ratios.  An * indicates a significant difference at p <0.05.   
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Figure 36.  The absence of androgens could lead to a reduction in the percentages of 
CD4+CD25+ and CD4+CD25+CD103+ cells in male mice.  One million lymph node cells 
of 24 weeks old treated and untreated female versus male NZB x NZW mice were 
labeled with anti-CD4, anti-CD25 and anti-CD103 antibodies and analyzed by FACS®.  
Stained CD4+ or CD4+CD25+ T cells were respectively gated and analyzed for the 
percentage of CD4+CD25+ or CD4+CD25+CD103+  cells by Student’s t test.  An * 
indicates a significant difference at p < 0.05. 
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Figure 37.  Castrated male mice have higher levels of serum antibodies to dsDNA than 
intact male controls that are comparable to those found in females.  At 12-20 weeks of 
age, serum samples from castrated or intact NZB x NZW male mice were collected 
monthly and evaluated by ELISA for the appearance of IgG antibodies to dsDNA in 
serum.  An * indicates a significant difference at p < 0.05.  These experiments were 
performed by Jean Manirarora. 
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Figure 38.  Androgen-treated female mice have levels of serum antibodies to dsDNA 
 that are comparable to intact male mice, but are significantly lower than in 
 placebo-treated female controls.  At 12-20 weeks of age, serum samples from male or 
androgen or placebo-treated female mice were evaluated monthly by ELISA for the 
 appearance of IgG antibodies to dsDNA in serum.  An * indicates a significant 
difference at p < 0.05.  These experiments were performed by Jean Manirarora. 
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Table 11a. Analysis of the percentage of lymph node CD4+CD25+ T cells 
in female and male NZB x NZW mice. 
 
                                        Exp#1                                                           Exp#2                                           Exp#3                                                     
              
                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NZB 
   X 
NZW 
  ♀ ♂   ♀ ♂  ♀ ♂ 
9 weeks 5.31± 
0.12(10) 
6.01*± 
0.13 (10) 
*p=0.001 
5.92± 
0.14(10) 
7.01*± 
0.42(10) 
* p=0.023 
  
16 weeks 4.50± 
0.10 (5) 
4.10± 
0.40 (5) 
p=0.274 
4.30± 
0.20 (5) 
5.40*± 
0.20 (5) 
*p=0.011 
  
18 weeks 6.09± 
0.20(9) 
7.67*± 
1.05(9) 
*p=0.0003 
    
28 weeks 7.49± 
0.80(4) 
7.66± 
0.361(8) 
p=0.824 
10.15± 
0.75(8) 
8.98± 
0.35(8) 
p=0.176 
12.0± 
0.4(10) 
 
11.2± 
0.61(10) 
p=0.328 
Table 11b.  Time course analysis of the percentage of blood  
CD4+CD25+ T cells in female and male NZB x NZW mice. 
 
          Exp # 1                       Exp # 2 
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NZB 
   X 
NZW 
  ♀ ♂   ♀ ♂ 
8  weeks 3.9 ± 0.2 
(6) 
4.9 ± 0.2 
(6) 
3.33 ± 0.4 
(6) 
2.73 ± 0.3 
(6) 
12 weeks 2.80 ± 0.2 
(6) 
3.00 ± 0.2 
(6) 
2.90 ± 0.4 
(3) 
2.82 ± 0.2 
(6) 
One million cells from lymph nodes (Table 11a) or blood (Table 11b) from female versus 
 male NZB x NZW mice of varying ages were labeled with anti-CD4 and anti-CD25 antibodies 
 and analyzed by FACS®.  Stained CD4+ T cells were gated and analyzed for the expression of  
the CD25 surface marker, and the percentage of CD4+ T cells that expressed CD25+.  Data were 
analyzed by student’s t test.  An * indicates a significant difference at p < 0.05. 
 
  
 
 
 
 
Table 12a. Analysis of the percentage of lymph node CD4+CD25+CD103+  
T cells in female and male NZB x NZW mice. 
 
                                                           Exp#1                                                  Exp#2                                                Exp#3                                                     
NZB 
   X 
NZW 
  Sick 
  ♀ 
Non-sick 
  ♀ 
Non-sick 
 ♂ 
Non-sick 
  ♀ 
Non-sick 
 ♂ 
  Sick 
  ♀ 
Non-sick 
  ♀ 
Non-sick 
 ♂ 
9 weeks  13.40± 
0.25(10) 
20.80*± 
0.73 (10) 
*p<0.0001 
13.98± 
0.60(10) 
14.10± 
0.87(10) 
p=0.99 
   
16 weeks  13.8± 
0.8 (6) 
17.6*± 
0.8 (6) 
*p=0.008 
8.69± 
0.43 (8) 
12.60*± 
1.43 (8) 
*p=0.04 
   
18 weeks  18.44± 
1.13(9) 
20.15± 
1.09(9) 
p =0.293 
     
28 weeks 24.22*± 
1.51(4) 
11.65± 
1.21(4) 
14.29± 
0.47(8) 
*p<0.0001 
17.61± 
2.26(8) 
14.29± 
0.48(8) 
p=0.195 
20.80*± 
3.18(5) 
16.70± 
1.83(5) 
18.60± 
1.49(10) 
*p=0.04 
 
Table 12b.  Time course analysis of the percentage of blood  
CD4+CD25+CD103+ T cells in female and male NZB x NZW mice. 
 
                     Exp # 1                                  Exp # 2 
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NZB 
   X 
NZW 
  ♀ ♂   ♀ ♂ 
8  weeks 
 
3.90 ± 0.7 
(6) 
5.50* ± 1.2 
(6) 
*p=0.041 
1.73 ± 0.8 
(3) 
4.22* ± 1.2 
(6) 
*p=0.039 
12 weeks 
 
9.60 ± 0.6 
(6) 
18.40* ± 1.0 
(6) 
*p=0.0002 
2.50 ±  
(1) 
2.40 ± 0.5 
(4) 
p=0.659 
One million lymph node (Table 12a) or blood (Table 12b) from female versus male 
 NZB x NZW mice of varying ages were labeled with anti-CD4, anti-CD25 and 
 anti-CD103 antibodies and analyzed by FACS®.  Stained CD4+CD25+ T cells were 
 gated and analyzed for the expression of the CD103 surface marker, and the percentage 
 of CD4+CD25+ T cells that expressed CD103.  Data were analyzed by student’s t test. 
  An * indicates a significant difference at p < 0.05. 
  
Table 13.  Analysis of the percentage of CD62L, CTLA-4 and Foxp3 by lymph 
                    node CD4+CD25+ T cells in female and male NZB x NZW mice. 
 
                                                            Exp#1                                          Exp#2                                                    Exp#3                                                     
              
NZB 
   X 
NZW 
Non-sick 
  ♀ 
Non-sick 
 ♂ 
Sick 
  ♀ 
Non-sick 
  ♀ 
Non-sick 
 ♂ 
Sick 
  ♀ 
Non-sick 
  ♀ 
Non-sick 
 ♂ 
9 weeks 
CD62L 
*42.54± 
0.95 (10) 
 
38.0± 
1.5 (10) 
*p= 0.016 
 39.0± 
1.4(10) 
 
38.0± 
1.2(10) 
p=0.061 
   
16 weeks 
CD62L 
*48.3± 
0.5 (5) 
40.0± 
1.4 (5) 
*p= 0.0007
 51.8± 
1.20 (5) 
51.30± 
2.4 (5) 
p=0.0781 
   
18 weeks 
CD62L 
45.93± 
2.3(9) 
44.50± 
0.74(9) 
p=0.55 
      
28 weeks 
CD62L 
42.04± 
1.86(10) 
*56.44± 
1.75(8) 
*p<0.0001 
48.0± 
2.5(5) 
50.9± 
1.5(8) 
50.6± 
2.5(8) 
p=0.176 
44.09± 
2.75(5) 
45.50± 
6.30(8) 
*56.40± 
1.75(8) 
*p=0.027 
28 weeks 
CTLA-4 
82.68± 
2.31 (8) 
77.73± 
2.0 (8) 
p=0.130 
86.06± 
(4) 
79.33± 
(4) 
77.73± 
(8) 
p=0.07 
48.00± 
2.5(5) 
50.90± 
1.5(5) 
50..60± 
2.5(10) 
p=0.10 
28 weeks 
(Foxp3) 
 89.8± 
1.65 
86.0± 
0.82 
p=0.08 
     
One million lymph node cells from female versus male NZB x NZW mice of 
varying ages were labeled with anti-CD4, -CD25, -CD62L, -CTLA-4, -Foxp3 or -CD103 
antibodies and analyzed by FACS®.  Stained CD4+CD25+ T cells were gated and analyzed 
for the expression of the CD62L, -CTLA-4, -Foxp3 (Table 13a) or CD103 (Table 13b) 
surface marker.  An * indicates a significant difference at p < 0.05. 
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Table 14.  Analysis of the percentage of thymus CD4+CD25+ or CD25+CD103+
       regulatory T cells in female and male NZB x NZW mice. 
 
                                                                            Exp#1                                          Exp#2                                             Exp#3                                                     
 
NZB 
   X 
NZW 
Non-sick 
  ♀ 
Non-sick 
 ♂ 
Non-sick 
  ♀ 
Non-sick 
 ♂ 
Non-sick 
  ♀ 
Non-sick 
 ♂ 
CD25+ 7.14± 
0.28(10) 
 
7.49± 
0.50(10) 
p=0.536 
 
*9.50± 
0.60(6) 
 
7.40± 
0.20(6) 
*P=0.027 
*13.58± 
1.63(10) 
 
7.74± 
0.74(10) 
*P=0.004 
CD25+CD103+ 18.3± 
0.95 (10) 
16.9± 
0.47(10) 
P=0.230 
*29.0± 
2.4(6) 
18.3± 
0.7(6) 
*P=0.007 
*44.6± 
3.21(10) 
23.4± 
1.01(10) 
*P<0.001 
 
 
 
 
 
One million thymus cells from female versus male NZB x NZW mice of 
varying ages were labeled with anti-CD4, -CD25, -CD62L, -CTLA-4, -Foxp3 or -CD103 
antibodies and analyzed by FACS®.  Stained CD4+CD25+ T cells were gated and analyzed for 
the expression of the CD62L, -CTLA-4, -Foxp3 (Table 14a) or CD103 (Table 14b) surface 
marker.  An * indicates a significant difference at p < 0.05. 
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Table 15a.  Analysis of the absolute numbers of lymph node CD4+CD25+ T cells 
        in female and male NZB x NZW mice. 
 
                                                                          Exp#1                                                                           Exp#2                                                                            
 
  NZB 
     X 
  NZW 
   Sick 
   ♀ 
 Non-sick 
   ♀ 
Non-sick 
  ♂ 
    Sick 
    ♀ 
  Non-sick 
     ♀ 
Non-sick 
  ♂ 
Non-sick 
   ♀ 
Non-sick 
  ♂ 
9 - 18 weeks  5.8 x 105 
±26543 (10) 
(9 weeks) 
 
*8.1 x 105 
±57097 (10) 
(9 weeks) 
*p = 0.04 
 6.0 x105 
±87654 (5) 
(16 weeks) 
 
*9.0 x105 
±76580 (5) 
(16 weeks) 
*p = 0.03 
1.3 x106
±9.8x104 (9) 
(18 weeks) 
 
9.8x105
±1.5x105 (9) 
(18 weeks) 
 
28 weeks *1.7x106
±6.0x105 (5)
*p = 0.006 
4.8x105
±8.5x104(10)
5.2x105
±6.1x104 (8)
*4.7x106
±9.7x105 (5)
*p = 0.029 
2.2x106
±5.0x105(8) 
9.8x105
±2.0x105 8) 
  
                                                                               
Table 15b. Analysis of the absolute numbers of lymph node CD4+CD25+CD103+ 
T cells in female and male NZB x NZW mice. 
 
                                                                 Exp#1                                                                             Exp#2                                                                                          
NZB 
   X 
NZW 
   Sick 
   ♀ 
 Non-sick 
   ♀ 
Non-sick 
  ♂ 
   Sick 
   ♀ 
 Non-sick 
   ♀ 
Non-sick 
  ♂ 
9 weeks  0.6 x 105± 
4605 (10) 
*1.0 x 105± 
9948(10) 
*p =0.016 
 6.50x104
±4605(10) 
*9.50x104
±9948(10) 
*p=0.0001 
16 & 18 weeks  4.2x104
±4605(5) 
 
*1.0x105
±4675 (5) 
(16 weeks) 
*p =0.036 
 2.7x105
±5.2x104(9) 
2.6x105
±8.8x104(9) 
(18 weeks) 
  p=0.879 
28 weeks *4.0x105
±1.7x105 (5) 
*p=0.006 
4.8x105
±8.5x104 (10) 
7.4x104
±1.1x104(8) 
 
*1.1x106
±3.5x105(5) 
*p=0.035 
4.0x105
±1.3x105(8) 
1.9x105
±3.5x104(8)  
          
One million lymph node cells from NZB x NZW mice of varying ages were labeled with 
 anti-CD4, anti-CD25 and anti-CD103 antibodies and analyzed by FACS®.  Total numbers 
 of CD4+CD25+  (Table 15a) or CD4+CD25+CD103+ (Table 15b) T cells were then 
 determined.  Data are represented as Mean ± SEM.  Data were analyzed by student’s t test.  
An * indicates a significant difference at p < 0.05. 
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Table 16a.  Comparison of CD4+CD25+ T cell regulatory function 
       between female and male NZB x NZW mice. 
Experiment Sex / inhibition          1:1          1:2          1:4          1:8          1:16 
♀ (9 wks) 
    ― 
6240 ± 902 10900 ± 1660 62400 ±11900 
 
98500 ±12700 117000 ±6360  
 
Exp # 1 
(NZB x NZW) ♂ (9 wks)     ― 
7220 ± 793 14200± 2470 58100 ±11100 100000± 2550 120000 ±4930 
♀ (9 wks) 
    ― 
571 ± 67 1325 ± 96 3266 ± 38 5800 ± 267 10709 ± 76  
 
Exp # 2 
NZB x NZW) 
 
♂ (9 wks) 
    ― 
265 ± 31 1497 ± 218 2429 ± 188 5496 ± 125 11702 ± 377 
 
Table 16b.  Comparison of CD4+CD25+CD103+ T cell regulatory 
        function between female and male NZB x NZW mice. 
Experiment Sex / inhibition            1:1          1:2          1:4          1:8 
♀ (9 wks) 
     ↓ 
7990 ± 931 26400 ± 6630 70000 ± 3140 
 
115000 ± 831 
♂ (9 wks) 
    ― 
*4240 ± 681 *10800 ± 3720 *53700 ± 657 
 
124000 ± 2345 
♀ (16 wks) 
     ↓ 
43300 ± 11800  78600 ± 1880 101200 ± 1160 
 
103000 ± 1570 
♂ (16 wks) 
    ― 
*5220 ± 1730 *14000 ± 854 *44900 ± 8460  *51300  ± 1370 
♀ (28 wks) 
     ↓ 
6030 ± 421  16900 ± 3210 39100 ± 2730 45000 ± 1670 
 
 
 
 
 
 
Exp # 1 
(NZB x NZW) 
 
 
 
 
♂ (28 wks) 
    ― 
*3320 ± 716 *8860 ± 1140 *22800 ± 3520 *38900 ± 909 
♀ (9 wks) 
    ― 
6024 ± 1397 15601 ± 1517 22272 ± 2690 26823 ± 2574 
♂ (9 wks) 
    ― 
5333 ± 1142 9599 ± 1831 20915 ± 3699 25860 ± 1051 
♀ (16 wks) 
     ↓ 
1245 ± 75 3414 ± 111 6568 ± 1467 13725 ± 569 
♂ (16 wks) 
    ― 
*518 ± 44 *1375 ± 142 *3436 ± 403 *6688 ± 1234 
♀ (28 wks) 
     ↓ 
2571 ± 67 4325 ± 96 8266 ± 38 17800 ± 267 
 
 
 
 
 
 
Exp # 2 
(NZB x NZW) 
 
 
 
 ♂ (28 wks) 
    ― 
*65  ± 31 *1493 ± 218 *3429 ± 188 *7496 ± 125 
CD4+CD25+ or CD4+CD25+CD103+ cells were harvested from NZB x NZW mice of  
varying ages, and co-cultured with CD4+CD25- responder cells in proliferation assays 
 to test CD4+CD25+ (Table 16a) or CD4+CD25+CD103+ (Table 16b) regulatory function.  
 ―  = no difference; ↓=  inhibition by females < males.  Data are represented as Mean ± SEM.  
Data were analyzed by student’s t test.   An * indicates a significant difference at p <0.05. 
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Table 17a.  Time course analysis of the percentage of blood CD4+CD25+
T cells in androgen-treated female NZB x NZW mice. 
 
NZB X NZW    Intact  
     ♂      
    Intact ♀ 
  + placebo 
Castrated  
     ♂ 
  Intact ♀ 
+ androgen 
8 weeks 
(Exp # 1)  
5.90 ± 0.3 
(6) 
3.90 a ± 0.2 
(6) 
4.90b ± 0.2 
(7) 
4.9 c ± 0.02 
(6) 
12 weeks 
(Exp # 1) 
3.00 ± 0.2 
(6) 
2.80 ± 0.2 
(6) 
3.10 ± 0.1 
(7) 
3.30 c ± 0.1 
(6) 
8 weeks 
(Exp # 2) 
2.73 ± 0.3 
(6) 
3.33 ± 0.4 
(6) 
2.83 ± 0.2 
(7) 
2.50 ± 0.2 
(6) 
12 weeks 
(Exp # 2) 
2.82 ± 0.2 
(6) 
2.90 ± 0.4 
(3) 
2.80 ± 0.1 
(7) 
2.40 ± 0.5 
(6) 
 
 
 
 
 
 
 
 
 
 
 
Table 17b.  Time course analysis of the percentage of blood CD4+CD25+CD103+ 
   T cells in androgen-treated female NZB x NZW mice. 
 
NZB X NZW    Intact  
     ♂      
    Intact ♀ 
  + placebo 
Castrated  
     ♂ 
  Intact ♀ 
+ androgen 
8 weeks 
(Exp # 1)  
5.50 ± 1.2 
(6) 
3.90 a ± 0.7 
(6) 
3.90b ± 0.6 
(6) 
4.45 ± 0.8 
(7) 
12 weeks 
(Exp # 1) 
18.40±1.0 
(6) 
9.60 a ± 0.6 
(6) 
10.40b ± 2.3 
(7) 
11.10 c ± 0.3 
(5) 
8 weeks 
(Exp # 2) 
2.40 ± 0.5 
(4) 
1.73 ± 0.8 
(3) 
2.80 ± 0.1 
(7) 
2.70 ± 0.4 
(5) 
12 weeks 
(Exp # 2) 
4.22 ± 1.2 
(6) 
2.50 a  ± 0.5 
(7) 
4.30 ± 0.5 
(7) 
3.71 ± 1.3 
(5) 
 
 
 
 
 
 
  One million cells from the blood of NZB x NZW mice of varying ages were labeled 
  with anti-CD4, anti-CD25 and anti-CD103 antibodies and analyzed by FACS®.  
   Percentages of CD4+CD25+ (Table 17a) or CD4+CD25+CD103+ (Table 17b) 
   T cells were then calculated using total cell counts and the results of FACS® analysis. 
  Data are represented as Mean ± SEM.  Data were analyzed by student’s t test. 
a= Intact ♂ versus Intact ♀ + Placebo, b= Intact ♂ versus Castrated ♂, 
  c= Intact ♀ + Placebo versus Intact ♀ + Androgen.  a, b, c = p< 0.05.   
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 Table 18.   Comparison of CD25+CD103+ T cell regulatory function between 
                    6 month old female and male NZB x NZW mice. 
 
Experiment  Treatment & 
  inhibition   
         1:2          1:4          1:8          1:16 
Castrated ♂ 
       ― 
46200 ± 5420 56600±10800 83000 ± 5320 98400 ± 7490 
Normal ♂ 
       ― 
49000 ± 4270 87500 ± 3910 99200 ± 8050 111000±4470 
Normal ♀ + placebo 
            ↓ 
43300±11800 78600 ± 1880 101000±11600 110300±1570 
 
 
 
      Exp #1  
(NZB x NZW) 
 
 
 Normal ♀ + androgen 
             ― 
*3102 ± 611 *15012 ±2220 *23837 ± 296 *48250±13800 
Castrated ♂ 
       ― 
30000 ± 543 63200 ± 342 122200 ± 1345 132021 ± 674 
Normal ♂ 
       ― 
28500 ± 1973 55432 ± 1320 119000 ±1130 126000 ± 104 
Normal ♀ + placebo 
            ↓ 
20031 ± 985 46321 ± 1082 73452 ± 2314 126389 ± 321 
 
 
 
      Exp #2  
(NZB x NZW) 
 
 
 Normal ♀ + androgen 
             ― 
*11232 ± 500 *20234 ± 456 *47325 ± 920 *88675± 467 
 
CD4+CD25+CD103+  T cells were harvested from vehicle or androgen-treated female 
and intact or castrated male NZB x NZW mice at 6 months of age, and co-cultured 
 with CD4+CD25- responder T cells in the presence of irradiated spleen cells (APC) 
 and anti-CD3 antibody.  CD4+CD25+CD103+ regulatory T cell function was tested 
 at various responder : regulatory cell ratios.  ―  = no difference; ↓=  inhibition by 
 placebo-treated females < androgen-treated females or intact male.  Data are 
 represented as Mean ± SEM.  Data were analyzed by student’s t test.  An * indicates a 
 significant difference at p <0.05. 
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Table 19. Analysis of the percentage of CD4+CD25+ and CD4+CD25+CD103+ T cells 
 in lymph nodes in castrated and androgen-treated female and male NZB x NZW mice. 
 
(a) 
 
   + placebo 
 
 
 
 
 
 
 
 
NZB 
   X 
NZW 
   Intact  
     ♂      
    Intact ♀ Castrated  
     ♂ 
  Intact ♀ 
+ androgen 
CD4+CD25+ 
(Exp #1) 
4.10 ± 0.4 
 (4) 
4.50 ± 0.1 
 (5) 
 
4.90 ± 0.2 
 (7) 
 
4.10 ± 0.2 
 (6) 
 
CD4+CD25+ 
(Exp #2) 
5.40± 0.2 
 (10) 
 
4.30± 0.2 
 (10) 
5.20± 0.4 
 (10) 
 
4.50± 0.2 
 (10) 
 
(b) 
 
NZB 
   X 
NZW 
   Intact  
     ♂      
    Intact ♀ 
  + placebo 
Castrated  
     ♂ 
  Intact ♀ 
+ androgen 
CD25+CD103+ 
(Exp #1) 
8.8 ± 0.4 
(4) 
8.69 ± 0.4  
(5) 
 
11.5 b ± 0.9 
 (7) 
 
8.41 ± 0.5 
 (6) 
CD25+CD103+ 
(Exp #2)
 
17.60± 0.8 
 (10) 
 
13.80 a ± 0.8  
(10) 
14.90 b ± 1.1  
(10) 
15.60± 0.6 
(10) 
 
 
 
 
 
 
 
 
 
One million lymph node cells from 24 weeks-old female versus male NZB x NZW mice 
 were labeled with anti-CD4, anti-CD25 and anti-CD103 antibodies and analyzed by FACS®. 
 Stained CD4+ or CD4+CD25+ T cells were respectively gated and analyzed for the  
expression of the CD25 or CD103 surface marker, and the percentage of CD4+CD25+ 
or CD4+CD25+CD103+ cells were analyzed by student’s t test.   
Data are represented as Mean ± SEM.  Data were analyzed by student’s t test. 
  a= Intact ♂ versus Intact ♀ + Placebo, b= Intact ♂ versus Castrated ♂.  a, b = p< 0.05.   
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Table 20. Analysis of the absolute numbers of lymph node CD4+CD25+and 
CD4+CD25+CD103+ T cells in lymph nodes in castrated and 
 androgen treated female and male NZB x NZW mice. 
 (a) 
 
  
 
 
 
 
 
NZB X NZW    Intact  
     ♂      
    Intact ♀ 
  + placebo 
Castrated  
     ♂ 
  Intact ♀ 
+ androgen 
CD4+CD25+ 
(Exp #1) 
6.3 x 105
±47650 (4) 
a 4.2 x 105 
±43252 (5) 
7.0 x106
±55432 (7) 
c 6.6 x105
±89754 (6) 
CD4+CD25+ 
(Exp #2) 
7.1 x 106
±3245 (10) 
a 5.5 x 106
±3214  (10) 
b 6.1 x 106
±32413 (10) 
c  6.3 x 106
±43210(10) 
 
(b) 
 NZB  X NZW    Intact  
     ♂      
    Intact ♀ 
  + placebo 
Castrated  
     ♂ 
  Intact ♀ 
+ androgen 
CD25+CD103+ 
(Exp #1)
 
5.7 x 104
±7654 (4) 
 
a 3.1 x 104
±7654 (5) 
6.1 x 105
±8932 (7) 
c 5.0 x 104
±9932 (6) 
 
CD25+CD103+ 
(Exp #2)
 
5.2 x 105
±6654(10) 
 
a 3.9 x 105
±9934(10) 
b 3.5 x 05
±7653(10) 
c 4.5 x 105
±4325(10) 
 
 
 
 
 
 
 
 
 
 
One million lymph node cells of 24 weeks old female versus male NZB x NZW mice 
were labeled with anti-CD4, anti-CD25 and anti-CD103 antibodies and analyzed by 
 FACS®.  Total numbers of CD4+CD25+ (Table 20a) or CD4+CD25+CD103+ (Table 20b) 
were determined.   Data are represented as Mean ± SEM.  Data were analyzed by 
 student’s t test.  
a= Intact ♂ versus Intact ♀ + Placebo, b= Intact ♂ versus Castrated ♂, 
  c= Intact ♀ + Placebo versus Intact ♀ + Androgen.  a, b, c = p< 0.05.   
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DISCUSSION 
 
CD4+CD25+ regulatory T cells play an important role in the maintenance of 
immunological homeostasis and self-tolerance (5) by suppressing autoreactive T cells 
that could potentially cause autoimmune diseases.  Sex steroids have been shown to 
strongly influence the immune response, in general, and autoimmune diseases, in 
particular (106, 114-119, 174, 175).  For example, females have a much higher incidence 
of a wide range of autoimmune diseases compared to men.  For these reasons, we 
hypothesized that sex steroids could influence the nature of autoimmune disease through 
an effect on CD4+CD25+ regulatory T cell number and/or function.   
We have found that androgens, but not estrogens, can, in fact, have an influence on the 
numbers, function and phenotype of CD4+CD25+ T cells.   
 
Androgens have a dramatic direct in vivo, but not in vitro effect, on CD4+CD25+ 
regulatory cell numbers and function.   
CD4+CD25+ regulatory T cells can be found in the lymph nodes, spleen, thymus 
and peripheral blood (5).  In the first two specific aims of this work, the in vivo or in vitro 
effect of dihydrotestosterone or estradiol on murine female and/or male CD4+CD25+ 
regulatory T cells was analyzed.  In our preliminary studies, flow cytometric analysis 
revealed that adult male mice appeared to have significantly more CD4+CD25+ cells than 
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females, unlike their pre-pubertal counterparts which showed no significant differences in 
the expression of CD4+CD25+ cells between females and males.  These data suggested 
that the differential expression of sex steroids in adult mice may influence the levels of 
CD4+CD25+ cells in adult mice.  Since increased estrogen levels are associated with 
exacerbation of SLE in mice and human females (112, 189), it is possible that estrogen 
may be responsible for the observed lower percentage of CD4+CD25+ T cells in females 
compared to males in our experiments.  Alternatively, the differences in CD4+CD25+ 
cells in females and males could be due to an androgen-mediated increase in CD4+CD25+ 
cells in males.  Our data strongly suggest that the latter is true: androgens increase the 
numbers and function of CD4+CD25+ cells whereas estrogen appears to have a minimal 
effect.     
With male mice exhibiting a tendency to produce higher levels of CD4+CD25+ T 
cells, compared with females, we further analyzed whether these cells from males are 
phenotypically and functionally different from female CD4+CD25+ T cells, by assessing 
the expression of various molecules such as CTLA-4, CD62L, GITR, CD45RB and 
CD103 that are associated with the regulatory function of CD4+CD25+ T cells.  
Interestingly, we found that a greater percentage of male CD4+CD25+ T cells expressed 
CD103, compared with females and that the mean intensity of expression of CTLA-4 by 
male CD4+CD25+ T cells was also significantly higher than that found in females.  These 
data suggest that CD103 and CTLA-4, which are involved in the homing to inflamed 
tissues (190), and costimulation (32, 33) of CD4+CD25+ T cells, respectively could be 
differentially expressed by CD4+CD25+ T cells in female and male mice because of the 
influence of sex steroids on these cells.  Thus two possibilities exist, either androgens 
133 
  
could up-regulate or estrogens could down-regulate the expression of CD103 and/or 
CTLA-4.   
Our hypothesis that sex steroids are responsible for the differences observed so far 
between females and males was supported by our data that showed that castration of male 
mice reduced the levels of CD4+CD25+, CD4+CD25+CD103+ or CD4+CD25+ CTLA-4+  T 
cells to levels comparable to females.  This phenomenon was also observed in androgen 
receptor deficient mice (Tfm) which had significantly reduced CD4+CD25+ , 
CD4+CD25+CD103+ or CD4+CD25+ CTLA-4+   T cells compared with wild-type male 
mice.  Moreover, levels of CD4+CD25+  or CD4+CD25+CD103+  T cells increased in 
females that were treated with testosterone, to levels comparable to males, and 
significantly higher than levels found in normal females.  Thus, castrating male mice to 
decrease testsosterone levels or using male mice inherently deficient in the androgen 
receptor led to a significant reduction in the percentages of CD4+CD25+ , 
CD4+CD25+CD103+ or CD4+CD25+ CTLA-4+   T cells.  Furthermore, providing androgen 
to females increased the percentage of CD4+CD25+ or CD4+CD25+CD103+ T cells to 
levels found in males.   
In our studies, we also observed that Foxp3, which is a specific marker for 
regulatory activity (78) and is essential for the development and function of CD4+CD25+ 
regulatory cells (81, 82) was expressed significantly more in male CD4+CD25+CD103+ T 
cells than in females, whereas with unfractionated CD4+CD25+ T cells, we found no 
differences in Foxp3 expression between females and males.  Foxp3 expression is 
required for suppression by CD4+CD25+ T cells (82, 191), and recent in vivo studies have 
shown that decreased Foxp3 expression levels by the CD4+CD25+  T cells in the 
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peripheral blood or thymocytes of multiple sclerosis or myasthenia gravis patients is 
quantitatively related to a reduction in functional suppression by these cells (192, 193).  
With male CD4+CD25+CD103+ T cells in our experiments expressing more Foxp3 than 
females, it is possible that this differential expression of Foxp3 between the two genders 
correlates with functional suppression.  To test this possibility, we compared the 
functional capacity of female and male CD4+CD25+ and CD4+CD25+CD103+ T cells.  
Although our results showed that both CD4+CD25+ and CD4+CD25+CD103+ T cells from 
male mice suppressed the proliferation of responder CD4+CD25- T cells significantly 
better than those from females, the regulatory function of CD4+CD25+CD103+ T cells 
was found at ratios as low as 1:1 and was more consistent than that found with the 
unfractionated CD4+CD25+ T cell regulatory cell population.  Furthermore, 
CD4+CD25+CD103+, but not CD4+CD25+ T cells, from intact male mice were 
significantly better than either castrated or Tfm male mice in suppressing CD4+CD25- T 
cells in vitro.  These data indicated that the CD103 expressing fraction of CD4+CD25+ T 
cells, particularly in males is more potent than the unfractionated CD4+CD25+ T cells.  
CD103 (αEβ7 intergrin) which recognizes epithelial cadherin (E-cadherin) is involved in 
the homing of regulatory T cells to sites of inflammation.  In light of our experimental 
results, we hypothesize that males might be less susceptible to autoimmune disease 
because they have more CD4+CD25+CD103+ regulatory cells that can reach inflamed 
tissues, than females, and in addition, these cells are more potent at suppressing cell 
proliferation than those found in females.  In support of this hypothesis, a recent study in 
experimental autoimmune encephalomyelitis (EAE) prone mice reported that male 
CD4+CD25+ regulatory T cells appear to control the expansion of autoreactive cells more 
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effectively than those of females which may contribute to the resistance of males to EAE 
(194).   
Our results indicate that androgens have a strong effect on both CD4+CD25+  cell 
numbers and function.  However, we do not know whether androgen affects these cells 
directly or, at which stage in their development.   By treating regulatory T cells in vitro 
with testosterone, we found no evidence that androgens have a direct effect on peripheral 
mature CD4+CD25+ regulatory T cells, at least as determined by in vitro assays.  Since 
androgens do not appear to have a direct effect on mature CD4+CD25+  regulatory cells, 
the other possibilities are either that they can affect these cells directly at an earlier stage 
in their development (i.e., precursor thymocyte or mature thymocyte stage) or at the level 
of the thymic environment itself (i.e., thymic epithelium).  The latter is a possibility 
because all T cells, including the CD4+CD25+ cells, require intimate contact with the 
thymic epithelium for normal selection and development. 
 We used radiation chimeras to determine whether androgens affected bone marrow- 
derived precursors of CD4+CD25+ cells or the thymic epithelium, and evaluated the 
effects of androgens on CD4+CD25+ cell numbers and function.  Interestingly, we found 
that androgens had different effects on the two different compartments.  Androgens 
appear to affect CD4+CD25+  function by a direct influence on the bone marrow, or 
hematopoietic, compartment, since our results show that regulatory function is enhanced 
only in mice that have received wild-type, and not androgen receptor-deficient, bone 
marrow and androgen treatment.  However, this treatment did not affect the numbers of 
CD4+CD25+ cells.  On the other hand, the thymus is apparently involved in androgen-
mediated increases in CD4+CD25+ cells, but not their function,  since mice implanted 
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with wild-type, and not androgen receptor-deficient, thymus exhibited increases in these 
cells, but not an increase in function.  As mentioned above, CD4+CD25+ cells develop 
primarily in the thymus and the thymic epithelium expresses significant levels of 
androgen receptor, therefore, the androgens most likely affect the percentage of 
CD4+CD25+ cells through the thymic epithelium.  These data are supported by well 
established findings that thymus weight, cellularity and cellular composition are very 
sensitive to changes in androgen status, and that thymic epithelial expression of androgen 
receptor is required for androgen effects on thymocyte development (146).  Moreover, 
previous studies to investigate the effects of androgens on the development of 
lymphocytes in the thymus and bone marrow using bone-marrow chimeras, indicated that 
thymic epithelial cells are mediators of androgenic effects on immature lymphocytes 
(150).   Contrary to the results obtained with androgens, we have found that estrogens had 
very little effect on regulatory T cell numbers, phenotype or function.  Our experiments 
concerning the estrous cycle indicated that CD4+CD25+  cells from female mice in 
diestrus (low estrogen levels) were very slightly better at inhibiting the proliferation of 
responder T cells, compared with CD4+CD25+ cells from female mice in proestrus (high 
estrogen levels).  In experiments where CD4+CD25+ cells were directly treated with 
estradiol in vitro, we found no differences in proliferation between CD4+CD25+ cells 
treated with estradiol or vehicle controls suggesting that estradiol does not directly affect 
mature CD4+CD25+ cells.  Like androgens, thymic epithelial cell expression of estrogen 
receptor is necessary for normal thymus development (127, 195).  However, studies have 
shown that treatment of mice with low to high doses of estradiol, corresponding to levels 
found in estrus and pregnancy, promotes proinflammatory (Th1) cell responses in vivo 
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(196) and also that estrogen prevents early T cell development in the thymus, with a 
dramatic reduction of thymus size and cellularity (197).  Thus unlike androgens, 
estrogens may exert a more negative effect on CD4+CD25+ regulatory T cells.   
Overall, our current studies show that androgens, but not estrogens, have a significant 
positive effect on CD4+CD25+ regulatory cell numbers and function, and may contribute 
to autoimmune disease resistance in males through this mechanism.     
 
The differential expression of androgen in males compared with females may 
account for the dramatic sex-based differences in SLE disease incidence observed in 
(NZB x NZW mice) F1 mice.   
Female NZB x NZW mice spontaneously develop a lupus-like disease that resembles 
human SLE, which involves Th1 cells (198-200).  The disease is characterized by high 
levels of circulating anti-DNA antibodies that are first detected at 2 months of age, and 
glomerulonephritis that occurs in the majority of female mice by 28 weeks of age.  In our 
experiments, the percentage of lymph node CD4+CD25+ T cells that expressed CD103 
from male mice at 9, 16, or 18 weeks was significantly higher than the percentage found 
in females of the same age, and these cells exhibited significantly better regulatory 
function.  However, at 28 weeks when the female mice became sick, a higher percentage 
of female lymph node CD4+CD25+ cells were observed to express significantly more 
CD103 cells, compared to males.  Interestingly, sick female mice at 28 weeks generally 
had significantly more CD4+CD25+ or CD4+CD25+CD103+ cells in the lymph nodes, 
although a large proportion of these cells had downregulated  CD62L, suggesting that 
these CD4+CD25+ cells may represent an activated phenotype.   
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 Our final series of experiments were designed to determine whether disease onset 
and progression correlated with CD4+CD25+ regulatory cell number and function.  
Disease progression was determined by quantitative analysis of circulating levels of anti-
DNA antibodies at 12, 16 and 20 weeks of age.  We found that females consistently 
produced higher levels of anti-DNA-antibodies than males which correlated with both the 
decreased numbers and function of CD4+CD25+CD103+ cells.  Furthermore, castrated 
males also had higher levels of anti-DNA antibodies than intact males which also 
correlated with a decrease in the number of CD4+CD25+CD103+ cells in these mice.  
Conversely, androgen-treated females had significantly lower levels of anti-DNA 
antibodies that correlated with enhanced regulatory function by CD4+CD25+CD103+ 
cells.    
   Our findings showing that decreased CD4+CD25+ cell number is associated with 
disease progression is supported by studies that the administration of anti-mouse CD25+ 
T-cell monoclonal antibody 3 days after birth, eliminates peripheral CD4+CD25+ T cells 
and consequently speeds up the development of glomerulonephritis during the reactive 
phase in autoimmune prone female NZB x NZW F1 mice (201).   Other studies have 
shown that the lower percentage and total number of peripheral CD4+CD25+ T cells in 
lupus-prone NZB x NZW mice permits the development of lupus-like disease in these 
mice, compared to sex- and age-matched nonautoimmune-prone strains of mice (202).  
Furthermore, a clinical study has shown that the levels of CD4+CD25+ T cells in the 
peripheral blood of patients with systemic lupus erythematosus (SLE) are significantly 
decreased, compared with normal/healthy controls (172, 203).   
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 The overall findings of our studies are that: 1) androgens appear to be associated 
with an increase in CD4+CD25+ cells; 2) androgens increase the percentage of 
CD4+CD25+ cells that express the important trafficking molecule, CD103; 3) androgens 
increase the regulatory function of these CD4+CD25+CD103+ cells; and 4) these 
androgen- mediated changes appear to correlate with prevention of disease.  Based on 
these observations, we tentatively conclude that androgens may mediate the differences 
in autoimmune disease incidence between females and males, at least partially, through 
an enhansive effect on CD4+CD25+ cell numbers and function.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
140 
  
 
 
 
 
 
REFERENCES 
 
 
1. Nishizuka, Y., and T. Sakakura. 1969. Thymus and reproduction: sex-linked 
dysgenesia of the gonad after neonatal thymectomy in mice. Science 166:753. 
 
2. Sakaguchi, S., T. Takahashi, and Y. Nishizuka. 1982. Study on cellular events in 
post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells 
in normal female mice for the prevention of oophoritis. Journal of Experimental 
Medicine 156:1577. 
 
3. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. 
Immunologic self-tolerance maintained by activated T cells expressing IL-2 
receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance 
causes various autoimmune diseases. Journal of Immunology 155:1151. 
 
4. Piccirillo, C. A., and E. M. Shevach. 2004. Naturally-occurring CD4+CD25+ 
immunoregulatory T cells: central players in the arena of peripheral tolerance. 
Seminars in Immunology 16:81. 
 
5. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory t cells for immunologic 
self-tolerance and negative control of immune responses. Annual Review of 
Immunology 22:531. 
 
6. Holm, T. L., J. Nielsen, and M. H. Claesson. 2004. CD4+CD25+ regulatory T 
cells: I. Phenotype and physiology. APMIS 112:629. 
 
7. Lindley, S., C. M. Dayan, A. Bishop, B. O. Roep, M. Peakman, and T. I. Tree. 
2005. Defective suppressor function in CD4(+)CD25(+) T-cells from patients 
with type 1 diabetes. Diabetes 54:92. 
 
8. Itoh, M., T. Takahashi, N. Sakaguchi, Y. Kuniyasu, J. Shimizu, F. Otsuka, and S. 
Sakaguchi. 1999. Thymus and autoimmunity: production of CD25+CD4+ 
naturally anergic and suppressive T cells as a key function of the thymus in 
maintaining immunologic self-tolerance. Journal of Immunology 162:5317. 
141 
  
9. Kanamaru, F., P. Youngnak, M. Hashiguchi, T. Nishioka, T. Takahashi, S. 
Sakaguchi, I. Ishikawa, and M. Azuma. 2004. Costimulation via glucocorticoid-
induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. 
Journal of Immunology 172:7306. 
 
10. Jordan, M. S., A. Boesteanu, A. J. Reed, A. L. Petrone, A. E. Holenbeck, M. A. 
Lerman, A. Naji, and A. J. Caton. 2001. Thymic selection of CD4+CD25+ 
regulatory T cells induced by an agonist self-peptide.[see comment]. Nature 
Immunology 2:301. 
 
11. Picca, C. C., and A. J. Caton. 2005. The role of self-peptides in the development 
of CD4+ CD25+ regulatory T cells. Current Opinion in Immunology 17:131. 
 
12. Jackson, A. L., H. Matsumoto, M. Janszen, V. Maino, A. Blidy, and S. Shye. 
1990. Restricted expression of p55 interleukin 2 receptor (CD25) on normal T 
cells. Clinical Immunology & Immunopathology 54:126. 
 
13. Kanegane, H., T. Miyawaki, K. Kato, T. Yokoi, T. Uehara, A. Yachie, and N. 
Taniguchi. 1991. A novel subpopulation of CD45RA+ CD4+ T cells expressing 
IL-2 receptor alpha-chain (CD25) and having a functionally transitional nature 
into memory cells. International Immunology 3:1349. 
 
14. Shevach, E. M. 2000. Regulatory T cells in autoimmmunity*. Annual Review of 
Immunology 18:423. 
 
15. Curotto de Lafaille, M. A., A. C. Lino, N. Kutchukhidze, and J. J. Lafaille. 2004. 
CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral 
expansion. Journal of Immunology 173:7259. 
 
16. Zelenay, S., T. Lopes-Carvalho, I. Caramalho, M. F. Moraes-Fontes, M. Rebelo, 
and J. Demengeot. 2005. Foxp3+ CD25- CD4 T cells constitute a reservoir of 
committed regulatory cells that regain CD25 expression upon homeostatic 
expansion. Proceedings of the National Academy of Sciences of the United States 
of America 102:4091. 
 
17. Liang, S., P. Alard, Y. Zhao, S. Parnell, S. L. Clark, and M. M. Kosiewicz. 2005. 
Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo 
requires B7 costimulation, but not the thymus. Journal of Experimental Medicine 
201:127. 
142 
  
18. Sakaguchi, S., N. Sakaguchi, J. Shimizu, S. Yamazaki, T. Sakihama, M. Itoh, Y. 
Kuniyasu, T. Nomura, M. Toda, and T. Takahashi. 2001. Immunologic tolerance 
maintained by CD25+ CD4+ regulatory T cells: their common role in controlling 
autoimmunity, tumor immunity, and transplantation tolerance. Immunological 
Reviews 182:18. 
 
19. Maloy, K. J., L. Salaun, R. Cahill, G. Dougan, N. J. Saunders, and F. Powrie. 
2003. CD4+CD25+ T(R) cells suppress innate immune pathology through 
cytokine-dependent mechanisms. Journal of Experimental Medicine 197:111. 
20. Wood, K. J., and S. Sakaguchi. 2003. Regulatory T cells in transplantation 
tolerance. Nature Reviews. Immunology 3:199. 
 
21. Asano, M., M. Toda, N. Sakaguchi, and S. Sakaguchi. 1996. Autoimmune disease 
as a consequence of developmental abnormality of a T cell subpopulation. 
Journal of Experimental Medicine 184:387. 
 
22. Malek, T. R., A. Yu, V. Vincek, P. Scibelli, and L. Kong. 2002. CD4 regulatory T 
cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for 
the nonredundant function of IL-2. Immunity 17:167. 
 
23. Furtado, G. C., M. A. Curotto de Lafaille, N. Kutchukhidze, and J. J. Lafaille. 
2002. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. 
Journal of Experimental Medicine 196:851. 
 
24. Stephens, L. A., and D. Mason. 2000. CD25 is a marker for CD4+ thymocytes 
that prevent autoimmune diabetes in rats, but peripheral T cells with this function 
are found in both CD25+ and CD25- subpopulations. Journal of Immunology 
165:3105. 
 
25. Thornton, A. M., and E. M. Shevach. 2000. Suppressor effector function of 
CD4+CD25+ immunoregulatory T cells is antigen nonspecific. Journal of 
Immunology 164:183. 
 
26. Shevach, E. M., R. S. McHugh, C. A. Piccirillo, and A. M. Thornton. 2001. 
Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunological 
Reviews 182:58. 
 
27. Suri-Payer, E., A. Z. Amar, A. M. Thornton, and E. M. Shevach. 1998. 
CD4+CD25+ T cells inhibit both the induction and effector function of 
143 
  
autoreactive T cells and represent a unique lineage of immunoregulatory cells. 
Journal of Immunology 160:1212. 
 
28. Takahashi, T., Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M. Iwata, J. 
Shimizu, and S. Sakaguchi. 1998. Immunologic self-tolerance maintained by 
CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune 
disease by breaking their anergic/suppressive state. International Immunology 
10:1969. 
 
29. Walker, L. S., A. Chodos, M. Eggena, H. Dooms, and A. K. Abbas. 2003. 
Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. 
Journal of Experimental Medicine 198:249. 
 
30. Powrie, F., M. W. Leach, S. Mauze, L. B. Caddle, and R. L. Coffman. 1993. 
Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic 
intestinal inflammation in C. B-17 scid mice. International Immunology 5:1461. 
 
31. Lehmann, J., J. Huehn, M. de la Rosa, F. Maszyna, U. Kretschmer, V. Krenn, M. 
Brunner, A. Scheffold, and A. Hamann. 2002. Expression of the integrin alpha 
Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. 
Proceedings of the National Academy of Sciences of the United States of America 
99:13031. 
 
32. Takahashi, T., T. Tagami, S. Yamazaki, T. Uede, J. Shimizu, N. Sakaguchi, T. W. 
Mak, and S. Sakaguchi. 2000. Immunologic self-tolerance maintained by 
CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T 
lymphocyte-associated antigen 4. Journal of Experimental Medicine 192:303. 
 
33. Read, S., V. Malmstrom, and F. Powrie. 2000. Cytotoxic T lymphocyte-
associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) 
regulatory cells that control intestinal inflammation. Journal of Experimental 
Medicine 192:295. 
 
34. Shimizu, J., S. Yamazaki, T. Takahashi, Y. Ishida, and S. Sakaguchi. 2002. 
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks 
immunological self-tolerance.[see comment]. Nature Immunology 3:135. 
 
35. McHugh, R. S., M. J. Whitters, C. A. Piccirillo, D. A. Young, E. M. Shevach, M. 
Collins, and M. C. Byrne. 2002. CD4(+)CD25(+) immunoregulatory T cells: gene 
expression analysis reveals a functional role for the glucocorticoid-induced TNF 
receptor.[see comment]. Immunity 16:311. 
144 
  
36. Gonzalez, A., I. Andre-Schmutz, C. Carnaud, D. Mathis, and C. Benoist. 2001. 
Damage control, rather than unresponsiveness, effected by protective DX5+ T 
cells in autoimmune diabetes. Nature Immunology 2:1117. 
 
37. Read, S., S. Mauze, C. Asseman, A. Bean, R. Coffman, and F. Powrie. 1998. 
CD38+ CD45RB(low) CD4+ T cells: a population of T cells with immune 
regulatory activities in vitro. European Journal of Immunology 28:3435. 
 
38. Singh, B., S. Read, C. Asseman, V. Malmstrom, C. Mottet, L. A. Stephens, R. 
Stepankova, H. Tlaskalova, and F. Powrie. 2001. Control of intestinal 
inflammation by regulatory T cells. Immunological Reviews 182:190. 
 
39. Herbelin, A., J. M. Gombert, F. Lepault, J. F. Bach, and L. Chatenoud. 1998. 
Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin 
mediate "active tolerance" in the nonobese diabetic mouse. Journal of 
Immunology 161:2620. 
40. Allison, J. P., and M. F. Krummel. 1995. The Yin and Yang of T cell 
costimulation.[see comment]. Science 270:932. 
 
41. Prud'homme, G. J. 2004. Altering immune tolerance therapeutically: the power of 
negative thinking. Journal of Leukocyte Biology 75:586. 
 
42. Bluestone, J. A. 1997. Is CTLA-4 a master switch for peripheral T cell tolerance? 
Journal of Immunology 158:1989. 
 
43. Haspot, F., F. Villemain, G. Laflamme, F. Coulon, D. Olive, J. Tiollier, J. P. 
Soulillou, and B. Vanhove. 2002. Differential effect of CD28 versus B7 blockade 
on direct pathway of allorecognition and self-restricted responses. Blood 99:2228. 
 
44. Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady, and S. 
M. Wahl. 2003. Conversion of peripheral CD4+CD25- naive T cells to 
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor 
Foxp3. Journal of Experimental Medicine 198:1875. 
 
45. Chambers, C. A., and J. P. Allison. 1999. Costimulatory regulation of T cell 
function. Current Opinion in Cell Biology 11:203. 
 
46. Peach, R. J., J. Bajorath, W. Brady, G. Leytze, J. Greene, J. Naemura, and P. S. 
Linsley. 1994. Complementarity determining region 1 (CDR1)- and CDR3-
145 
  
analogous regions in CTLA-4 and CD28 determine the binding to B7-1. Journal 
of Experimental Medicine 180:2049. 
 
47. Tang, Q., E. K. Boden, K. J. Henriksen, H. Bour-Jordan, M. Bi, and J. A. 
Bluestone. 2004. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ 
regulatory T cell function. European Journal of Immunology 34:2996. 
 
48. Zheng, S. G., J. H. Wang, J. D. Gray, H. Soucier, and D. A. Horwitz. 2004. 
Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop 
suppressive activity: the role of IL-2, TGF-beta, and IL-10. Journal of 
Immunology 172:5213. 
 
49. Nishimura, E., T. Sakihama, R. Setoguchi, K. Tanaka, and S. Sakaguchi. 2004. 
Induction of antigen-specific immunologic tolerance by in vivo and in vitro 
antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T 
cells. International Immunology 16:1189. 
 
50. Paust, S., L. Lu, N. McCarty, and H. Cantor. 2004. Engagement of B7 on effector 
T cells by regulatory T cells prevents autoimmune disease. Proceedings of the 
National Academy of Sciences of the United States of America 101:10398. 
 
51. Chen, M. L., M. J. Pittet, L. Gorelik, R. A. Flavell, R. Weissleder, H. von 
Boehmer, and K. Khazaie. 2005. Regulatory T cells suppress tumor-specific CD8 
T cell cytotoxicity through TGF-beta signals in vivo. Proceedings of the National 
Academy of Sciences of the United States of America 102:419. 
 
52. Vasu, C., B. S. Prabhakar, and M. J. Holterman. 2004. Targeted CTLA-4 
engagement induces CD4+CD25+CTLA-4high T regulatory cells with target 
(allo)antigen specificity. Journal of Immunology 173:2866. 
 
53. Bottomly, K., M. Luqman, L. Greenbaum, S. Carding, J. West, T. Pasqualini, and 
D. B. Murphy. 1989. A monoclonal antibody to murine CD45R distinguishes 
CD4 T cell populations that produce different cytokines. European Journal of 
Immunology 19:617. 
 
54. Lee, W. T., X. M. Yin, and E. S. Vitetta. 1990. Functional and ontogenetic 
analysis of murine CD45Rhi and CD45Rlo CD4+ T cells. Journal of Immunology 
144:3288. 
 
146 
  
55. Oida, T., X. Zhang, M. Goto, S. Hachimura, M. Totsuka, S. Kaminogawa, and H. 
L. Weiner. 2003. CD4+CD25- T cells that express latency-associated peptide on 
the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent 
mechanism. Journal of Immunology 170:2516. 
 
56. Gavin, M. A., S. R. Clarke, E. Negrou, A. Gallegos, and A. Rudensky. 2002. 
Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nature 
Immunology 3:33. 
 
57. Piccinni, M. P., M. G. Giudizi, R. Biagiotti, L. Beloni, L. Giannarini, S. 
Sampognaro, P. Parronchi, R. Manetti, F. Annunziato, and C. Livi. 1995. 
Progesterone favors the development of human T helper cells producing Th2-type 
cytokines and promotes both IL-4 production and membrane CD30 expression in 
established Th1 cell clones. Journal of Immunology 155:128. 
 
58. Tang, Q., K. J. Henriksen, E. K. Boden, A. J. Tooley, J. Ye, S. K. Subudhi, X. X. 
Zheng, T. B. Strom, and J. A. Bluestone. 2003. Cutting edge: CD28 controls 
peripheral homeostasis of CD4+CD25+ regulatory T cells. Journal of 
Immunology 171:3348. 
 
59. Ronchetti, S., O. Zollo, S. Bruscoli, M. Agostini, R. Bianchini, G. Nocentini, E. 
Ayroldi, and C. Riccardi. 2004. GITR, a member of the TNF receptor 
superfamily, is costimulatory to mouse T lymphocyte subpopulations. European 
Journal of Immunology 34:613. 
 
60. Stephens, G. L., R. S. McHugh, M. J. Whitters, D. A. Young, D. Luxenberg, B. 
M. Carreno, M. Collins, and E. M. Shevach. 2004. Engagement of glucocorticoid-
induced TNFR family-related receptor on effector T cells by its ligand mediates 
resistance to suppression by CD4+CD25+ T cells. Journal of Immunology 
173:5008. 
 
61. Roncarolo, M. G., and M. K. Levings. 2000. The role of different subsets of T 
regulatory cells in controlling autoimmunity. Current Opinion in Immunology 
12:676. 
 
62. Nakamura, K., A. Kitani, and W. Strober. 2001. Cell contact-dependent 
immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell 
surface-bound transforming growth factor beta. Journal of Experimental Medicine 
194:629. 
 
147 
  
63. Brunkow, M. E., E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S. A. 
Yasayko, J. E. Wilkinson, D. Galas, S. F. Ziegler, and F. Ramsdell. 2001. 
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal 
lymphoproliferative disorder of the scurfy mouse. Nature Genetics 27:68. 
 
64. Asseman, C., S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie. 1999. An 
essential role for interleukin 10 in the function of regulatory T cells that inhibit 
intestinal inflammation. Journal of Experimental Medicine 190:995. 
 
65. Yamagiwa, S., J. D. Gray, S. Hashimoto, and D. A. Horwitz. 2001. A role for 
TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells 
from human peripheral blood. Journal of Immunology 166:7282. 
 
66. Liu, H., B. Hu, D. Xu, and F. Y. Liew. 2003. CD4+CD25+ regulatory T cells cure 
murine colitis: the role of IL-10, TGF-beta, and CTLA4. Journal of Immunology 
171:5012. 
 
67. Nakamura, K., A. Kitani, I. Fuss, A. Pedersen, N. Harada, H. Nawata, and W. 
Strober. 2004. TGF-beta 1 plays an important role in the mechanism of 
CD4+CD25+ regulatory T cell activity in both humans and mice. Journal of 
Immunology 172:834. 
 
68. Manzotti, C. N., H. Tipping, L. C. Perry, K. I. Mead, P. J. Blair, Y. Zheng, and D. 
M. Sansom. 2002. Inhibition of human T cell proliferation by CTLA-4 utilizes 
CD80 and requires CD25+ regulatory T cells. European Journal of Immunology 
32:2888. 
 
69. Green, E. A., L. Gorelik, C. M. McGregor, E. H. Tran, and R. A. Flavell. 2003. 
CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-
beta-TGF-beta receptor interactions in type 1 diabetes. Proceedings of the 
National Academy of Sciences of the United States of America 100:10878. 
 
70. Huber, S., C. Schramm, H. A. Lehr, A. Mann, S. Schmitt, C. Becker, M. 
Protschka, P. R. Galle, M. F. Neurath, and M. Blessing. 2004. Cutting edge: TGF-
beta signaling is required for the in vivo expansion and immunosuppressive 
capacity of regulatory CD4+CD25+ T cells. Journal of Immunology 173:6526. 
 
71. Seddon, B., and D. Mason. 1999. Regulatory T cells in the control of 
autoimmunity: the essential role of transforming growth factor beta and 
interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral 
148 
  
CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes. Journal of Experimental 
Medicine 189:279. 
 
72. Shull, M. M., I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. 
Allen, C. Sidman, G. Proetzel, and D. Calvin. 1992. Targeted disruption of the 
mouse transforming growth factor-beta 1 gene results in multifocal inflammatory 
disease. Nature 359:693. 
 
73. Powrie, F., J. Carlino, M. W. Leach, S. Mauze, and R. L. Coffman. 1996. A 
critical role for transforming growth factor-beta but not interleukin 4 in the 
suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. 
Journal of Experimental Medicine 183:2669. 
 
74. Bridoux, F., A. Badou, A. Saoudi, I. Bernard, E. Druet, R. Pasquier, P. Druet, and 
L. Pelletier. 1997. Transforming growth factor beta (TGF-beta)-dependent 
inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major 
histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell 
lines. Journal of Experimental Medicine 185:1769. 
 
75. Gorelik, L., and R. A. Flavell. 2000. Abrogation of TGFbeta signaling in T cells 
leads to spontaneous T cell differentiation and autoimmune disease. Immunity 
12:171. 
 
76. Weiner, H. L. 2001. The mucosal milieu creates tolerogenic dendritic cells and 
T(R)1 and T(H)3 regulatory cells. Nature Immunology 2:671. 
 
77. Fantini, M. C., C. Becker, G. Monteleone, F. Pallone, P. R. Galle, and M. F. 
Neurath. 2004. Cutting edge: TGF-beta induces a regulatory phenotype in 
CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. 
Journal of Immunology 172:5149. 
 
78. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell 
development by the transcription factor Foxp3.[see comment]. Science 299:1057. 
 
79. Luo, X., H. Yang, I. S. Kim, F. Saint-Hilaire, D. A. Thomas, B. P. De, E. 
Ozkaynak, T. Muthukumar, W. W. Hancock, R. G. Crystal, and M. Suthanthiran. 
2005. Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ 
regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell 
function in overtly diabetic nonobese diabetic mice. Transplantation 79:1091. 
149 
  
80. Gambineri, E., T. R. Torgerson, and H. D. Ochs. 2003. Immune dysregulation, 
polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome 
of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of 
T-cell homeostasis. Current Opinion in Rheumatology 15:430. 
 
81. Khattri, R., T. Cox, S. A. Yasayko, and F. Ramsdell. 2003. An essential role for 
Scurfin in CD4+CD25+ T regulatory cells.[see comment]. Nature Immunology 
4:337. 
 
82. Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the 
development and function of CD4+CD25+ regulatory T cells.[see comment]. 
Nature Immunology 4:330. 
 
83. Fontenot, J. D., J. P. Rasmussen, L. M. Williams, J. L. Dooley, A. G. Farr, and A. 
Y. Rudensky. 2005. Regulatory T cell lineage specification by the forkhead 
transcription factor foxp3. Immunity 22:329. 
 
84. El-Asady, R., R. Yuan, K. Liu, D. Wang, R. E. Gress, P. J. Lucas, C. B. 
Drachenberg, and G. A. Hadley. 2005. TGF-{beta}-dependent CD103 expression 
by CD8(+) T cells promotes selective destruction of the host intestinal epithelium 
during graft-versus-host disease. Journal of Experimental Medicine 201:1647. 
 
85. Dujardin, H. C., O. Burlen-Defranoux, L. Boucontet, P. Vieira, A. Cumano, and 
A. Bandeira. 2004. Regulatory potential and control of Foxp3 expression in 
newborn CD4+ T cells. Proceedings of the National Academy of Sciences of the 
United States of America 101:14473. 
 
86. Schubert, L. A., E. Jeffery, Y. Zhang, F. Ramsdell, and S. F. Ziegler. 2001. 
Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell 
activation. Journal of Biological Chemistry 276:37672. 
 
87. Cameron, D. R., and G. D. Braunstein. 2005. The use of dehydroepiandrosterone 
therapy in clinical practice. Treatments in Endocrinology 4:95. 
 
88. Cepek, K. L., S. K. Shaw, C. M. Parker, G. J. Russell, J. S. Morrow, D. L. Rimm, 
and M. B. Brenner. 1994. Adhesion between epithelial cells and T lymphocytes 
mediated by E-cadherin and the alpha E beta 7 integrin. Nature 372:190. 
 
 
150 
  
89. Kutlesa, S., J. T. Wessels, A. Speiser, I. Steiert, C. A. Muller, and G. Klein. 2002. 
E-cadherin-mediated interactions of thymic epithelial cells with CD103+ 
thymocytes lead to enhanced thymocyte cell proliferation. Journal of Cell Science 
115:4505. 
 
90. Erle, D. J., T. Brown, D. Christian, and R. Aris. 1994. Lung epithelial lining fluid 
T cell subsets defined by distinct patterns of beta 7 and beta 1 integrin expression. 
American Journal of Respiratory Cell & Molecular Biology 10:237. 
 
91. Erle, D. J., and R. Pabst. 2000. Intraepithelial lymphocytes in the lung: a 
neglected lymphocyte population.[comment]. American Journal of Respiratory 
Cell & Molecular Biology 22:398. 
 
92. Lefrancois, L., T. A. Barrett, W. L. Havran, and L. Puddington. 1994. 
Developmental expression of the alpha IEL beta 7 integrin on T cell receptor 
gamma delta and T cell receptor alpha beta T cells. European Journal of 
Immunology 24:635. 
 
93. Kilshaw, P. J., and S. J. Murant. 1991. Expression and regulation of beta 7(beta p) 
integrins on mouse lymphocytes: relevance to the mucosal immune system. 
European Journal of Immunology 21:2591. 
 
94. Zelenika, D., E. Adams, S. Humm, L. Graca, S. Thompson, S. P. Cobbold, and H. 
Waldmann. 2002. Regulatory T cells overexpress a subset of Th2 gene transcripts. 
Journal of Immunology 168:1069. 
 
95. Huehn, J., K. Siegmund, J. C. Lehmann, C. Siewert, U. Haubold, M. Feuerer, G. 
F. Debes, J. Lauber, O. Frey, G. K. Przybylski, U. Niesner, M. de la Rosa, C. A. 
Schmidt, R. Brauer, J. Buer, A. Scheffold, and A. Hamann. 2004. Developmental 
stage, phenotype, and migration distinguish naive- and effector/memory-like 
CD4+ regulatory T cells. Journal of Experimental Medicine 199:303. 
 
96. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. 
CD4+CD25+ regulatory T cells control Leishmania major persistence and 
immunity. Nature 420:502. 
 
97. Rosen, S. D. 1999. Endothelial ligands for L-selectin: from lymphocyte 
recirculation to allograft rejection.[comment]. American Journal of Pathology 
155:1013. 
 
151 
  
98. You, S., G. Slehoffer, S. Barriot, J. F. Bach, and L. Chatenoud. 2004. Unique role 
of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T 
cell receptor transgenic mice. Proceedings of the National Academy of Sciences of 
the United States of America 101 Suppl 2:14580. 
 
99. Szanya, V., J. Ermann, C. Taylor, C. Holness, and C. G. Fathman. 2002. The 
subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of 
diabetes expresses L-selectin and high levels of CCR7. Journal of Immunology 
169:2461. 
 
100. Fu, S., A. C. Yopp, X. Mao, D. Chen, N. Zhang, M. Mao, Y. Ding, and J. S. 
Bromberg. 2004. CD4+ CD25+ CD62+ T-regulatory cell subset has optimal 
suppressive and proliferative potential. American Journal of Transplantation 
4:65. 
 
101. Salomon, B., D. J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, and J. 
A. Bluestone. 2000. B7/CD28 costimulation is essential for the homeostasis of the 
CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. 
Immunity 12:431. 
 
102. Lohr, J., B. Knoechel, S. Jiang, A. H. Sharpe, and A. K. Abbas. 2003. The 
inhibitory function of B7 costimulators in T cell responses to foreign and self-
antigens. Nature Immunology 4:664. 
 
103. Nakajima, A., M. Azuma, S. Kodera, S. Nuriya, A. Terashi, M. Abe, S. Hirose, T. 
Shirai, H. Yagita, and K. Okumura. 1995. Preferential dependence of 
autoantibody production in murine lupus on CD86 costimulatory molecule. 
European Journal of Immunology 25:3060. 
 
104. Chakrabarti, D., B. Hultgren, and T. A. Stewart. 1996. IFN-alpha induces 
autoimmune T cells through the induction of intracellular adhesion molecule-1 
and B7.2. Journal of Immunology 157:522. 
 
105. Rao, P. E., A. L. Petrone, and P. D. Ponath. 2005. Differentiation and expansion 
of T cells with regulatory function from human peripheral lymphocytes by 
stimulation in the presence of TGF-{beta}. Journal of Immunology 174:1446. 
 
106. Dalal, M., S. Kim, and R. R. Voskuhl. 1997. Testosterone therapy ameliorates 
experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the 
autoantigen-specific T lymphocyte response. Journal of Immunology 159:3. 
152 
  
107. Kim, S., and R. R. Voskuhl. 1999. Decreased IL-12 production underlies the 
decreased ability of male lymph node cells to induce experimental autoimmune 
encephalomyelitis. Journal of Immunology 162:5561. 
 
108. Jansson, L., and R. Holmdahl. 1998. Estrogen-mediated immunosuppression in 
autoimmune diseases. Inflammation Research 47:290. 
 
109. Korn-Lubetzki, I., E. Kahana, G. Cooper, and O. Abramsky. 1984. Activity of 
multiple sclerosis during pregnancy and puerperium. Annals of Neurology 16:229. 
 
110. Birk, K., C. Ford, S. Smeltzer, D. Ryan, R. Miller, and R. A. Rudick. 1990. The 
clinical course of multiple sclerosis during pregnancy and the puerperium. 
Archives of Neurology 47:738. 
 
111. Confavreux, C., M. Hutchinson, M. M. Hours, P. Cortinovis-Tourniaire, and T. 
Moreau. 1998. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy 
in Multiple Sclerosis Group.[see comment]. New England Journal of Medicine 
339:285. 
 
112. Whitacre, C. C., S. C. Reingold, and P. A. O'Looney. 1999. A gender gap in 
autoimmunity. Science 283:1277. 
 
113. Whitacre, C. C. 2001. Sex differences in autoimmune disease. Nature 
Immunology 2:777. 
 
114. Jacobson, D. L., S. J. Gange, N. R. Rose, and N. M. Graham. 1997. Epidemiology 
and estimated population burden of selected autoimmune diseases in the United 
States. Clinical Immunology & Immunopathology 84:223. 
 
115. Bebo, B. F., Jr., A. A. Vandenbark, and H. Offner. 1996. Male SJL mice do not 
relapse after induction of EAE with PLP 139-151. Journal of Neuroscience 
Research 45:680. 
 
116. Bebo, B. F., Jr., J. C. Schuster, A. A. Vandenbark, and H. Offner. 1998. Gender 
differences in experimental autoimmune encephalomyelitis develop during the 
induction of the immune response to encephalitogenic peptides. Journal of 
Neuroscience Research 52:420. 
 
153 
  
117. Roubinian, J. R., N. Talal, J. S. Greenspan, J. R. Goodman, and P. K. Siiteri. 
1978. Effect of castration and sex hormone treatment on survival, anti-nucleic 
acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. Journal of 
Experimental Medicine 147:1568. 
 
118. Serreze, D. V., and E. H. Leiter. 1994. Genetic and pathogenic basis of 
autoimmune diabetes in NOD mice. Current Opinion in Immunology 6:900. 
 
119. Voskuhl, R. R., H. Pitchekian-Halabi, A. MacKenzie-Graham, H. F. McFarland, 
and C. S. Raine. 1996. Gender differences in autoimmune demyelination in the 
mouse: implications for multiple sclerosis. Annals of Neurology 39:724. 
 
120. Sambrook, P. N., J. A. Eisman, G. D. Champion, and N. A. Pocock. 1988. Sex 
hormone status and osteoporosis in postmenopausal women with rheumatoid 
arthritis. Arthritis & Rheumatism 31:973. 
 
121. Lahita, R. G., H. L. Bradlow, H. G. Kunkel, and J. Fishman. 1981. Increased 16 
alpha-hydroxylation of estradiol in systemic lupus erythematosus. Journal of 
Clinical Endocrinology & Metabolism 53:174. 
 
122. Beato, M., and A. Sanchez-Pacheco. 1996. Interaction of steroid hormone 
receptors with the transcription initiation complex. Endocrine Reviews 17:587. 
 
123. Chakraborty, T. R., G. Rajendren, and A. C. Gore. 2005. Expression of estrogen 
receptor {alpha} in the anteroventral periventricular nucleus of hypogonadal 
mice. Experimental Biology & Medicine 230:49. 
 
124. Edwards, D. P. 2005. Regulation of signal transduction pathways by estrogen and 
progesterone. Annual Review of Physiology 67:335. 
 
125. Beato, M., and J. Klug. 2000. Steroid hormone receptors: an update. Human 
Reproduction Update 6:225. 
 
126. Olsen, N. J., and W. J. Kovacs. 1996. Gonadal steroids and immunity. Endocrine 
Reviews 17:369. 
 
127. Staples, J. E., T. A. Gasiewicz, N. C. Fiore, D. B. Lubahn, K. S. Korach, and A. 
E. Silverstone. 1999. Estrogen receptor alpha is necessary in thymic development 
and estradiol-induced thymic alterations. Journal of Immunology 163:4168. 
154 
  
128. Thurmond, T. S., F. G. Murante, J. E. Staples, A. E. Silverstone, K. S. Korach, 
and T. A. Gasiewicz. 2000. Role of estrogen receptor alpha in hematopoietic stem 
cell development and B lymphocyte maturation in the male mouse. 
Endocrinology 141:2309. 
 
129. Bellido, T., G. Girasole, G. Passeri, X. P. Yu, H. Mocharla, R. L. Jilka, A. 
Notides, and S. C. Manolagas. 1993. Demonstration of estrogen and vitamin D 
receptors in bone marrow-derived stromal cells: up-regulation of the estrogen 
receptor by 1,25-dihydroxyvitamin-D3. Endocrinology 133:553. 
 
130. Cohen, J. H., L. Danel, G. Cordier, S. Saez, and J. P. Revillard. 1983. Sex steroid 
receptors in peripheral T cells: absence of androgen receptors and restriction of 
estrogen receptors to OKT8-positive cells. Journal of Immunology 131:2767. 
 
131. Gulshan, S., A. B. McCruden, and W. H. Stimson. 1990. Oestrogen receptors in 
macrophages. Scandinavian Journal of Immunology 31:691. 
 
132. Haruki, Y., K. Seiki, T. Enomoto, H. Fujii, and K. Sakabe. 1983. Estrogen 
receptor in the "non-lymphocytes" in the thymus of the ovariectomized rat. Tokai 
Journal of Experimental & Clinical Medicine 8:31. 
 
133. Kawashima, I., K. Seiki, K. Sakabe, S. Ihara, A. Akatsuka, and Y. Katsumata. 
1992. Localization of estrogen receptors and estrogen receptor-mRNA in female 
mouse thymus. Thymus 20:115. 
 
134. Smithson, G., K. Medina, I. Ponting, and P. W. Kincade. 1995. Estrogen 
suppresses stromal cell-dependent lymphopoiesis in culture. Journal of 
Immunology 155:3409. 
 
135. Stimson, W. H. 1988. Oestrogen and human T lymphocytes: presence of specific 
receptors in the T-suppressor/cytotoxic subset. Scandinavian Journal of 
Immunology 28:345. 
 
136. Tornwall, J., A. B. Carey, R. I. Fox, and H. S. Fox. 1999. Estrogen in 
autoimmunity: expression of estrogen receptors in thymic and autoimmune T 
cells. Journal of Gender-Specific Medicine 2:33. 
 
137. Mosselman, S., J. Polman, and R. Dijkema. 1996. ER beta: identification and 
characterization of a novel human estrogen receptor. FEBS Letters 392:49. 
155 
  
138. Palaszynski, K. M., K. K. Loo, J. F. Ashouri, H. B. Liu, and R. R. Voskuhl. 2004. 
Androgens are protective in experimental autoimmune encephalomyelitis: 
implications for multiple sclerosis. Journal of Neuroimmunology 146:144. 
 
139. Kuiper, G. G., E. Enmark, M. Pelto-Huikko, S. Nilsson, and J. A. Gustafsson. 
1996. Cloning of a novel receptor expressed in rat prostate and ovary. 
Proceedings of the National Academy of Sciences of the United States of America 
93:5925. 
 
140. Paech, K., P. Webb, G. G. Kuiper, S. Nilsson, J. Gustafsson, P. J. Kushner, and T. 
S. Scanlan. 1997. Differential ligand activation of estrogen receptors ERalpha and 
ERbeta at AP1 sites.[see comment]. Science 277:1508. 
 
141. Cutolo, M., and R. L. Wilder. 2000. Different roles for androgens and estrogens in 
the susceptibility to autoimmune rheumatic diseases. Rheumatic Diseases Clinics 
of North America 26:825. 
 
142. Jansson, L., T. Olsson, and R. Holmdahl. 1994. Estrogen induces a potent 
suppression of experimental autoimmune encephalomyelitis and collagen-induced 
arthritis in mice. Journal of Neuroimmunology 53:203. 
 
143. Kim, S., S. M. Liva, M. A. Dalal, M. A. Verity, and R. R. Voskuhl. 1999. Estriol 
ameliorates autoimmune demyelinating disease: implications for multiple 
sclerosis. Neurology 52:1230. 
 
144. Garidou, L., S. Laffont, V. Douin-Echinard, C. Coureau, A. Krust, P. Chambon, 
and J. C. Guery. 2004. Estrogen receptor alpha signaling in inflammatory 
leukocytes is dispensable for 17beta-estradiol-mediated inhibition of experimental 
autoimmune encephalomyelitis. Journal of Immunology 173:2435. 
 
145. Carlsten, H., A. Tarkowski, R. Holmdahl, and L. A. Nilsson. 1990. Oestrogen is a 
potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clinical & 
Experimental Immunology 80:467. 
 
146. Olsen, N. J., G. Olson, S. M. Viselli, X. Gu, and W. J. Kovacs. 2001. Androgen 
receptors in thymic epithelium modulate thymus size and thymocyte 
development. Endocrinology 142:1278. 
 
156 
  
147. Viselli, S. M., N. J. Olsen, K. Shults, G. Steizer, and W. J. Kovacs. 1995. 
Immunochemical and flow cytometric analysis of androgen receptor expression in 
thymocytes. Molecular & Cellular Endocrinology 109:19. 
 
148. Rosen, J. L., H. T. Tran, A. Lackey, and S. M. Viselli. 1999. Sex-related immune 
changes in young mice. Immunological Investigations 28:247. 
 
149. Olsen, N. J., M. B. Watson, G. S. Henderson, and W. J. Kovacs. 1991. Androgen 
deprivation induces phenotypic and functional changes in the thymus of adult 
male mice. Endocrinology 129:2471. 
 
150. Olsen, N. J., and W. J. Kovacs. 2001. Effects of androgens on T and B 
lymphocyte development. Immunologic Research 23:281. 
 
151. Olsen, N. J., P. Zhou, H. Ong, and W. J. Kovacs. 1993. Testosterone induces 
expression of transforming growth factor-beta 1 in the murine thymus. Journal of 
Steroid Biochemistry & Molecular Biology 45:327. 
 
152. Fitzpatrick, F., F. Lepault, F. Homo-Delarche, J. F. Bach, and M. Dardenne. 1991. 
Influence of castration, alone or combined with thymectomy, on the development 
of diabetes in the nonobese diabetic mouse. Endocrinology 129:1382. 
 
153. Stahl, N. I., and J. L. Decker. 1978. Androgenic status of males with systemic 
lupus erythematosus. Arthritis & Rheumatism 21:665. 
 
154. Walker, S. 2001. Modulation of hormones in the treatment of lupus. Am J Manag 
Care 7:S486. 
 
155. Alarcon-Segovia, D. 2001. The future of treatment for systemic lupus 
erythematosus. Israel Medical Association Journal: Imaj 3:127. 
 
156. Weinstein, Y., and Z. Berkovich. 1981. Testosterone effect on bone marrow, 
thymus, and suppressor T cells in the (NZB X NZW)F1 mice: its relevance to 
autoimmunity. Journal of Immunology 126:998. 
 
157. Fox, H. S. 1992. Androgen treatment prevents diabetes in nonobese diabetic mice. 
Journal of Experimental Medicine 175:1409. 
 
157 
  
158. Maccio, D. R., G. Calfa, and G. A. Roth. 2005. Oral testosterone in male rats and 
the development of experimental autoimmune encephalomyelitis. 
Neuroimmunomodulation 12:246. 
 
159. Tomassini, V., E. Onesti, C. Mainero, E. Giugni, A. Paolillo, M. Salvetti, F. 
Nicoletti, and C. Pozzilli. 2005. Sex hormones modulate brain damage in multiple 
sclerosis: MRI evidence. Journal of Neurology, Neurosurgery & Psychiatry 
76:272. 
 
160. Beato, M. 1989. Gene regulation by steroid hormones. Cell 56:335. 
 
161. AyanlarBatuman, O., A. P. Ferrero, A. Diaz, and S. A. Jimenez. 1991. Regulation 
of transforming growth factor-beta 1 gene expression by glucocorticoids in 
normal human T lymphocytes. Journal of Clinical Investigation 88:1574. 
 
162. Sader, M. A., K. C. McGrath, M. D. Hill, K. F. Bradstock, M. Jimenez, D. J. 
Handelsman, D. S. Celermajer, and A. K. Death. 2005. Androgen receptor gene 
expression in leucocytes is hormonally regulated: implications for gender 
differences in disease pathogenesis. Clinical Endocrinology 62:56. 
 
163. Viselli, S. M., S. Stanziale, K. Shults, W. J. Kovacs, and N. J. Olsen. 1995. 
Castration alters peripheral immune function in normal male mice. Immunology 
84:337. 
164. Ansar Ahmed, S., W. J. Penhale, and N. Talal. 1985. Sex hormones, immune 
responses, and autoimmune diseases. Mechanisms of sex hormone action. 
American Journal of Pathology 121:531. 
 
165. Yao, G., and X. J. Shang. 2005. A comparison of modulation of proliferation of 
thymocyte by testosterone, dehydroisoandrosterone and androstenedione in vitro. 
Archives of Andrology 51:257. 
 
166. Karpuzoglu-Sahin, E., R. M. Gogal, Jr., C. Hardy, P. Sponenberg, and S. A. 
Ahmed. 2005. Short-term administration of 17-beta estradiol to outbred male CD-
1 mice induces changes in the immune system, but not in reproductive organs. 
Immunological Investigations 34:1. 
 
167. Medina, K. L., K. P. Garrett, L. F. Thompson, M. I. Rossi, K. J. Payne, and P. W. 
Kincade. 2001. Identification of very early lymphoid precursors in bone marrow 
and their regulation by estrogen. Nature Immunology 2:718. 
158 
  
168. Sadovnick, A. D., D. Bulman, and G. C. Ebers. 1991. Parent-child concordance in 
multiple sclerosis.[see comment]. Annals of Neurology 29:252. 
 
169. Smith, R., and J. W. Studd. 1992. A pilot study of the effect upon multiple 
sclerosis of the menopause, hormone replacement therapy and the menstrual 
cycle. Journal of the Royal Society of Medicine 85:612. 
 
170. Stoll, M. L., and J. Gavalchin. 2000. Systemic lupus erythematosus-messages 
from experimental models. Rheumatology 39:18. 
 
171. McMurray, R. W. a. M. W. 2003. Sex Hormones and Systemic Lupus 
Erythematosus: Review and Meta-Analysis. Arthritis and Rheum . 48:2100. 
 
172. Liu, M. F., C. R. Wang, L. L. Fung, and C. R. Wu. 2004. Decreased CD4+CD25+ 
T cells in peripheral blood of patients with systemic lupus erythematosus. 
Scandinavian Journal of Immunology 59:198. 
 
173. Monk, C. R., M. Spachidou, F. Rovis, E. Leung, M. Botto, R. I. Lechler, and O. 
A. Garden. 2005. MRL/Mp CD4+,CD25- T cells show reduced sensitivity to 
suppression by CD4+,CD25+ regulatory T cells in vitro: a novel defect of T cell 
regulation in systemic lupus erythematosus. Arthritis & Rheumatism 52:1180. 
 
174. Grossman, C. 1989. Possible underlying mechanisms of sexual dimorphism in the 
immune response, fact and hypothesis. Journal of Steroid Biochemistry 34:241. 
 
175. Schuurs, A. H., and H. A. Verheul. 1990. Effects of gender and sex steroids on 
the immune response. Journal of Steroid Biochemistry 35:157. 
 
176. Gallatin, W. M., I. L. Weissman, and E. C. Butcher. 1983. A cell-surface 
molecule involved in organ-specific homing of lymphocytes. Nature 304:30. 
 
177. Siegelman, M. H., I. C. Cheng, I. L. Weissman, and E. K. Wakeland. 1990. The 
mouse lymph node homing receptor is identical with the lymphocyte cell surface 
marker Ly-22: role of the EGF domain in endothelial binding. Cell 61:611. 
 
178. Gomes-Pereira, S., O. R. Rodrigues, and G. M. Santos-Gomes. 2004. Dynamics 
of CD62L/CD45RB CD4+ and CD8+ lymphocyte subsets in hepatic and splenic 
tissues during murine visceral leishmaniasis. Immunology Letters 95:63. 
159 
  
179. Sakaguchi, S. 2005. Naturally arising Foxp3-expressing CD25+CD4+ regulatory 
T cells in immunological tolerance to self and non-self. Nature Immunology 6: 
345  
 
180. Smithson, G., J. F. Couse, D. B. Lubahn, K. S. Korach, and P. W. Kincade. 1998. 
The role of estrogen receptors and androgen receptors in sex steroid regulation of 
B lymphopoiesis. Journal of Immunology 161:27. 
 
181. Bebo, B. F., Jr., E. Zelinka-Vincent, G. Adamus, D. Amundson, A. A. 
Vandenbark, and H. Offner. 1998. Gonadal hormones influence the immune 
response to PLP 139-151 and the clinical course of relapsing experimental 
autoimmune encephalomyelitis. Journal of Neuroimmunology 84:122. 
 
182. Roubinian, J. R., R. Papoian, and N. Talal. 1977. Androgenic hormones modulate 
autoantibody responses and improve survival in murine lupus. Journal of Clinical 
Investigation 59:1066. 
 
183. Roubinian, J., N. Talal, P. K. Siiteri, and J. A. Sadakian. 1979. Sex hormone 
modulation of autoimmunity in NZB/NZW mice. Arthritis & Rheumatism 
22:1162. 
 
184. Melez, K. A., W. A. Boegel, and A. D. Steinberg. 1980. Therapeutic studies in 
New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1 females 
of different ages. Arthritis & Rheumatism 23:41. 
 
185. Jiang, J. F., H. Liu, and C. X. Zhang. 2005. Sex hormones in female patients with 
systemic lupus erythmatosus. Zhong Nan Da Xue Bao Yi Xue Ban 30:315. 
 
186. Suffia I, R. S., Salay G, Belkaid Y. 2005. A role for CD103 in the retention of 
CD4+CD25+ Treg and control of Leishmania major infection. J Immunol. 174: 
5444. 
 
187. Banz, A., A. Peixoto, C. Pontoux, C. Cordier, B. Rocha, and M. Papiernik. 2003. 
A unique subpopulation of CD4+ regulatory T cells controls wasting disease, IL-
10 secretion and T cell homeostasis. European Journal of Immunology 33:2419. 
 
188. Walker, S. E., L. W. Keisler, C. W. Caldwell, A. B. Kier, and F. S. vom Saal. 
1996. Effects of altered prenatal hormonal environment on expression of 
autoimmune disease in NZB/NZW mice. Environmental Health Perspectives 104 
Suppl 4:815. 
160 
  
189. Carlsten, H., N. Nilsson, R. Jonsson, K. Backman, R. Holmdahl, and A. 
Tarkowski. 1992. Estrogen accelerates immune complex glomerulonephritis but 
ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL 
lpr/lpr mice. Cellular Immunology 144:190. 
 
190. Siegmund, K., M. Feuerer, C. Siewert, S. Ghani, U. Haubold, A. Dankof, V. 
Krenn, M. P. Schon, A. Scheffold, J. B. Lowe, A. Hamann, U. Syrbe, and J. 
Huehn. 2005. Migration matters: regulatory t-cell compartmentalization 
determines suppressice activity in vivo. Blood 1:3097. 
 
191. Walker, M. R., D. J. Kasprowicz, V. H. Gersuk, A. Benard, M. Van Landeghen, J. 
H. Buckner, and S. F. Ziegler. 2003. Induction of FoxP3 and acquisition of T 
regulatory activity by stimulated human CD4+CD25- T cells.[see comment]. 
Journal of Clinical Investigation 112:1437. 
 
192. Balandina, A., S. Lecart, P. Dartevelle, A. Saoudi, and S. Berrih-Aknin. 2005. 
Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients 
with autoimmune myasthenia gravis. Blood 105:735. 
 
193. Huan, J., N. Culbertson, L. Spencer, R. Bartholomew, G. G. Burrows, Y. K. 
Chou, D. Bourdette, S. F. Ziegler, H. Offner, and A. A. Vandenbark. 2005. 
Decreased Foxp3 levels in multiple sclerosis patients. J. Neurosci. Res. 1:45. 
 
194. Reddy J, W. H., Zhang X. Illes Z, Wucherpfennig KW, Sobel RA and Kuchroo 
VK. 2005. CD4+CD25+ regulatory T cells contribute to gender differences in 
susceptibility to experimental autoiimune encephalomyelitis. J. Immunol. 
175:5591. 
 
195. Nancy, P., and S. Berrih-Aknin. 2005. Differential estrogen receptor expression in 
autoimmune myasthenia gravis. Endocrinology 146:2345. 
 
196. Delpy, L., V. Douin-Echinard, L. Garidou, C. Bruand, A. Saoudi, and J. C. Guery. 
2005. Estrogen enhances susceptibility to experimental autoimmune myasthenia 
gravis by promoting type 1-polarized immune responses. J. Immunol. 15:5050. 
 
197. Rijhsinghani, A. G., K. Thompson, S. K. Bhatia, and T. J. Waldschmidt. 1996. 
Estrogen blocks early T cell development in the thymus. American Journal of 
Reproductive Immunology 36:269. 
161 
  
198. Richards, H. B., M. Satoh, J. C. Jennette, B. P. Croker, H. Yoshida, and W. H. 
Reeves. 2001. Interferon-gamma is required for lupus nephritis in mice treated 
with the hydrocarbon oil pristane. Kidney International 60:2173. 
 
199. Theofilopoulos, A. N., S. Koundouris, D. H. Kono, and B. R. Lawson. 2001. The 
role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 
paradigm in autoimmunity. Arthritis Research 3:136. 
 
200. Pollard, K. M., P. Hultman, and D. H. Kono. 2003. Using single-gene deletions to 
identify checkpoints in the progression of systemic autoimmunity. Annals of the 
New York Academy of Sciences 987:236. 
 
201. Hayashi, T., K. Hasegawa, and C. Adachi. 2005. Elimination of CD4+CD25+ T 
cell accelerates the development of glomerulonephritis during the preactive phase 
in autoimmune-prone female NZBxNZW F mice. Int. J. Exp. Pathol. 86:289. 
 
202. Wu, H. Y., and N. A. Staines. 2004. A deficiency of CD4+CD25+ T cells permits 
the development of spontaneous lupus-like disease in mice, and can be reversed 
by induction of mucosal tolerance to histone peptide autoantigen. Lupus 13:192. 
 
203. Crispin, J. C., A. Martinez, and J. Alcocer-Varela. 2003. Quantification of 
regulatory T cells in patients with systemic lupus erythematosus. Journal of 
Autoimmunity 21:273. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
162 
  
 
 
 
 
 
LIST OF ABBREVIATIONS 
 
 
 
APC  Allophycocyanine 
 
APC  Antigen presenting cells   
 
AR  Androgen receptor 
 
BSA  Bovine serum albumin 
 
CFSE  Carboxy-fluorescein diacetate, succinimidyl ester 
 
CTLA-4 Cytotoxic T-lymphocyte-associated molecule 4 
 
DHEA  Dehydroepiandrostene 
 
DHT  Dihydrotestosterone 
 
dsDNA Double-stranded deoxy-ribonucleic acid 
 
E2  Estradiol 
 
EAE  Experimental autoimmune encephalomyelitis 
 
ELISA  Enzyme-linked immunosorbent assay 
 
ER  Estrogen receptor 
 
ERKO  Estrogen receptor knockout 
 
FACS  Fluorescence activated cell sorter 
 
FCS  Fetal calf serum 
 
FITC  Fluorescein isothiocyanate 
 
Foxp3  Forkhead box P3 
 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
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GITR  Glucocorticoid-induced tumor-necrosis factor receptor 
 
HBSS  Hank’s balanced salt solution 
 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
 
HEV  High endothelial venule 
 
HPLC  High Performance Liquid Chromatography 
 
IFN  Interferon 
 
Ig  Immunoglobulin  
 
IL  Interleukin 
 
IPEX  Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome 
 
LN  Lymph node 
 
MG  Myasthenia gravis 
 
MHC  Major histocompatibility complex 
 
mRNA  Messenger ribonucleic acid 
 
MS  Multiple sclerosis 
 
NOD  Non-obese diabetes 
 
NZB  New Zealand black 
 
NZW  New Zealand white 
 
OVA  Ovalbumin 
 
PBS  Phosphate-buffered saline 
 
PE  Phycoerythrin 
 
PerCP  Peridinin-chlorophyll-protein Complex   
 
RT-PCR Reverse transcriptase PCR 
 
SLC  Secondary lymphoid tissue chemokine 
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SLE  Systemic lupus erythematosus 
 
TCR  T cell receptor 
 
Tfm  Testicular feminization mouse 
 
TGFβ  Transforming growth factor beta 
 
TNFR  Tumor necrosis factor receptor 
 
Treg  Regulatory T cell 
 
nTreg  Naturally occurring regulatory T cell 
 
WT  Wildtype 
 
TH  T helper 
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